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Title: A Molecular Perspective for the Understanding of Polymer‒Drug Interactions
Major Professor: Lynne S. Taylor
Polymers are often used to stabilize amorphous drug formulations enabling the maintenance of
high drug supersaturations. However, the molecular mechanism of stabilization is unclear, making
the rational design of new polymers challenging. This research has focused on understanding the
effectiveness of polymers to inhibit drug crystallization using experimental and computational
modeling approaches. This thesis has six sections. The first section reviews the pharmaceutical
significance of amorphous solid dispersions. The second section describes a study to evaluate the
phase behavior of supersaturated drug solutions of telaprevir, a compound that undergoes glassliquid phase separation when the amorphous solubility is exceeded. The third section presents a
study of the crystallization inhibition properties of commercial and newly synthesized polymers
with various functional groups, as well as computational modeling to understand variations in the
polymer intramolecular interactions. In the fourth section, cellulose polymers with carboxylic
acids are explored for a group of nine different drugs; and drug-polymer interactions are analyzed
through simulations. The fifth section describes a study of the performance of amorphous solid
dispersions of telaprevir and commercial polymers by performing dissolution and diffusion
measurements. The final chapter details an exploration of a group of nine newly synthesized
polymers to show how variations in the functional groups and the starting cellulose material
influence the performance of the amorphous formulation. Overall, this dissertation provides insight
into the optimization of polymer properties such as chemical functionality and polymer solubility,
using the guidance from molecular modeling to understand solution-interactions, with the end goal
of contributing to the rational design of new polymers that can be employed to stabilize amorphous
solid dispersions.

1

1. INTRODUCTION

Statement of the problem, the significance of the problem, hypotheses, and specific
aims
1.1.1 Statement of the problem
A significant percentage of commercialized and developmental drugs are poorly water-soluble,
which may affect the expected therapeutic effect following oral delivery since the drug must be
first dissolved to be absorbed by enterocytes and reach the systemic circulation. Drug solubility
is determined by the crystal lattice energy and the drug-solvent intermolecular interactions.
Solubility enhancement strategies such as surfactants, cyclodextrins, co-solvents, and amorphous
formulations influence one of these two factors: crystal lattice energy or drug-solvent
intermolecular interactions.
Amorphous materials can improve the dissolution rate and the maximum achievable solution
concentrations due to the disruption of the crystal lattice. However, this is a high energy state that
may undergo crystallization losing the solubility advantage. Although polymers are employed to
kinetically stabilize amorphous drugs against crystallization, the mechanism of stabilization is not
well understood. As a result, it is unclear why some polymers are more effective than others, and
why the polymer effectiveness changes depending on if the drug is in the solution or the solid state.
Therefore, the selection and synthesis of novel polymers is still an empirical process.
1.1.2 The significance of the problem - originality and potential impact
Amorphous solid dispersions (ASD), composed of drug-polymer blends, are used to generate
highly supersaturated solutions and improve drug bioavailability. In selecting the right polymer,
its effectiveness in inhibiting crystallization in solution and during the ASD dissolution must be
considered.
Although there are several proposed mechanisms for polymer inhibition of drug crystallization,
including intermolecular interactions and polymer-drug hydrophobicity, previous reports do not
provide enough information to understand what is happening at a molecular level between the drug
and polymer. Therefore, it is unclear how modifications in molecular structure and hydrophobicity
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influence polymer effectiveness, making the rational selection of existing polymers and the design
of new polymers challenging.
This project involves an experimental and computational approach to understand, from a molecular
level, the factors that might impact polymer effectiveness, i.e., intra and intermolecular interactions.
The experimental efforts start with the design of novel cellulose polymers with various chemical
functionalities, in collaboration with Prof. Kevin Edgar’s group at Virginia Tech. The solution
crystallization inhibition properties of the polymers are first evaluated by measuring nucleation
induction times, allowing determination of key chemical groups needed for optimal polymer
effectiveness. Next, ASDs are prepared with selected polymers, and the formulations are compared
regarding the maximum amount of free drug available to permeate across a membrane. Finally, in
collaboration with Prof. Lyudmila Slipchenko’s group at Purdue, computational chemistry is used
to assist in explaining intra and intermolecular interactions with drug molecules.
1.1.3 Specific aims
o

To elucidate the impact of polymer chemistry and hydrophobicity on the crystallization
inhibition of supersaturated drug solutions, by linking variations in nucleation induction times
to changes in polymer adsorption onto amorphous films of the drug, and drug-polymer
intermolecular interactions.

o

To ascertain the performance of amorphous solid dispersions by connecting variations in the
maximum achievable diffusive flux to differences in the polymer efficacy at releasing and
stabilizing the drug in solution.

1.1.4 Hypotheses
o

Differences in the chemical structure and hydrophobicity of polymers will generate diverse
polymer conformations, which will impact the intra and intermolecular interactions and hence
the polymer effectiveness at inhibiting crystallization in solution.

o

Differences in the chemical structure and aqueous solubility of polymers will influence the
drug release and phase transformations in solution, which will impact mass flow
measurements through a side-by-side diffusion cell.
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Figure 1-1 Summary of content included in different chapters.
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Solubility advantage of amorphous materials
The solubility of a crystalline material, represented by the mole fraction xcrystal, depends on the
energy required to overcome the strength of drug-drug intermolecular forces in the crystalline state,
and the energy generated by the drug-solvent interaction in solution, as in Eq. (1-1).1,2 The
disruption of the crystal lattice contribution is given by xideal, and the strength of the drug-solvent
interactions is represented by the activity coefficient, γ.1
1-1

Figure 1-2 Schematic of the ideal solubilization of a crystalline material.

The process needed to disrupt the crystal lattice of a solid is exemplified in Figure 1-2.3 The total
enthalpy, ΔH, required to disrupt the forces in the solid state is given by the sum of the enthalpy
of heating, ΔHh; melting, ΔHm; and cooling, ΔHc; as established in Eq. (1-2).
1-2
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The crystalline solubility, xcrystal, is described in Eq. (1-3), where Tm is the melting temperature, T
is the experimental temperature, R is the ideal gas constant, and ΔCp is the heat capacity difference
associated with the conversion from a crystalline material to a liquid or glass at room temperature.1

1-3
In contrast, the solubility of an amorphous solid, xamorphous, only depends on the drug-solvent
interaction, due to the absence of a crystalline lattice, yielding Eq. (1-4).
1-4
The solubility of an amorphous solid will be significantly improved concerning that of a crystal,
as described in Eq. (1-5),4 where the ratio of amorphous versus crystalline solubility, or more
precisely the ratio between activities, α, depends on the free energy difference between an
amorphous and crystalline solid, ΔGa→c.4

1-5
Typically, ΔGa→c is calculated using the Hoffman equation, Eq. (1-6).5

1-6
The Hoffman equation assumes a constant heat capacity, and for some systems, a more accurate
description of the free energy term is needed. Eq. (1-7) includes the heat capacity change, ΔCP, as
a part of the calculation of the ΔGa→c term.

1-7
Murdande et al.6,7 stated that the predicted amorphous solubility, xamorphous or αamorphous is depressed
by water present in the amorphous solid and also by ionization effects. Eq. (1-8) considers these
effects, where the function −I(a2) represents the activity of the amorphous solute saturated with
water; and the superscript “ionized” denotes the fraction of ionized species.
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1-8
The solubility advantage provided by amorphous solids is due to the free energy difference
between the amorphous and crystalline forms.4 Hence, a larger ΔGa→c will represent a higher
solubility enhancement, but also a more pronounced tendency to crystallize.8
Amorphous materials have a higher enthalpy, entropy, and volume than crystalline solids, Figure
1-35,9 which explains their propensity to crystallize. It also illustrates the process of generation of
an amorphous glass after melting a crystalline solid. Explicitly, a crystalline material can be melted
and quench cooled, which will generate a supercooled liquid followed by glass. The glass
transition temperature, Tg, is the temperature at which the supercooled liquid transforms into a
glass. At the Tg, there is a discontinuity in specific thermodynamic properties of the system.9

Figure 1-3 Enthalpy versus temperature diagram. Amorphous materials present higher volume,
enthalpy, and entropy than crystalline solids. Figure adapted from Hoffman, and Baird and
Taylor. 5,9

1.2.1 Stability of supersaturated solutions
The high supersaturation created by the dissolution of an amorphous material generates a
metastable solution that will eventually crystallize. The change in the chemical potential of a
molecule in a supersaturated versus in a saturated solution, Δμ, gives the thermodynamic driving
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force for crystallization. Eq. (1-9) describes the dependence between Δμ and supersaturation ratio
(S).

1-9
S is defined as the ratio of the activity of a supersaturated and a saturated, αcrystal, solution, which
is approximated as a ratio of concentrations, kB is the Boltzmann constant, and T is the temperature.
1.2.1.1 Nucleation and crystal growth
The degree of supersaturation will determine if the driving force for crystallization is enough.
There are three regions in a supersaturation-saturation diagram, classified based on the tendency
of a solute to crystallize: a stable, a metastable, and a labile region, Figure 1-4. In the stable region,
the activity of the solute in solution (α) is lower than its activity in the equilibrium (αcrystal),
unsaturated solution. Nucleation and growth are observed in the metastable region, α > αcrystal. It
is possible to obtain supersaturated solutions in this region; and additives can be used to increase
the width of the metastable region, delaying crystallization. In the labile region, α >> αcrystal, and
the supersaturation (α − αcrystal) is larger than the metastable zone width; thus spontaneous
nucleation occurs.10,11
The crystallization process divides into nucleation and crystal growth. Nucleation is the process of
creating a second phase, nuclei, from a supersaturated solution. Crystal growth consists in the
diffusion of drug molecules to the crystal surface followed by their integration to the surface.10
The nucleation process is classified based on the absence or presence of existing crystals in
solution, primary or secondary nucleation, respectively. Primary nucleation is divided into
homogenous or heterogeneous nucleation. Homogeneous nucleation is uncommon and is only
observed in pure solutions, hence very clean environments, and procedures that reduce interfaces
are required. In contrast, during heterogeneous nucleation, the process of nuclei formation is
facilitated by the presence of a surface or interface.12 Almost all crystallization processes involve
contact with an interface or surface, which makes heterogeneous nucleation the most common
process.
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Figure 1-4 Supersaturation-saturation diagram, showing the regions of stability: stable,
metastable and labile regions.

1.2.1.1.1 Classical nucleation theory (CNT)
Classical nucleation theory has been used to describe the formation of a nucleus from
supersaturated solutions, Eq. (1-10).13,14 The steady-state rate of nucleation (J) depends on the free
energy associated with the formation of a critical nucleus (ΔGa→c ≈ ΔGCritical).14 ΔGCritical is
determined by a balance between the surface free energy ΔGs (unfavorable) and the volume free
energy ΔGv (favorable), Eq. (1-11) and Figure 1-5.14 Here, γ1|2 is the surface tension of the interface
between the nucleus (1) and the medium (2), and S is the supersaturation.

1-10

1-11
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The creation of a new surface disrupts previous intermolecular interactions between dissolved
molecules and solvent hence ΔGs is unfavorable, while the formation of an ordered nucleus leads
to a reduction in the volume occupied by molecules in the solid state and ΔGv is favorable.15
However, CNT has various limitations, such as the assumption of spherical clusters, constant
surface tension, and linear growth of clusters.15 Also, CNT does not account for the effect of
intermolecular interactions between drug and additives that influence crystallization, complicating
the prediction of nucleation rates in the presence of additives.

Figure 1-5 Free energy diagram for nucleation. Adapted from Erdemir et al.15

1.2.1.1.2 Two-step nucleation theory
In this alternative theory, there are two steps in the formation of a nucleus: the creation of a liquidaggregate and the rearrangement of molecules to an ordered structure in the droplets: a density
fluctuation followed by a structural variation;16-18 where the structural variation is the rate-limiting
step for crystal nucleation.17 This two-step process is widely documented for proteins.16-22
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1.2.1.2

“Amorphous solubility”: Maximum achievable free drug in solution

Amorphous materials present a higher apparent solubility than crystalline solids allowing the
generation of supersaturated drug solutions. The crystalline solubility represents the
thermodynamic solubility because it is the lowest energy state. Meanwhile, the “amorphous
solubility” is a kinetic solubility, since it is a metastable state.23 Precipitation in the form of
crystalline or amorphous solid can be observed in supersaturated drug solutions.24
It has been recently noted that the maximum concentration of free drug in supersaturated solutions
created by the solvent-shifting method is in agreement with the predicted “amorphous solubility”
described by Eq. (1-8).24 When a concentrated stock solution of the drug is added to an aqueous
environment, there is a limiting concentration above which the second phase of drug-rich
aggregates will be generated.24 The concentration at which the phase transition is detected, from
the free drug in solution to a colloidal drug-rich phase, is referred to as liquid-liquid phase
separation (LLPS),24 or glass–liquid phase separation (GLPS).3,25 The term, liquid or glass, will
depend upon the glass transition temperature of the amorphous precipitate of the drug (Figure 12). For example, the reported Tg value for the water saturated-amorphous precipitate of ritonavir
is 0.4 °C24 while the telaprevir amorphous precipitate Tg is 52 °C.25 Thus, at 37 °C ritonavir will
be a supercooled liquid while telaprevir will be glass.
Figure 1-6 illustrates the predicted and experimental “amorphous solubility” for a group of 18
compounds.3,24-27 The predicted solubility was calculated with the Hoffman equation, Eq. (1-6) as
well as considering the heat capacity variation, Eq. (1-7). The Hoffman Equation generally predicts
accurate values, especially for compounds that are supercooled liquids at the experimental
temperature.3,25 However, there is a discrepancy between the predicted solubility with the Hoffman
equation and the experimental values for some glassy compounds, including griseofulvin and
telaprevir.3,25 Interestingly, the most accurate predicted values for the above compounds were
given when using the heat capacity change (ΔCP) from the crystal to the supercooled liquid. The
overestimation of the solubility when the ΔCP from the crystal to the glass is used can be explained
based on the different thermodynamic properties of the glass that is formed during the differential
scanning calorimetry (DSC) method, and the one that is created as a result of the precipitation
method.3,25
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Figure 1-6 Predicted and experimental amorphous solubility for a group of 18 compounds.
Figure based on values reported by Ilevbare and Taylor,24 Almeida e Sousa et al.,3 Raina et al.,26
Jackson et al.,27 and Mosquera-Giraldo and Taylor.25 Note: The amorphous solubility for
griseofulvin, ibuprofen, phenylbutazone, diclofenac, sorafenib, tolfenate, and felodipine were at
25 °C. The values reported for the other compounds, including felodipine* are at 37 °C.
Griseofulvin, telaprevir and sorafenib are glasses at the experimental temperatures.

The implications of having an amorphous precipitate instead of a crystalline one can be explained
regarding the mass flow of the drug through a side by side diffusion cell, Figure 1-7. The maximum
flux obtained for an amorphous precipitate is much higher than for a crystalline solid.25,26,28-30 The
flux increases as a function of concentration up to the LLPS or GLPS concentration of the
compound, and then a constant value is obtained.25,26,28 The mass flow is a function of the
thermodynamic activity of the drug in solution, which varies depending on the amount of free drug.
Once the limit of LLPS or GLPS is reached, the amount of free drug is steady, hence the activity
and the flux are constant.25,26 It has been recently demonstrated that this second phase acts as a
reservoir of drug that contributes to constantly replenish the free drug in solution that has
permeated.31
It has been also reported that certain formulations undergo LLPS or GLPS upon dissolution.30,3235

Particularly, formulations with a low drug loading, 10% or 30% drug; while the 50% drug

loading formulations do not undergo LLPS.32-34 As a result, it will be expected that a formulation
that undergoes LLPS will be advantageous over one that does not. There are two reported
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mechanisms about the generation of the drug-rich phase upon ASD contact with an aqueous
environment. The first one proposes that once nano-size drug domains are formed inside the ASD
matrix due to amorphous-amorphous phase separation, followed by the release of the drugdomains into solution.36 The second mechanism proposes that the drug is first released from the
ASD, followed by the drug aggregation in solution.37

Figure 1-7 Schematic showing the increase in mass flow as a function of concentration using a
side by side diffusion cell. The amorphous solubility is the limiting concentration above which
the diffusive flux is kept constant.

Incorporation of excipients to improve the stability of amorphous materials
The instability of supersaturated drug solutions is one of the leading challenges associated with
employing amorphous drugs. As a consequence, polymers are used to stabilize the amorphous
state and prolong the duration of the supersaturated solutions generated following their
dissolution.38 In essence, the polymer and drug are intimately mixed by either melting the two
components followed by quench cooling of the mixture, or dissolving both ingredients, and then
evaporating the solvent.38 At an industrial scale, the processes are hot melt extrusion39-41 and spray
drying42, respectively.
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A common question when designing an ASD is: which polymer has the optimum properties for
formulation with a particular drug? A suitable polymer must prevent crystallization of the drug in
the amorphous matrix, release the drug at the desired rate, and prevent drug crystallization from
the supersaturated solution produced by dissolution.23 Therefore, solid state and solution
crystallization studies are an essential part of the selection process for ASD polymer. Arguably,
inhibition of crystallization from solution should be assessed before solid-state stability studies,
since the ultimate goal of employing an amorphous formulation is to achieve enhanced dissolution
rates and solution concentrations.
This section shows the proposed mechanisms of the stabilization of amorphous materials by
polymers. It discusses several studies related to solid state and solution stability, in the presence
of additives such as polymers and surfactants.
1.3.1 Stabilization mechanisms of amorphous materials by polymeric additives
The stabilization mechanisms of amorphous materials are related to a reduction in the molecular
mobility of the drug molecules due to the presence of a polymer, favorable drug-polymer
interactions and the polymer hydrophobicity.
One explanation of improved stability in ASDs is the decrease in the molecular mobility of ASDs
due to the presence of a polymer, reflected by an increase in the Tg of the dispersion relative to the
drug alone.43 At temperatures below the Tg, a decrease in the molecular mobility and increase in
viscosity will cause a reduced probability of crystallization due to the slow diffusion of drug
molecules to create a crystal.
The crystallization tendency of a compound may be related to differences in viscosity, with higher
viscosities for slow crystallizers.44 However, an increase in Tg is not necessary reflected in more
stable ASDs.9 Kestur et al. did not find correlation between the Tg of the polymer used and the
crystal growth rates observed.45
Another explanation of improved stability in ASDs is the strength of the intermolecular
interactions.45-47 Crystal growth results of felodipine in the presence of four different polymers
showed a clear correlation between the strength of drug-polymer hydrogen bond interactions and
the crystal growth inhibition: felodipine-PVP had the strongest hydrogen bond interaction and the
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slowest growth.46 They found that intra and intermolecular interactions are a crucial point to
consider when choosing a polymer.45 Moreover, Trasi and Taylor showed that although the
strength and number of hydrogen bonds affect the crystal growth of flutamide, there is not a clear
trend regarding nucleation.47 Only the polymers with hydrogen bond acceptors were effective
growth inhibitors for flutamide, attributed to the unavailability of an acceptor group in flutamide
due to intramolecular hydrogen bonds.47
Interestingly, the inhibition of crystallization due to the strength of hydrogen bond interactions
between drug and polymer is, most likely, only applicable to solid-state. Although PVP prevents
crystallization and reduces crystal growth of ASDs in the solid state,45,46 it is not useful at avoiding
crystallization in solution,48-50 except for acetaminophen supersaturated solutions,51 which is
intriguing and requires further study.
Researchers have proposed that the matching of polymer and drug hydrophobicity is essential for
effective materials. Calculated solubility parameters (SP) have been used as a metric to access
polymer hydrophobicity.49 However, there is no clear trend between SP and effectiveness when
the chemical complexity of the polymer increases.
The commercially available polymers are typically highly complex, posing an obstacle for
mechanistic studies intended to identify the chemical groups that improve polymer effectiveness.
As a result, diverse analogs of hydroxypropyl methylcellulose (HPMC) and acetate succinate
(HPMC-AS) have been synthesized to discriminate the effect of each substituent.52-54 Ting et al.
demonstrated the importance of succinoyl, as well as hydroxyl substituents, in the performance of
HPMCAS analogs;53,54 and Yin and Hillmyer obtained effective polymers when HPMC esters
were substituted with succinoyl and thioethers attached to cyclohexyl and benzene groups.52 Also,
some new cellulose derivatives have been produced to determine the ability of polymers with
various degrees of hydrophobicity at inhibiting nucleation and crystal growth.55-61
AFM has been used as a tool to explain differences in crystal growth rates.62,63 They proposed that
crystal growth inhibition can be related to the polymer conformation on the surface, based on
topographical and phase images.62,63 Figure 1-8 shows that desupersaturation due to crystal growth
occurs faster in the absence of polymer. The crystal growth is reduced when HPMCAS is at neutral
pH, explained by a uniform covering of the surface due to the ionization of the carboxylic acid
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groups. In contrast globules of the polymer are observed at pH 3.0 due to self-aggregation of the
mainly unionized polymer, and the crystal-growth inhibition is reduced.62

Figure 1-8 I) Desupersaturation of felodipine solutions due to crystal growth: blue triangles:
predissolved HPMCAS at pH 6.8. Red squares: HPMCAS at pH 3. Black diamonds buffer pH
6.8. II) Schematic of polymer adsorption onto the crystal surface: the polymer is spread at
high pH and constrained at low pH. III) AFM images of a) HPMCAS adsorbed to felodipine
in pH 3, b) HPMCAS adsorbed to felodipine in pH 6.8, c) No HPMCAS. Figure adapted from
Schram et al.62
1.3.2 Impact of polymers on thermodynamic and kinetic properties
The process of crystallization from an amorphous material to a crystalline solid depends on
thermodynamic and kinetic descriptors.8,13,64 The free energy difference between the two states,
ΔGa→c, represents the thermodynamic contribution, and the free energy barrier for the conversion
from amorphous to a crystalline material, ΔGact, gives the kinetic contribution.8 This section will
focus on various experimental studies that describe how these parameters are measured for pure
amorphous materials and ASDs when evaluating crystallization in the solid state.
The thermodynamic quantities are configurational enthalpy, entropy, and free energy, Hconf, Sconf,
and Gconf, respectively, while the molecular mobility is a kinetic descriptor.64 That is, the
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configurational entropy is a measurement of the degrees of freedom of a material, materials with
higher entropy will be less likely to crystallize.64 While, the molecular mobility determines the
probability of molecular movement, hence more viscous materials have less molecular mobility,
and in theory are less prone to crystallize.64
Conflicting studies discuss the importance of thermodynamic versus kinetic descriptors. On the
one hand, these descriptors were measured for a group of five compounds, and the crystallization
tendency was in agreement with the configurational entropy and molecular mobility.64 For instance,
ritonavir has a low tendency to crystallize, in accord with the configurational entropy and
molecular mobility, and in opposition to the free energy measurements.64 On the other hand, two
chemically similar compounds and with similar Tg and molecular mobility values, nifedipine and
felodipine, have different tendencies to crystallize, attributed to the enthalpy change, a
thermodynamic descriptor.8
It has been hypothesized, that the kinetic descriptor, or free energy of activation, was the primary
determinant on the crystallization of amorphous solid dispersions of felodipine with different
polymers PVP, HPMC, and HPMCAS, and that polymers mainly influence the height of the
barrier.13
The previous studies suggest that kinetic descriptors play a significant role in influencing the
crystallization tendency of a material.13,64 However, when the molecular mobility of different
materials seems similar, thermodynamic properties are the primary determinants of the propensity
to crystallize of a compound.8 The research conducted in this area is in the solid state, and it is still
questionable if the same results will be exhibited in aqueous solutions, considering the different
polymer effectiveness results obtained when working in solid or in solution.
1.3.3 Impact of surfactants on the stability of amorphous formulations
Surfactants are commonly used to improve the dissolution behavior or to facilitate the hot melt
extrusion of ASDs.40,65,66 Thus, the crystallization behavior in surfactant-polymer-drug mixtures
needs to be studied.
The crystallization tendency of etravirine in the presence of HPMC and different types of
surfactants were explored.66 ASDs prepared with an anionic surfactant were stable while those
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with a non-ionic surfactant recrystallized, attributed to the formation of polymer-anionic surfactant
complexes, that encapsulated the drug and prevented the free drug from crystallizing.66 In contrast,
Chen et al. reported that amorphous solid dispersions of celecoxib-HPMCAS-SDS rapidly
crystalized upon contact with water.67 The increased solubility of HPMCAS in the presence of
sodium dodecyl sulfate (SDS), lead to a faster drug release, and thus a more significant driving
force to crystallize.67 Studies in the solid state also showed that surfactants enhance crystal growth,
while the simultaneous presence of polymer and surfactant improved stability.68
Crystallization induction time experiments for a group of eleven different drugs, in the presence
of surfactants, revealed that surfactants with bulky groups, e.g., sodium taurocholate (STC), were
more effective crystallization inhibitors than those with long hydrophobic chains, e.g., SDS. 67,69
Moreover, variations in the bile salt chemical structure have shown to influence their
crystallization inhibition properties; which is due to changes in the intermolecular interactions, as
demonstrated by molecular dynamics simulations.70
Lu et al. studied the impact of monomeric and micellar bile salt in the crystallization of telaprevir.71
They showed that bile salts with two or three hydroxyl groups were effective at inhibiting
crystallization when used at the monomeric level; however, dihydroxy bile salts were less effective
than the trihydroxy ones when micelles were present.71 This variation in the chemical structure not
only influenced primary nucleation, but additional processes such as secondary nucleation, and
crystal growth.33
Studies in the presence of surfactants such as SDS and bile salt have suggested that concentration
ratios are not accurate to describe the degree of supersaturation of a system. As a result, diffusion
cell measurements are required to obtain the real supersaturation, allowing to normalize the
supersaturation when comparing different systems.72,73
The in vitro testing of pharmaceutical formulations involves the use of biorelevant media to have
a better idea of the in vivo performance of the formulation.74 Some of the media used include:
fasted state simulated intestinal fluid (FaSSIF), and fed state simulated intestinal fluid (FeSSIF).
These media have different components that allow reproducing the conditions of the fasted and
fed state .75 Bile salts, precisely sodium taurocholate (STC) is used as part of these media. However,
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as described by different authors, the bile salts encountered in the human body have different
chemical structures and various abilities to inhibit crystallization.70,75
The previous studies suggest that surfactants may have different impacts on drug crystallization.
Therefore, it is essential to consider their impact when adding surfactants to a formulation, and
designing biorelevant media.

Computational chemistry simulations
In the past years, the number of computational chemistry studies in the literature has increased
considerably. Simulations offer molecular insight when experimental information is limited.76-85
There are various types of computational methods applicable to chemical systems, but the choice
will depend on the problem, the properties of interest, and the size of the system. The
computational methods that were used in this project are divided in quantum- and classical
mechanics based.
The quantum chemical calculations solve the Schrödinger equation to obtain information about
the molecular electronic structure.86,87 The electronic structure of a molecule is a rich source of
information about its fundamental properties. Electronic structure phenomena can explain
chemical interactions between molecules. Thus, this type of methods is widely used to study
chemical reactions, charge-transfer processes, and intermolecular and intramolecular interactions.
Nonetheless, these methods have a high computational cost, due to the need to numerically
approximate a solution to the Schrödinger equation.88 In particular, the electron correlation term
(electron-electron interaction) is highly demanding. The scaling of these methods that is the time
that it takes to simulate as a function of the number of electrons in the system is not linear. It will
depend on the complexity of the method, on the type of mathematical representation of the
electrons or basis set, and on the kind of property calculated. Thus, in most cases, it is impractical
to use quantum chemical calculations for systems larger than several dozen atoms.
There are different alternatives to explore larger systems such as proteins and polymers: the Monte
Carlo procedure (MC) and molecular dynamics (MD), for instance.87 A Metropolis MC algorithm
follows the next sequence: firstly, a random particle is selected, and its potential energy is
calculated, U(rN)o; then the particle is displaced, and the potential energy of the new position is
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calculated, U(rN)n; finally, Eq. (1-12) Is used as the criterion to accept or reject the move. The
calculated value, representing the energy change from the previous conformation to the new one,
is compared with a random number between 0 and 1, rand(0,1). If the calculated value is higher
than the random number, the movement is accepted, if not it is rejected.87

1-12
In MD simulations, the atoms are represented as spheres with a parametrized radius and charge,
and the bonds are modelled as springs with parametrized force constants. Then, Newton’s second
law of motion is solved to gather information about the dynamics of the system87: “The vector sum
of the forces, F, on an object is equal to the mass m of that object multiplied by the acceleration
vector a of the object: F = ma”.89
The main differences between MC and MD methods are: first, MC provides a static picture,
whereas MD evaluates the evolution of a system throughout a period; second, usually MC is most
efficient when displacing only one particle per step, meanwhile in MD usually all particles move
at every step; and finally, MC displacements are randomly accepted which allows the exploration
of kinetically-inaccessible regions of the potential energy surface (PES), while MD is limited to
the PES region surrounding the initial configuration, impeding the exploration of other kineticallyinaccessible conformations. The former is usually the most critical limitation of MD.87
A few alternatives are available to avoid entrapment around local PES minima in MD. One is
simulated annealing, a method that could offer the advantages of both methods, MD and MC. This
type of simulation consists of three stages: first, the system is heated to a high temperature; second,
the system is kept at high temperature for a lapse, such that the molecules are provided with enough
energy and time to move over an ample region of the PES; finally, the system is cooled, at an
extremely slow rate, to a given final temperature, giving a different initial conformation that can
be used to run standard MD.87
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1.4.1 Drug-polymer computational simulations
Quantum mechanical calculations of monomer-drug binding energies in the gas phase have been
one of the leading approaches to study drug-polymer interactions.77,90,91 Molecular and coarsegrained dynamics have also been used to study larger systems.76,81-85
There are multiple studies where monomer-drug binding energies are used as an estimation of
polymer effectiveness. There are two similar reported studies, the first one with felodipine-PVP
and felodipine-PEG, and the second one involved benznidazole-PVP and benznidazole-PEG. In
both cases, the most favorable energy of interaction, and the most stable dispersions were those
with PVP.90,91 Maniruzzaman et al. calculated binding energies for monomer-drug complexes and
showed evidence of these interactions using X-ray photoelectron spectroscopy (XPS).77,92
There is one study in which drug-polymer conformations are investigated using simulated
annealing in MD simulations.93 This is an interesting idea considering the exploration of multiple
structures in the potential energy surface. However, there are different properties of the system
that are unexplored, such as the radius of gyration, radial distribution functions, or thermodynamic
quantities.
Molecular and coarse-grained dynamics of drug-polymer systems are reported.

76,81-85,94,95

The

model of phenytoin with various concentrations of HPMC-AS (polymer) indicated that an increase
in polymer concentration causes a decrease in the probability of crystallization, attributed to a
reduction in molecular mobility.76 They have also studied the interactions of phenytoin with certain
copolymers using MD simulations.94 Additionally, the simulation of a tolazamide crystal in the
presence of two types of oligomers revealed that van der Waals and hydrophobic interactions
between polymer and crystal are essential for inhibiting crystal growth.85 Coarse-grained
simulations have also been used to study the crystal growth process of a model drug, phenytoin,
in the presence of a cellulose-based polymer.95 Other studies have been performed to better grasp
the mechanism of incorporation of drug molecules into polymeric carriers for nanoparticle drug
delivery systems. The enthalpy of mixing is determined and subsequently used for the calculation
of the Flory-Huggins interaction parameters, which indicates drug-polymer miscibility.81,83
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2. GLASS-LIQUID PHASE SEPARATION IN HIGHLY
SUPERSATURATED AQUEOUS SOLUTIONS OF TELAPREVIR

This chapter is a reprint with minor modifications of a manuscript published in Molecular
Pharmaceutics in December 2014 with the same title by: Laura I. Mosquera-Giraldo, and Lynne
S. Taylor.

Abstract
Amorphous solid dispersions are of great current interest because they can improve the delivery
of poorly water-soluble compounds. It has been recently noted that the highly supersaturated
solutions generated by dissolution of some ASDs can undergo a phase transition to a colloidal,
disordered, drug-rich phase when the concentration exceeds the “amorphous solubility” of the
drug. The purpose of this study was to investigate the phase behavior of supersaturated solutions
of telaprevir, which is formulated as an amorphous solid dispersion in the commercial product.
Different analytical techniques including proton nuclear magnetic resonance spectroscopy (NMR),
ultraviolet spectroscopy (UV), fluorescence spectroscopy and flux measurements were used to
evaluate the properties of aqueous supersaturated solutions of telaprevir. It was found that highly
supersaturated solutions of telaprevir underwent glass-liquid phase separation (GLPS) when the
concentration exceeded 90 μg/mL, forming a water-saturated colloidal, amorphous drug-rich phase
with a glass transition temperature of 52 °C. From flux measurements, it was observed that the
“free” drug concentration reached a maximum at the concentration where GLPS occurred, and did
not increase further as the concentration was increased. This phase behavior, which results in a
precipitate and a metastable equilibrium between a supersaturated solution and a drug-rich phase,
is obviously important in the context of evaluating amorphous solid dispersion formulations and
their crystallization routes.

Introduction
A high percentage of commercialized drugs and an even higher percentage of developmental
compounds are poorly water-soluble, which can negatively impact their bioavailability.23 The
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solubility of the crystal is determined by the crystal lattice energy and the drug−solvent
intermolecular interactions. Converting the drug to an amorphous solid can improve both the
dissolution rate as well as the maximum achievable solution concentrations2. Nevertheless, the
amorphous drug is in a high free energy state relative to the crystalline form and, thus, can undergo
crystallization.96 Consequently, amorphous solid dispersions consisting of a drug blended with a
polymeric crystallization inhibitor are used routinely to reduce crystallization rates and allow the
generation of a supersaturated solution upon dissolution of the dosage form.46,97,98 Supersaturated
solutions have been found to enhance bioavailability by increasing the rate of passive
absorption,99,100 therefore it is important to understand the properties of such solutions.
Over the past few years, the formation of colloidal aggregates in aqueous media has been the
subject of intense investigation. These aggregates have been observed to form during and interfere
with high-throughput enzymatic screens of molecule biological activity;101 this phenomenon has
been termed promiscuous aggregation.102,103 Recently, it has been suggested that the underlying
mechanism of aggregate formation is the process of liquid−liquid phase separation (LLPS)
whereby a single phase supersaturated solution forms a second disordered drug-rich phase when a
certain concentration of drug is exceeded.24 It has been further noted that, for compounds with
melting points far above ambient, the concentration at which these aggregates forms coincides
with the so-called “amorphous solubility”24 which can be estimated from the crystal solubility and
the free energy difference between the crystal and supercooled liquid forms of the compound.
Thus, these aggregates form in supersaturated rather than saturated or subsaturated solutions, and
are a precursor phase to crystallization for compounds that are solids at the temperature of interest.
In addition to their negative effects of interfering with enzymatic assays, it has been proposed that
drug-rich aggregates formed in some solutions may improve drug absorption104 and that this
second phase could act as a drug reservoir, maintaining the supersaturation at a constant and
elevated level.26 Furthermore, it has been observed that the passive diffusive flux reaches a
maximum value at the concentration where LLPS occurs, leading to a plateau in flux values at
higher concentrations.26 The implication of this observation is that there is a maximum in the free
drug concentration in solution, and an increase in concentration beyond this point leads to the
formation of drug-rich aggregates. A second implication is that there is a maximum in
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supersaturation that can be achieved and that the supersaturation does not increase further once the
aggregates form.
The majority of active pharmaceutical ingredients that have been evaluated for their potential to
form colloidal aggregates in supersaturated solutions have low glass transition temperatures (Tg).
Thus, the drug-rich phase, which typically contains a low percent water, is a supercooled liquid.
Consequently, its thermodynamic properties are reasonably well-defined.24 However, the
corresponding phase behavior of high Tg compounds, where the second phase is a glass, has not
been explored to date.
The goal of this study was to characterize the phase behavior of supersaturated aqueous solutions
of a high Tg drug, telaprevir. Telaprevir was approved in 2011 and is used in the treatment of
hepatitis C infections.105 It is a poorly soluble compound that was developed as an amorphous
solid dispersion formulation due to issues with the bioavailability of the crystalline form.105 The
crystalline form has a very high melting point of 246 °C and an aqueous solubility of 4.7 μg/mL.105
The Tg of the drug has been reported as 105 °C. In this study, highly supersaturated aqueous
solutions of telaprevir were produced using the solvent exchange method and characterized using
a variety of analytical techniques including nuclear magnetic resonance (NMR), fluorescence and
ultraviolet spectroscopies as well as dynamic light scattering (DLS). Diffusive flux as a function
of concentration was measured to evaluate how supersaturation impacted the transport rates across
a membrane.

Materials
Telaprevir (Figure 2-1) was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada).
Hydroxypropyl methyl cellulose acetate succinate grade AS-MF was obtained from Shin-Etsu
Chemical Co., Ltd. (Tokyo, Japan). 4-Di-2-ASP [4-(4-(Diethylamino)styryl)-N-methylpyridinium
iodide] was purchased from Invitrogen (Oregon, U.S.A.). Regenerated cellulose membrane with a
molecular weight cutoff (MWCO) of 6−8 kDa was acquired from Spectrum Laboratories, Inc.
(Rancho Dominguez, California). The aqueous media used in all experiments was 100 mM sodium
phosphate buffer pH 6.8 with and without 5 μg/mL HPMCAS-MF. HPMCAS-MF was used to
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inhibit crystallization over the time frame of the experiment where necessary. Telaprevir is
predominantly unionized at pH 6.8 (acid pKa of 11.8 and basic pKa of 0.31).106

Methods
2.4.1 Crystalline Solubility Measurement
An excess of crystalline telaprevir was added to 20 mL of 100 mM sodium phosphate buffer pH
6.8 with and without 5 μg/mL HPMCAS-MF. The samples were mixed at 300 rpm, 37°C for 48 h.
The solution was separated from the excess solid by ultracentrifugation at 40,000 rpm for 20 min,
using an Optima L-100 XP ultracentrifuge equipped with Swinging-Bucket Rotor SW 41 Ti
(Beckman Coulter, Inc., Brea, CA). The concentration of the supernatant was determined using a
SI Photonics UV spectrometer (Tuscon, Arizona) coupled to a fiber optic probe (path length 10
mm) at a wavelength of 270 nm. Samples were analyzed in triplicate. The standard curve presented
good linearity (r2 > 0.999) over the relevant concentration range.
2.4.2 Estimation of the Theoretical Amorphous Solubility
The amorphous solubility can be calculated if the crystalline solubility [Ceq], the activity of the
amorphous solute saturated with water [-I(a2)], and the free energy difference between crystal and
amorphous forms [∆𝐺𝑎→𝑐 ] are known as shown in Eq. 2-1.6

2-1
where T is temperature, and R is the gas constant. The Hoffman equation (Eq. 2-2) is frequently
used to estimate the last term ∆Ga→c.5

2-2
where ΔHm is the enthalpy of melting, T is the experimental temperature, and Tm is the melting
temperature. However, this approach may not be appropriate at for large undercoolings, as with a
high melting point compound such as telaprevir. For such compounds, a more appropriate method
is to consider contributions from the heat capacity difference for the different phases, as shown in
Eq. 2-3.
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2-3
where ΔCP is the heat capacity difference between the crystal and amorphous form. The melting
temperature, the glass transition temperature, the enthalpy of fusion, and the heat capacity of
crystalline and amorphous forms were measured using a TA Q2000 differential scanning
calorimeter (TA Instruments, Newcastle, Delaware). The instrument was calibrated for enthalpy
and temperature using indium and tin. 50 mL min-1 of nitrogen was used as the purge gas. A total
of 4−5 mg of the sample was added into aluminum Tzero sample pans. To obtain the melting point,
the enthalpy of fusion, and the glass transition temperature (Tg), a linear heating and cooling ramp
of 10 °C min-1 was used. For the heat capacity measurements on the crystal, glass and supercooled
liquid, modulated DSC was used; the samples were heated at a rate of 2 °C min-1 with a modulation
amplitude of 1°C min-1 every 60 s, and the values were normalized with respect to a sapphire
reference. For these measurements, the amorphous material was created in situ in the DSC pan by
cooling of the melt at 10 °C min-1. The thermal properties of the precipitate obtained by adding a
high concentration of telaprevir predissolved in methanol to buffer, followed by
ultracentrifugation, and addition of the pelleted material to a DSC pan were evaluated at a scanning
rate of 10 °C min-1.
To calculate the I(a2) term, determination of the moisture sorption profile is necessary.6 The
moisture sorption profile was determined using a symmetrical gravimetric analyzer (SGA-100)
(TA Instruments, New Castle, DE) as described previously by Hsieh et al.107
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Figure 2-1 Molecular structures of (a) telaprevir, (b) HPMCAS (c) 4-Di-2-ASP

2.4.3 UV-Visible Extinction Measurements
The formation of a drug-rich phase in solution leads to light scattering and can be detected from
an increase in the UV signal at a nonabsorbing wavelength, manifested as a change in the baseline.
A syringe pump was used to add a stock solution (6.7 mg/mL of telaprevir dissolved in methanol)
at a rate of 0.050 mL/min to 10 mL of 100 mM sodium phosphate buffer, pH 6.8 at 37 °C, stirred
at 300 rpm. The change in the signal at 370 nm was monitored using the UV spectrometer
described above using an in situ probe.
2.4.4 Dynamic Light Scattering (DLS)
To confirm the generation of a colloidal phase, DLS was used. The particle size and count rate
were measured at different drug concentrations using a Nano-Zetasizer and dispersion technology
software (DTS) (Malvern Instruments, Westborough, MA). At each concentration, the particle
size and the count rate were monitored over 20 min with measurements taken every 2 min.
Experiments were performed using a quartz flow-through cuvette provided by Malvern
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Instruments, coupled with a MasterFlex Easy-Load peristaltic pump (Cole Parmer, Vernon Hills,
IL).
2.4.5 Fluorescence Spectroscopy
In order to determine the concentration where telaprevir forms drug-rich aggregates, an
environmentally sensitive fluorescence probe was employed. Fluorescence spectra were acquired
using a RF-5301 PC Spectrofluorophotometer SHIMADZU (Tokyo, Japan). 4-Di-2-ASP was used
as the environment-sensitive fluorescence probe; its emission maximum wavelength and intensity
are dependent on the polarity of the local environment. Samples were prepared by adding a
specific amount of the stock solution (7 mg/mL) to 10 mL of 100 mM sodium phosphate buffer
pH 6.8 containing 5 μg/mL HPMCAS-MF (to prevent crystallization during the experiment) and
3 μg/mL 4-DI-2-ASP. The amount of stock solution was gradually increased to obtain telaprevir
concentrations between 20 μg/mL and 160 μg/mL. Emission spectra were obtained by exciting the
sample at 488 nm, with a 15 nm excitation slit width and 5 nm emission slit width. The change in
the emission maximum wavelength and intensity was measured as a function of concentration.
2.4.6 Proton Nuclear Magnetic Resonance (NMR) Spectroscopy
One-dimensional solution proton NMR spectroscopy is a useful technique to determine the
concentration of the chemical species in solution, and therefore it was used to confirm the
concentration where the drug-rich aggregates formed. NMR samples were prepared by mixing 4
mL of 100 mM sodium phosphate buffer pH 6.8 containing 5 μg/mL HPMCAS-MF and 1 mL of
deuterium oxide (D2O) with different amounts of telaprevir stock solution (7 mg/mL) to obtain
concentrations between 40 μg/mL and 200 μg/mL. An aliquot of 500μL of each sample was then
analyzed in an NMR tube. A Bruker AVANCE DRX500 spectrometer equipped with an inverse
proton cryoprobe and single axis (z) gradient was used to conduct the NMR experiments at 37 °C.
Each sample was monitored for 16 min, and 128 scans were collected for each spectrum with an
interscan delay of 5 s. This procedure was done in triplicate. The sweep (spectral) width was 14
ppm and 16,384 complex points for the time domain data were obtained. Three peaks were
integrated (9.13, 8.81, and 8.74 ppm) to calculate the relative concentration of telaprevir using
water as the reference. An apodization function (1 Hz exponential line broadening), Fourier
transformation, manual phasing, and baseline corrections were applied.
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2.4.7 Diffusion Rate Experiments
The diffusive flux of telaprevir solutions at 37 °C was evaluated using a side-by-side diffusion cell
(PermeGear, Inc. Hellertown, Pennsylvania) of a 34 mL volume (each compartment) and 30 mm
orifice diameter as shown in Figure 2-2. The donor and receiver cell were separated by a
regenerated cellulose membrane with a MWCO of 6−8KDa. Each compartment contained 32 mL
of 100 mM sodium phosphate buffer pH 6.8 with 5 μg/mL HPMCAS-MF. Various amounts of the
telaprevir stock solution (7 mg/mL) were added to the donor compartment to obtain concentrations
ranging from the crystalline solubility to above the amorphous solubility.
A fiber optic probe (path length 10 mm) coupled to a UV spectrometer was inserted into the
receiver cell and the change in absorbance as a function of time was measured at a wavelength of
270 nm. The slope of a plot of concentration vs. time was used to determine the flux value. The
experiments were conducted under sink conditions; the maximum concentration obtained in the
receiver compartment was less than one-half of the crystalline solubility.
As shown in Eq. 2-4, the mass flux rate (F), is directly related to the diffusion coefficient (D), the
membrane cross-sectional area (S), and the thermodynamic activity of the solute (a) and is
inversely related to the membrane thickness (ℎ) and the activity coefficient of the drug in the
membrane (𝛾𝑚 ). For all the experiments, D, S, ℎ, and 𝛾𝑚 are constants, and hence, the differences
in mass flow rate are due to changes in the solute thermodynamic activity. This in turn will depend
on the concentration (C) and the activity coefficient of the drug in the bulk solution (donor
compartment), given by Eq. 2-5.

2-4
2-5
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Figure 2-2 Schematic of the diffusion cell

Results
2.5.1 Phase Behavior of Supersaturated Solutions of Telaprevir
The melting point and enthalpy of fusion of crystalline telaprevir were 238 °C (onset) and 55.8
kJ/mol, respectively, whereas the Tg of amorphous telaprevir prepared by melt quenching was 103
°C. The equilibrium solubility of crystalline telaprevir was found to be 4.6 μg/mL. This value is in
good agreement with the value of 4.7 μg/mL reported by Kwong et al.105 Addition of different
amounts of telaprevir to aqueous buffer yielded initially clear solutions until the concentration
generated exceeded around 90 μg/mL; at these higher concentrations, the solutions were visually
turbid, indicating the formation of a scattering phase, but with no obvious particles. These solutions
developed visible particles after approximately 15 min; these particles were birefringent when
examined under polarized light. The turbid solution could be maintained for several hours by
adding a small quantity of the polymer, HPMCAS, which was subsequently used in some
experiments so that the properties of the scattering phase could be better evaluated. DSC analysis
of the material pelleted from turbid solutions by ultracentrifugation showed the presence of a Tg
event at 52 °C. The estimated water content of telaprevir at 100% RH was ~ 4.6% based on the
moisture sorption profile obtained for a melt quenched glass. Therefore, the Tg of the precipitated
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material is consistent with amorphous telaprevir phase containing a few percent water. It has been
noted previously that for each 1% of sorbed water, the Tg will be drop by approximately 10
°C.8,24,108 Figure 2-3 summarizes the thermal properties of telaprevir and shows that under the
experimental conditions of this study, an amorphous precipitate of telaprevir is a glass rather than
a supercooled liquid.

Figure 2-3 Adapted enthalpy vs. temperature diagram.5 The figure shows that telaprevir will be a
glass at experimental temperatures.
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Table 2-1 Physicochemical properties for Telaprevir
MW
(g/mol)

679.85

Log P

4.0

ɑ

Melting point
(°C)

238

Enthalpy of
fusion

Tg (°C)b

Tg (°C)c

103

52

(kJ/mol)
55.8

Moisture
Sorption (%)d

exp [-I(ɑ2)]e

4.31

0.30

ɑ

Value from Kwong et al.105
Glass Transition Temperature for pure telaprevir.
c
Glass Transition Temperature for amorphous precipitate.
d
Percent moisture gain at 95% relative humidity determined experimentally.
e
Activity of moisture saturated supercooled liquid (amorphous material).
b

2.5.2 UV-Extinction Measurements
To determine the concentration at which the second phase was created, different analytical
techniques were employed. Figure 2-4 shows the result of a UV experiment, in which the increase
in extinction at 370 nm (where telaprevir has no absorbance) as a function of concentration was
monitored. At low telaprevir concentrations, there is minimal light scattering, as expected for a
visually clear solution. However, after concentrations of 92 ± 2 μg/mL, the scattering increases
rapidly due to the formation of a second phase. DLS experiments (data not shown) showed that at
approximately the same concentration, a sudden increase in the count rate occurred. The initial
size of the species formed was approximately 300 nm based on the DLS measurements.
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Figure 2-4 GLPS concentration of telaprevir determined by UV extinction. The figure shows an
increase in the scattering at 370 nm when the second phase is generated.

2.5.3 Environment Sensitive Fluorescence Probes
Fluorescence spectroscopy in combination with an environmentally sensitive probe, in this case,
4-Di-2-Asp, can be used to probe the formation of drug aggregates.24 It is well known that there is
a wavelength shift (Stokes shift) between the excitation and emission spectrum that is attributed
to solvent reorganization to allow favorable dipole interactions with the dye in the excited state.109111

The more polar the medium, the greater the Stokes shift, or in other words, the peak of the

emission spectrum appears at a higher wavelength in a polar solvent relative to a nonpolar solvent.
In the context of the system under evaluation in this study, it is expected that if a disordered
telaprevir phase is formed, the hydrophobic dye will partition into this phase, reducing the
concentration in the aqueous phase. Thus, the extent of the Stokes shift will be reduced causing a
blue shift with respect to the initial emission peak for the probe in pure buffer. Figure 2-5 shows
the emission spectrum of the probe at different telaprevir concentrations. It is apparent that when
the telaprevir concentration exceeds ~90−100 μg/mL, the peak maximum undergoes a blue shift,
as well as sudden increase in intensity. The peak position and intensity are plotted in Figure 2-6,
which clearly shows the increasing blue shift in peak maximum with increasing telaprevir
concentration at concentrations greater than 90 μg/mL and the coincident intensity increase.
Subsequently reducing the telaprevir concentration to 70 μg/mL resulted in a red shift of the probe
emission spectrum suggesting that the drug aggregates had dissolved. After dilution, about 2 min
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was required for the fluorescence spectrum to revert to the original wavelength demonstrating that
the drug aggregates dissolve rapidly. Because the telaprevir aggregates are glassy, we wanted to
also check that the probe was not being entrapped during the formation process. Thus, aggregates
were formed in the absence of the probe molecule, and the probe molecule was subsequently added
to the solution. The resultant fluorescence spectrum was identical to that obtained previously. An
additional control experiment, where impact of crystalline telaprevir on the probe emission
spectrum was evaluated, showed no blue shift. These data, therefore, support the supposition that
when the telaprevir concentration exceeds 90 μg/mL, the probe is present in a more hydrophobic
environment, consistent with the formation of a disordered telaprevir-rich phase.

Figure 2-5 Fluorescence emission intensity of 4-Di-2-ASP at different telaprevir concentrations.
The figure shows a hypsochromic or blue shift (to shorter wavelengths) after the GLPS
concentration as a result of the change in polarity environment for the fluorescence probe.
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Figure 2-6 Wavelength and intensity of the 4-Di-2-ASP emission peak as a function of telaprevir
concentration. The figure shows that after the GLPS concentration, ~90 μg/mL, the maximum
wavelength is shifted to shorter wavelengths and the intensity of the emission peak increases.

2.5.4 Nuclear Resonance Spectroscopy
It has been pointed out that NMR is a good technique to detect promiscuous aggregators because
these slow-tumbling assemblies produce “unusual” spectra caused by the molecules proximity.112
Furthermore, a very broad resonance would be expected from large colloids,112 and if the NMR
lines are very broad, it may be hard to detect them.113 The intensity of the NMR peaks will be
affected by the spin−spin relaxation time (T2). Eq. 2-6 describes an inverse relationship between
T2 and the correlation time (τc). The latter term depends on the particle size (r) and viscosity of the
medium (η) as shown in Eq. 2-7.114

2-6

2-7
As explained by Resing,115 a distribution of correlation times could be related to an apparent phase
transition; in this case, we will have two populations of telaprevir molecules, the fast-moving
molecules (present in aqueous phase) and the slow moving molecules (in the drug-rich glassy
aggregates). According to the DLS data, the second phase will have aggregates greater than 300
nm (particle diameter), and a high viscosity is expected at 37 °C because the material is in the
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glassy state, hence a fast T2 is anticipated for molecules in the telaprevir-rich phase which the
instrument will not be able to resolve. As a consequence, T2 will be mainly determined by the
population of telaprevir molecules in the aqueous solution, and therefore, after the second drugrich phase is generated, it is expected that the peak intensity will remain constant, independent of
how much additional telaprevir is added to the medium. In Figure 2-7, the concentration
determined from the NMR spectra by integration of the peaks is plotted against the added
concentration. It is apparent that for telaprevir concentrations greater than ~90 μg/mL, the NMR
concentration reaches a plateau. Thus, addition of telaprevir at concentrations higher than 90
μg/mL does not lead to an increase in telaprevir in the aqueous phase but increases the amount of
the telaprevir-rich phase, which is not detected by the NMR instrument, leading the observed
plateau.

Figure 2-7 NMR concentration as a function of the added concentration. The result shows that
after the GLPS concentration ~92 μg/mL, the NMR concentration reaches a plateau.

2.5.5 Diffusive Flux as a Function of Concentration
The passive diffusion of telaprevir through a cellulose acetate membrane was measured to study
the relationship between flux and telaprevir concentration. Figure 2-8 shows the change of the
concentration as a function of time in the receiver compartment, and from the slope of these curves,
the flux was determined at each donor concentration level. Figure 2-9 shows the change in the
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diffusive flux as a function of telaprevir concentration. For the range 5 μg/mL−90 μg/mL, the flux
increases linearly with concentration. At concentrations higher than 90 μg/mL the flux reaches a
plateau; it is relatively independent of the amount of telaprevir added. A similar pattern of behavior
has been observed for supersaturated solutions of felodipine and nifedipine, where a maximum in
the flux is reached at some concentration.26

Figure 2-8 Concentration versus time profile for telaprevir in the receiver compartment. The
slope of the concentration versus time plot represents the flux.

Figure 2-9 Diffusive flux versus concentration for telaprevir. The figure shows a linear increase
in the flux up to the GLPS concentration, after this one the flux reaches a plateau.

37

Table 2-2 Crystalline solubility, Estimated Amorphous Solubility and GLPS Concentration
Measured Using Different Analytical Techniques at 37°C.
Crystalline

Crystalline

GLPS concentration (μg/mL)

solubility (μg/mL)

Solubility

Solubility
(μg/mL)

Estimated amorphous

w/HPMCAS
5μg/mL (μg/mL)

ɑ

b

c

UV

NMR

Fluorescence

4.7±0.2

245±5

97±8

189±16

92±2

92±2

90±1

4.6±0.1

n=3; errors indicate one standard deviation.
ɑ
Using Hoffman Equation.
c
Considering heat capacity variation from the crystal to the supercooled liquid.
c
Considering heat capacity variation from the crystal to the glass.

Discussion
Based on the various experimental results (summarized in Table 2-2), a noncrystalline phase of
telaprevir is formed in aqueous media when the concentration exceeds 90 μg/mL. It has been
observed for compounds that phase separate as supercooled liquids that the concentration where
the drug-rich phase is formed is in good agreement with the estimated amorphous solubility of the
compound, calculated using Eq 2-1. Furthermore, it has been found that the use of the Hoffman
equation will generally provide a reasonable estimate of the free energy difference between the
amorphous and crystalline phases and, hence, good agreement between the predicted and
experimentally observed amorphous solubilities.24,26 However, the predicted value for the
amorphous solubility of telaprevir was 245 ± 5 μg/mL using the free energy estimate obtained with
the Hoffman equation. This value is a factor of 2.7 higher than the experimentally observed value.
The large difference between the observed and predicted value most likely arises because of the
high melting point of telaprevir relative to the experimental temperature; the Hoffman equation
was derived based on the assumption that the temperature of interest is reasonably close to the
melting point, an assumption that is clearly violated for the telaprevir system. Therefore, the
amorphous solubility was predicted using a more rigorous method to estimate the ΔG term in Eq
2-1. This method took into account changes in the heat capacity difference between the crystal and
the glass, and the crystal and the supercooled liquid and yielded an amorphous solubility estimate
of 189 ± 16 μg/mL. This value is still a factor of 2.1 higher than the experimentally observed value.
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The most likely reason for this discrepancy is that the glass formed during the precipitation
experiment has different thermodynamic properties from the glass formed in the DSC by quench
cooling and used to determine the heat capacity differences shown in Eq 3. More specifically, it is
expected that the glass formed in the DSC has a greater excess enthalpy and entropy than the glass
formed in solution. Hence we applied a third calculation method where it was assumed that the
free energy difference could be approximated using the heat capacity difference between the
crystal and the supercooled liquid, extrapolating the properties of the supercooled liquid to the
experimental temperature. Here, the assumption made is that the glass formed in an aqueous
environment is highly relaxed and has similar thermodynamic properties to a supercooled liquid
at the same temperature. This calculation yielded a value of 97 ± 8 μg/mL, which is in good
agreement with the experimental results. Similar agreement between experiment and predictions
for two additional high Tg compounds using this approach has been seen in our lab.
Based on our results with telaprevir, it appears that high Tg drugs behave similarly to lower Tg
compounds, in that when the amorphous solubility is exceeded, and in the absence of
crystallization, rapid unmixing of the homogeneous solution to form a disordered drug-rich phase
dispersed in a drug-lean phase occurs. In the case of telaprevir, because the Tg of the second phase
formed in aqueous solution is higher than the experimental temperature, the drug-rich phase is a
glass rather than a supercooled liquid. However, the properties of the system containing a glassy
drug-rich phase appear very similar to systems containing a drug-rich phase that is a supercooled
liquid. Thus, the telaprevir-rich phase forms at a specific and reproducible concentration, its
redissolution is rapid following dilution (within 2 min), and due to the disordered nature,
environmentally sensitive fluorescent probes can readily partition into the glassy phase, registering
a more hydrophobic environment. Crystallization also occurs fairly quickly from solutions
containing drug-rich amorphous particles; in the absence of a polymeric inhibitor, telaprevir
solutions crystallized within approximately 15 min.
Of particular interest are the flux measurements. The crystal solubility of telaprevir is around 5
μg/mL, so increasing the solution concentration beyond this value yields a supersaturated solution.
In line with previous studies, a linear relationship between flux and supersaturation is observed116
over a certain supersaturation range. This is important in the context of passive absorption.
Supersaturated solutions have been found to enhance bioavailability of drugs with solubility-
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limited absorption.117 Furthermore, the degree of supersaturation is likely to be important in
determining the extent of enhancement in absorption.118 However, it is clear that we cannot
indefinitely increase the supersaturation and, hence, the flux. Thus, the linear relationship between
flux and concentration breaks down once the amorphous solubility is reached (Figure 2-9), and no
further enhancement in flux is seen above this concentration; similar results have been found for
supersaturated solutions of felodipine and nifedipine.26 Hence, the maximum supersaturation ratio
that can be achieved is dictated by the amorphous solubility and is approximately 18 for telaprevir
at 37 °C. Supersaturation does not increase once the drug-rich phase forms because there is an
equilibrium between the drug-rich and the drug-lean phases so that when more drug is added, the
concentration in the drug-lean phase remains constant, and the amount of the drug-rich phase
increases. This can be clearly seen from Figure 2-9 where a solution of a total concentration of 130
μg/mL has the same flux as a solution with a concentration of 90 μg/mL. The split of the system
into two liquid-like phases occurs in a metastable region of the phase diagram as discussed by
Bonnet et al.,119 because it is supersaturated with respect to the crystalline form, and crystallization
can occur at any time. Hence the amorphous precipitate is a precursor phase. Such metastable
precursors, both amorphous and crystalline are commonly observed in highly supersaturated
solutions and have been extensively studied in inorganic systems,120,121 in particular in the area of
biomineralization where amorphous precursor phases are commonly observed.122 Understanding
such precursor phases is also important in terms of characterizing the crystallization behavior of
API solutions, in particular, because the supersaturation is correlated to the solid phase present.
Clearly in the case of telaprevir, when high supersaturation is rapidly generated, phase separation
to a relatively short-lived disordered phase occurs prior to crystallization.
The results presented herein, thus, are important for understanding the phase behavior of
supersaturated solutions produced using solubility enhancing formulations such as amorphous
solid dispersions. This is particularly relevant for telaprevir because its commercial formulation is
as an ASD. Our data suggest that if an ASD formulation dissolves in a given medium to produce
a concentration greater than the amorphous solubility in that medium, then precipitation will be
observed. This precipitation is not necessarily an indication that crystallization has occurred, but
instead could occur through the process of liquid−liquid (or in the case of telaprevir, glass−liquid)
phase separation, and when this occurs, the solution is maximally supersaturated. Thus, the
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resultant membrane flux will be at the maximum value for the system that contains a noncrystalline
precipitate. As discussed previously,26,123 this precipitate will also provide a reservoir, maintaining
the supersaturation at the maximum value.

Conclusion
The maximum achievable supersaturation for aqueous telaprevir solutions is limited by the
amorphous solubility. If this concentration is exceeded, a drug-rich phase evolves rapidly in
solution, leading to the formation of turbid solutions. The maximum free drug concentration was
measured using a variety of techniques and found to be approximately 18-fold higher than the
crystal solubility at 37 °C. The drug-rich aggregates formed in telaprevir solutions are glassy
particles based on measurement of the precipitate glass transition temperature. However, they were
found to dissolve rapidly upon dilution. The membrane flux was observed to increase linearly up
to the concentration where the drug-rich aggregates evolved and then attained a plateau. The flux
at the plateau was approximately 18-fold greater than that obtained from a saturated solution.
Determining the phase behavior of supersaturated solutions is important for understanding
enhancements in bioavailability achieved with amorphous solid dispersions and other
supersaturating dosage forms.
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3. MECHANISTIC DESIGN OF CHEMICALLY DIVERSE POLYMERS
WITH APPLICATIONS IN ORAL DRUG DELIVERY

This chapter is a reprint with minor modifications of a manuscript published in Biomacromolecules
in October 2016 with the same title by: Laura I. Mosquera-Giraldo, Carlos H. Borca, Xiangtao
Meng, Kevin J. Edgar, Lyudmila V. Slipchenko, and Lynne S. Taylor.

Abstract
Polymers play a key role in stabilizing amorphous drug formulations, a recent strategy employed
to improve solubility and bioavailability of drugs delivered orally. However, the molecular
mechanism of stabilization is unclear. Therefore, the rational design of new crystallizationinhibiting excipients remains a substantial challenge. This article presents a combined
experimental and computational approach to elucidate the molecular features that improve the
effectiveness of cellulose polymers as solution crystallization inhibitors, a crucial first step towards
their rational design. Polymers with chemically diverse substituents including carboxylic acids,
esters, ethers, alcohols, amides, amines, and sulfides were synthesized. Measurements of
nucleation induction times of the model drug, telaprevir, show that the only effective polymers
contained carboxylate groups in combination with an optimal hydrocarbon chain length.
Computational results indicate that polymer conformation as well as solvation free energy are
essential determinants of effectiveness at inhibiting crystallization, and show that simulations are
a promising predictive tool in the screening of polymers. This study suggests that polymers need
to have adequate hydrophilicity to promote solvation in an aqueous environment, and sufficient
hydrophobic regions to drive interactions with the drug. Particularly, the right balance between
key substituent groups and lengths of hydrocarbon sidechains is needed to create effective
materials.

Introduction
The increasing number of new drugs with low aqueous solubility poses a challenge for their oral
delivery, since a bioactive substance must be dissolved to have a therapeutic effect.23,124,125 This
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has bolstered the interest in amorphous materials, i.e. solids that lack long-range, threedimensional order, as a strategy to improve drug solubility and bioavailability.23,124-126 However
the amorphous form of a drug is thermodynamically unstable due to its high free energy, and it
will eventually crystallize, decreasing its solubility.96 Polymers can be employed to stabilize the
amorphous state of a drug and prolong the duration of the higher drug concentrations achieved in
an aqueous medium following dissolution.38 In essence, the polymer and the drug are intimately
mixed, and the resultant polymer-drug molecular blend is typically referred to as an amorphous
solid dispersion (ASD).23
Perhaps the most important question when designing an ASD is: which polymer is best suited for
formulation with a specific drug? Unfortunately, polymer selection is still largely empirical, 127
and the majority of marketed ASDs are formulated with the same limited set of commercially
available polymers. The lack of chemical diversity of polymers used in these formulations,
combined with the increasing interest in ASDs, has stimulated the creation of materials with
optimized properties for crystallization inhibition of drugs.49,53-55,128 Nonetheless, the
understanding of how chemical modifications to the polymer impact its effectiveness is incomplete,
posing an obstacle for the rational selection of existing polymers and the design of new ones.
The complexity of commercial cellulose polymers impedes mechanistic studies to identify the
chemical groups that most improve polymer effectiveness. As a result, diverse analogs of
hydroxypropyl methyl cellulose (HPMC) and acetate succinate (HPMCAS) have been synthesized
to determine the effects of each substituent.52-54 Ting, et al. demonstrated the importance of
succinoyl, as well as alcohol substituents, in the performance of HPMCAS analogs;53,54 and Yin
and Hillmyer obtained effective polymers when HPMC esters were substituted with succinoyl and
thioethers attached to cyclohexyl and benzene groups.52
In recent years, a number of cellulose derivatives have been produced, taking advantage of
innovative synthetic approaches.55-58,60,61,129,130 The ability of these polymers to inhibit the
crystallization of poorly water-soluble drugs has been evaluated in turn.49,50 Ilevbare, et al.
reported nucleation induction times for three model drugs in the presence of newly synthesized
and commercial polymers.49 Some of these new polymers were equally or more effective than their
commercial counterparts, an improvement explained by a good match between the solubility
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parameter of drug and polymer.49 In addition, the polymers were effective at reducing crystal
growth,48 due to the favorable adsorption of the polymer on the crystal surface, as corroborated by
recent studies employing atomic force microscopy (AFM).62,63 It was further proposed that crystal
growth inhibition can be related to the conformation of the polymer on the surface.62,63
Although several cellulose-based polymers have been studied previously regarding their ability to
delay nucleation, they were chemically similar: cellulose ester substituents with various
hydrocarbon lengths and a carboxylic acid termination. Recent development in innovative
cellulose modification methods by Meng et al., including hydroboration-oxidation,60 olefin crossmetathesis,56-58 and a double modification strategy by post cross-metathesis thiol-Michael
addition,130 provide an opportunity to obtain a variety of functionalized cellulose derivatives.
Investigating polymers with greater chemical diversity enables deeper fundamental insight into
structure-property-activity relationships, which in turn helps inform the design of new materials,
and will ultimately lead to rational, rather than empirical, polymer selection.
There are significant limitations in the current approach to design new, effective polymers. Certain
properties of existing polymers have been recognized to be important. For example, one approach
has been optimizing solubility parameter.49,61,131 Tuning the glass-transition temperature has been
another approach. Carboxylic and bulky groups have been identified as features impacting polymer
performance.49 However, when exploring polymers with significantly different chemical or
structural modifications, there is no clear correlation between these properties and their
effectiveness. Thus, determination of the effectiveness of newly synthesized polymers is an
expensive trial and error process. A deeper understanding of the underlying chemistry of these
systems is required to overcome those limitations.
Computational techniques, such as molecular dynamics (MD) simulations and quantum chemical
calculations offer an alternative perspective to explore the chemistry of these polymers in atomistic
detail. There is a small number of modeling studies related to ASDs, despite its importance in the
area of oral drug delivery. Anwar et al. performed Lennard-Jones MD simulations showing that
the effectiveness of an additive at inhibiting nucleation is dependent on a balance between the
degree of self-interaction of the additive and on the additive-solute affinity.132 Jha, et al. performed
MD simulations with phenytoin and HPMC with and without acetate and succinate groups.76 They
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showed that an increase in polymer concentration causes a decrease in the probability of
crystallization, possibly due to a reduction in the molecular mobility.76 Gao and Olsen simulated
a tolazamide crystal in the presence of two types of oligomers and reported that van der Waals and
hydrophobic interactions between polymer and crystal influence crystal growth inhibition.85 There
are also reports of simulations that calculate monomer-drug binding energies; and drug
encapsulation in polymeric carriers.77,81,84,92
Herein we present a combined experimental and computational approach to illuminate, from a
molecular level, factors that may impact polymer effectiveness. We explore how chemically
diverse substituents influence the effectiveness of cellulose polymers as crystallization inhibitors.
The chemical substituents include carboxylic acids, esters, ethers, alcohols, amides, amines, and
sulfides. Telaprevir, a protease inhibitor used in the treatment of hepatitis C, and formulated as an
ASD due to its poor aqueous solubility, is used as the model drug compound.105 The experimental
work provides information about which chemical modifications generate polymers with the best
crystallization inhibitory properties for this compound. Computational modeling is used to
rationalize how changes in the chemical structure influence intramolecular interactions in the
polymer, which in turn explain variations in crystallization inhibition effectiveness. Our
contribution constitutes a generalizable example of how computational simulations, aimed at
guiding polymer synthesis, permit the design of new materials and optimization of future
pharmaceutical formulations.

Materials
Telaprevir was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada). The
commercially available polymers (Table 3-1) were obtained from various suppliers: HPMC 606
grade, and HPMCAS-MF (Shin-Etsu Chemical Co., Ltd, Tokyo, Japan); PVP K29/32, PAA, CAPh,
and pectin from citrus peel (Sigma-Aldrich Co St. Louis MO); Eudragit L100 (Degussa, Rohm
GmbH & Co. KG, Germany); and PVP-VA K28 (BASF, Germany). The new cellulose-based
polymers (Figure 3-1 and Table A1 in the Appendix A) were synthesized as described in the next
subsection.
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The aqueous media used in all experiments was 100 mM sodium phosphate buffer pH 6.8 prepared
by adding 6.956 g sodium phosphate dibasic anhydrous and 7.0375 g monosodium phosphate
monohydrate in 1 L of DI water.

Table 3-1 Abbreviations of commercially available polymers
Polymer

Abbreviation

Poly(vinylpyrrolidone) (K 29/32)

PVP

Polyacrylic acid

PAA

Poly (vinylpirrolidone vinyl acetate) (K 28)

PVPVA

Cellulose acetate phthalate

CAPhth

Hydroxypropyl methyl cellulose

HPMC

Hydroxypropyl methyl cellulose acetate succinate (AS-MF)

HPMCAS

Eudragit L100

EUD L100

Methods
3.4.1 Polymer Synthesis
The newly synthesized polymers are summarized in Table A1 in the Appendix A, and their
chemical structures are shown in Figure 3-1. In most cases, their syntheses have been previously
described by us, and the original references are given below. These polymers were classified
depending on the synthesis method employed.
For the synthesis of polymers 1 to 6 (Table A1), monobenzyl adipoyl/suberoyl/sebacoyl chlorides
were synthesized from adipic/suberic/sebacic acids respectively.55 The afforded acid chloride was
then employed in esterification reaction with a commercial cellulose ester, e.g., cellulose acetate,
to give a benzyl cellulose ester. The final cellulose ω-carboxyalkanoate was afforded by
hydrogenolysis of the benzyl protecting group using Pd(OH)2/C as a catalyst in a H2 atmosphere.55
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Polymers 7 to 18 were prepared as previously described.56-60 Commercially available cellulose
esters (cellulose acetate CA-320S, cellulose acetate butyrate CAB-553-0.4, and cellulose acetate
propionate CAP-504-0.2) were esterified with two terminally olefinic acid chlorides, i.e. pent-4enoyl chloride or undec-10-enoyl chloride, to be used as the starting materials for olefin crossmetathesis (CM). Three reaction pathways were then sorted for the synthesis of three groups of
polymers.
Reaction pathway 1: For polymers 7 and 11 to 14, CM of the starting materials with different
partners (acrylic acid, 2-hydroxyethyl acrylate, poly(ethylene glycol) methyl ether acrylate, and
acrylamide)56-58 was performed to give various functionalized cellulose esters. A subsequent
hydrogenation step using either H2-Pd/C56 or p-toluenesulfonyl hydrazide58 was performed to
eliminate the α,β-unsaturation and give stable products.
Reaction pathway 2: For polymers 15 to 18, CM of the starting materials with partners (2hydroxyethyl acrylate and [2-(acryloyloxy)ethyl]trimethylammonium chloride) was first
conducted. Instead of eliminating the α,β-unsaturation by hydrogenation, hydrothiolation (the
addition of a thiol across a double bond) was performed by thiol-Michael addition reaction
between 2-mercaptoethanol or 3-mercaptopropoinic acid and the α,β-unsaturation on the polymer
sidechain.130 Using this double modification method, the cellulosic sidechain can bear two types
of functional groups. Although CM reaction has proven powerful and gave mostly complete
conversion to various CM substrates, this was not the case when reacting short chain terminal
olefin (CA-Pen079) with [2-(acryloyloxy)ethyl]trimethylammonium chloride to synthesize CAPen079-TMA. This is probably due to repulsion between trimethylammonium cationic moieties
that are held nearby by the short ethers to the cellulose backbone. Long side-chain derivatives such
as CA-Un067 did not display such an issue since the longer chains permit larger spacing between
charges. Thus, CA-Un067-TMA and the related derivatives were synthesized successfully.
Definitions of these polymer abbreviations (reported in previous articles) relative to the ones
shown in Table A2 can be found in the Appendix A.
Reaction pathway 3: For polymers 8 to 10, the sidechain terminal olefins on the starting materials
were transformed quantitatively to hydroxyl functionality by hydroboration-oxidation reaction.60
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3.4.2 Solubility Parameter (SP) Calculations
SP values were calculated by the Fedor’s method and following a procedure similar to that
of Babcock, et al.131,133 It considers the energy of vaporization, molar volume and the degree of
substitution for the diverse substituents. The SP calculation procedure is described in detail in the
supporting information in the paper by Dong et al.61
3.4.3 Nucleation-Induction Time Experiments
The newly synthesized cellulose polymers were predissolved by adding a small amount of
organic solvent (Table A1 in the Appendix A), followed by sonication until complete dissolution
was achieved. Then, sodium phosphate buffer pH 6.8 100 mM was added, and the solution was
further sonicated. Polymer solutions were visually inspected to verify that the polymers were
soluble at the concentration used (5 μg/mL and/or 50 μg/mL). Commercially available polymers
were directly dissolved in buffer.
The experimental nucleation time (tind) is defined as the sum of the time for critical nucleus
formation (tn) and for growth to a detectable size (tgrowth) Eq. (3-1).
3-1
It has been previously reported that when telaprevir concentration in solution exceeds ~90-100
μg/mL a drug-rich phase is created, which consists of spherical aggregates with sizes in the range
of 200-400 nm.25 This second phase is glassy in nature due to the high temperature glass transition
of telaprevir. Consequently, the process of phase separation which occurs when the binodal
concentration is exceeded is termed glass-liquid phase separation (GLPS).3,25 Because the presence
of a second phase is likely to impact nucleation kinetics, by providing interfaces for heterogeneous
nucleation, it is important to evaluate the effectiveness of polymers as nucleation inhibitors at
supersaturations below and above where GLPS occurs, to compare and contrast crystallization in
a homogeneous solution (molecularly dissolved drug) and a two phase solution (molecularly
dissolved drug and drug-rich particles).
Supersaturated solutions were prepared by adding 80 or 150 μg/mL of a telaprevir (TPV)
methanolic stock solution (7 mg/mL) to 47 mL phosphate buffer (pH 6.8, 100 mM) held at 37 ˚C
using a 50 mL jacketed flask coupled to a water bath, with magnetic stirring at 300 rpm.
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The crystallization induction time from unseeded samples was measured using an SI Photonics
UV/vis spectrometer (Tucson, Arizona) coupled to a fiber optic probe (path length 5 and 10 mm).
Measurements were recorded every minute at two wavelengths: the maximum UV absorbance
wavelength of TPV (270 nm) and a non-absorbing wavelength (370 nm) to accounts for
fluctuations in scattering caused by the existence of a second phase. The difference in absorbance
between the two wavelengths was converted to concentration by using a standard curve with good
linearity (R2 > 0.999).
For experiments performed at 80 μg/mL TPV, which is below the GLPS concentration for
telaprevir, the increase in the non-absorbing wavelength (370 nm) and the decrease in the
absorbing wavelength (270 nm) were taken as the induction times. For experiments performed at
150 μg/mL TPV concentration, the non-absorbing wavelength was not used since scattering
centers are already present in the solution, hence induction times were inferred from changes in
the signal at 270 nm.
3.4.4 Scanning Electron Microscopy (SEM)
Liquid samples were extracted from the induction time experiments, added to a coverslip, and
placed into the vacuum oven to remove any remaining liquid. Next, the samples were sputtered
with platinum for 120 seconds and imaged with a FEI NOVA nanoSEM field emission SEM
(Hillsboro, Oregon), using an Everhart−Thornley detector (ETD) and through-the-lens detector
(TLD). The parameters were 5 kV accelerating voltage, ∼ 5 − 6 mm working distance, beam spot
size of 3, 30 μm aperture and magnifications in the 5,000 − 30,000× range.
3.4.5 Computational Simulations
3.4.5.1 Quantum Chemical Calculations
To provide insight into the effect of substituents on the chemical properties of the cellulose-based
polymers, Density Functional Theory (DFT) calculations were performed. The hybrid PerdewBurke-Ernzerhof exchange-correlation density functional (PBE0)134,135 with Pople’s 6-31+G*
basis set were employed in all cases. All the calculations were performed using the Polarizable
Continuum Model (PCM) with the dielectric constant for water (78.39), to account for solvent
effects.136,137 Chemical structures of average repeat units (termed herein “monomers”) of the newly
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synthesized polymers were drawn in the visualization software IQmol 2.5.138 The monomer chain
terminals were capped with methyl groups, to diminish any border effects. Substitutions were
applied on the R6 group, which is the most stereo-accessible location in the monomers. The other
R groups were substituted by hydrogen atoms. Models including carboxylic acid groups were
simulated in their anionic form, to resemble experimental pH conditions. In the cellulose polymer
with the adipate substitution, the carboxylic acid group was simulated in both protonated and ionic
forms.
A conformational search for each monomer was performed with CHARMM force field in
HyperChem 8.0.3.139 In each case, specific torsions were chosen, and a random walk method was
used to vary these torsions, with an acceptance criterion of maximum 6 kcal/mol above best, and
a total of 1000 optimization cycles. After each conformational search, the structure with lower
energy was selected for the following steps. The initial telaprevir structure was extracted from a
crystalline structure report, and this conformation was then optimized.140
Using the Q-Chem 4.3141 computational chemistry package, the structures were optimized using
tight convergence criteria for the Self-Consistent Field Procedure. Then, single-point energy
calculations were executed over the optimized structures, using the same level of theory and basis
set. The outputs of the latter calculations were employed to produce plots of the Molecular
Electrostatic Potential mapped over the electronic density, based on the Gasteiger-Marsili
empirical atomic partial charges, using IQmol 2.5.138 The free energy of solvation for each
monomer is reported as well.
3.4.5.2 Molecular Dynamics Simulations
To provide insight into the dynamics of oligomers, atomistic MD simulations were carried out in
GROMACS 5.0,142,143 using the CHARMM force field.144,145 The systems were prepared in 8 steps.
(1) First, chemical structures of the oligomers were drawn in HyperChem 8.0.3.139 Each oligomer
included seven monomers, and three of the monomers were substituted, with the same side chain,
on the R6 group. A general schematic is shown in Figure 3-8.
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(2) An energy minimization was performed on these structures, with the Polak-Ribière (conjugategradient) algorithm, using a maximum of 3 × 105 steps, and a root-mean-square (RMS) gradient
of 1.0 × 10−2 kcal Å−1 mol−1 as convergence conditions.
(3) These structures were submitted to the on-line topology building tool SwissParam,146 used to
obtain topology files in GROMACS format. Then, the oligomers were solvated using the extended
simple point charge (SPC/E) water model. Three Na+ ions were used as mobile counterions for
oligomers with carboxylate groups. The largest oligomer included more than 300 atoms. When
solvated, the systems included ∼21,000 water molecules in cubic boxes with edges of up to 8.6
nm.
The five subsequent steps, four equilibration stages, and the production run were executed using
GROMACS 5.0. The velocity-Verlet algorithm was used as an integrator. Periodic Boundary
Conditions were employed with the Verlet cut-off scheme for neighbor searching. Short-range
electrostatic interactions were modeled with a cut-off of 1 nm, and the Particle Mesh Ewald
(PME)147 method was used for long-range electrostatics. van der Waals interactions were
calculated until a cut-off of 1 nm.
(4) First, a microcanonical ensemble (NVE) equilibration was run in GROMCAS for 50 ps (0.5
fs/step), to relax the system and minimize any close contacts introduced in the solvation process.
(5) Second, a canonical ensemble equilibration (NVT) was performed for 5 ns (1 fs/step) using the
v-rescale thermostat, at a reference temperature of 310 K, with a coupling constant (tau-t) of 0.2
ps.
(6) Third, a fast isothermal-isobaric equilibration (NPT) was employed for 5 ns (1 fs/step) using
the v-rescale thermostat, at a reference temperature of 310 K, with a coupling constant (tau-t) of
0.2 ps; and the Berendsen barostat at a reference pressure of 1 bar, with a coupling constant (taup) of 0.2 ps.
(7) Fourth, an isothermal-isobaric equilibration (NPT) was run for 5 ns (1 fs/step) using the NoséHoover thermostat, at a reference temperature of 310 K, with a coupling constant (tau-t) of 0.2 ps;
and the Martyna-Tuckerman-Tobias-Klein barostat at a reference pressure of 1 bar, with a coupling
constant (tau-p) of 1.0 ps.
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(8) Finally, the production run was performed for 40 ns (1 fs/step recording output every 5 fs) in
the isothermal-isobaric (NPT) ensemble using the Nosé-Hoover thermostat, at a reference
temperature of 310 K, with coupling constant (tau-t) of 0.2 ps; and the Martyna-TuckermanTobias-Klein barostat at a reference pressure of 1 bar, with coupling constant (tau-p) of 1.0 ps.
The trajectories from the production run were examined. The radius of gyration (Rg), radial
distribution functions (RDF), and solvent accessible surface (SAS) areas were analyzed for each
type of oligomer.
Rg is a scalar metric that describes the structure and dimensions of a distribution of particles. For
a system containing N particles, Rg is defined in Eq. 3-2.

3-2
where mi and r are the mass and position vector of the i-th particle, respectively, and rcom is the
position of the molecular center of mass.
If each of the atoms of a molecule is represented by a sphere of its corresponding van der Waals
radius, the SAS is the outermost contour described by a 1.4 Å-radius ball, which represents a water
molecule, rolling over each of the atoms in the molecule. Then the total area is normalized by the
number of atoms in each molecule.
The radial distribution function (RDF), gαβ(r), is a type of a pair correlation function that describes
the orientation-normalized probability of finding a particle, of a given type, at a certain distance
from a reference particle. For a system containing Nα particles of type α, and Nβ particles of type
β, the RDF is defined in Eq. 3-3.

3-3
where the angled brackets signify a time average, δ denotes the Dirac delta function, |rij| is the
magnitude of the separation vector between particles i and j, and r represents the average distance
between particles in an ideal gas distribution.
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Results
3.5.1 Influence of polymer structure on nucleation-induction times
Supersaturated solutions of telaprevir crystallize rapidly in the absence of polymers. Therefore,
the addition of crystallization inhibitors is necessary to maintain supersaturation for biologically
relevant timeframes. A diverse set of commercially available and new cellulose polymers
synthesized for this purpose was therefore evaluated with the goal of determining which chemical
and structural features are critical for crystallization inhibition.
The set of commercial polymers included pectin, PVP, PAA, PVPVA, HPMC, CAPhth, HPMCAS,
and EUD L100 with induction time results shown in Figure 3-2a. The polymers are ranked in order
of decreasing solubility parameter (SP) from left to right, pectin with the highest SP and EUD
L100 with the lowest SP.63 When the initial telaprevir concentration was 80 μg/mL (homogeneous
solution), HPMC and HPMCAS maintained the supersaturation for more than 700 minutes.
Increasing the drug concentration to 150 μg/mL and thus creating a drug-rich amorphous phase,25
led to reduced induction times relative to the comparable system with a lower TPV concentration.
An increase in polymer concentration from 5 to 50 μg/mL resulted in longer induction times for
HPMCAS. In contrast, increasing the HPMC concentration did not change the induction time
relative to the lower concentration of this polymer. Therefore, in a maximally supersaturated TPV
solution containing drug-rich amorphous particles, HPMCAS-MF was more effective than HPMC
at 50 μg/mL.
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Figure 3-1 Molecular structures of synthesized cellulose polymers. Substituent R can be H or the
moieties illustrated below the polymer structure.

The newly synthesized polymers were divided into two groups based on their structures. The first
group comprises the cellulose ω-carboxyalkanoates (Figure 3-2b), which are cellulose esters
containing substituents with various hydrocarbon lengths and a terminal carboxylic acid group.
The second group encompasses polymers with chemically diverse functionalities including
carboxylic acids, esters, ethers, alcohol, amides, amines and sulfides (Figure 3-2c).
In Figure 3-2b the cellulose ω-carboxyalkanoates are ordered from high to low SP, whereby CAAdp-067 has the highest SP and CP-TOD-202 the lowest SP within the group. Results obtained
with the cellulose ω-carboxyalkanoates suggest that optimal SP, as well as the number of
carboxylic acid groups, were influential features of the most effective polymers. For example,
CAP-Adp-085 and CA-Sub-090 have SP values in the 22.46 - 23.18 MPa1/2 range, and a high
degree of substitution (DS) of carboxylic acid substituents, 0.85 and 0.90 respectively. In contrast,
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CAP-Seb-024 is ineffective (SP = 23.04 MPa1/2), which may be attributed to the low extent of
groups with a carboxylic acid termination (0.24), and the correspondingly higher number of other
groups such as butyrate and acetate. In other words, SP alone is not sufficient to predict polymer
effectiveness.
Polymers with a broad range of chemical substituents (Figure 3-1) were evaluated next. The degree
of substitution and molecular weight were maintained as constant as possible, with the aim of
exploring the effect of changing a specific functional group. The polymers were further classified
depending on their synthesis reaction pathway, as described in the methodology section. The olefin
cross-metathesis chemistry used to synthesize many of these polymers is modular and thus wellsuited to this approach, since it permits attachment of a variety of terminal functional groups to a
single polysaccharide derivative under mild conditions, thus holding other variables like degree of
polymerization (DP), DS, and position of other substituents constant.56-58,61,130 In this way the
contribution of the single variable, the nature of the terminal functional group, can be evaluated in
isolation.
The first subset of these polymers varies based on the terminal functional group, allowing for the
evaluation of the impact of amide, ester, ether, alcohol, and carboxylic acid groups. From the
induction times observed for these polymers (Figure 3-2c, in medium purple), it is clear that the
only effective polymer, CA-Adp-056, possessed a terminal carboxylic acid group.
Next, polymers with a structure similar to A4 but with an additional branch were synthesized,
using metathesis followed by thiol-Michael addition (reaction pathway 2),130 and then evaluated:
(A5a and A5b Figure 3-2c, in dark purple). These results suggest that the addition of a branch that
includes a terminal carboxylic acid group can drastically improve polymer effectiveness (A5a
substituent, CA-A5a-079 polymer). However, the length of the hydrocarbon chain has a significant
impact on induction times. The polymer with a two-carbon chain length (A5a substituent, CAA5a-079 polymer) was considerably more effective than the equivalent polymer that contained an
eight carbon chain (A5b substituent, CA-A5b-067 polymer).
Polymers A6 and A7 also present similar functionality to A4, but are terminated with a quaternary
amine group instead of an alcohol. The main difference between A6 and A7 is the branch
termination: carboxylic acid vs. alcohol group. Neither of these polymers were effective at
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inhibiting crystallization, which may be attributed either to the trimethylammonium cationic
functionality or to the long hydrocarbon chain. Unfortunately, it was impossible to synthesize
short-chain derivatives possessing trimethylammonium termination. The results with these
polymers show that the presence of structural modifications such as branches and/or bulky groups
on the cellulose backbone may improve the effectiveness of the polymers, but only when key
functional groups are present.
Lastly, polymers with an alcohol termination were obtained using reaction pathway 3: A1a and
A1b substituents. These polymers were ineffective at inhibiting nucleation.
We do not find any correlation between SP and effectiveness within this diverse set of chemical
substituents, although this approach had worked to some extent for the more chemically
homogeneous set of cellulose ω-carboxyalkanoates. While CA-A5a-079 and CA-A5b-067 have
similar solubility parameters, one is effective whereas the other is not (Table A1). Therefore, the
single, simple metric SP, is again insufficient to predict polymer performance at inhibiting the
crystallization of poorly water-soluble compounds. Even though SP values are usually used as an
estimation of hydrophobicity,49,62 they are not a direct measure of this property, limiting their
application.
It has been previously hypothesized that the role of the carboxylic acid group is to impart
amphiphilicity in polymers used as crystallization inhibitors. In particular, when ionized, these
groups allow interaction of hydrophobic polymer regions with the hydrophobic drug, and the
interaction of ionized groups with the aqueous phase at the drug-water interface, thus interfering
with crystal nucleation and growth.49 Figure 3-3 clearly shows that polymers with a terminal
carboxylic acid are only effective when ionized.
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Figure 3-2 Induction time for telaprevir (TPV) in the presence of predissolved polymers (n = 3).
(a) commercially available polymers at 5 and 50 μg/mL concentrations with 150 or 80 μg/mL
TPV, (b) cellulose ω-carboxyalkanoates polymers at 5 and 50 μg/mL concentrations with 150 or
80 μg/mL TPV, (c) polymers with chemically diverse substituents prepared by three different
reaction pathways; 5 μg/mL polymer and 150 μg/mL drug were used. The substituent sidechain
abbreviation is indicated on the label above each bar.
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Figure 3-3 Induction time for telaprevir in the presence of predissolved polymers; 5 μg/mL
polymer and 150 μg/mL drug (n = 3). The polymers were predissolved in buffer at two different
pH values: pH 6.8 sodium phosphate buffer and pH 3.0 sodium citrate buffer. The figure shows
that polymers with a carboxylic acid termination are effective when ionized, at pH 6.8, and
ineffective when protonated, at pH 3.0.

3.5.2 Influence of polymer concentration in nucleation-induction times and crystal sizes
and shapes
The impact of polymer concentration on nucleation induction times has not been widely studied
and will likely depend on the polymer evaluated. Figure 3-4 shows the effect of polymer
concentration on the induction times for telaprevir solutions. Although low, these are polymer
concentrations that might be present in vivo following the dissolution of an amorphous solid
dispersion formulation. Notably, PVP is ineffective at any of the concentrations evaluated, while
HPMCAS and CA-Sub-090 become more effective when the concentration is increased. Also, at
5 μg/mL of polymer, HPMCAS is considerably more effective than CA-Sub-090, whereas at 50
μg/mL they are equally effective.
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Figure 3-4 Induction time for telaprevir in the presence of predissolved polymers HPMCAS, CASub-090 and PVP at different concentrations and 150 μg/mL drug (n = 3). The figure shows that
the effectiveness of polymers at inhibiting crystallization does not follow a linear relationship in
all cases.

These polymers impact not only nucleation but also crystal growth, as reflected by the diverse
resultant crystal shapes and sizes exhibited in Figure 3-5. The crystals obtained from HPMCASMF and CA-Sub-090 induction time experiments are much smaller than crystals formed in the
absence of polymer or in the presence of PVP. From these preliminary observations, these two
cellulose polymers may be effective crystal growth inhibitors, which will be evaluated in future
work.
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Figure 3-5 SEM images corresponding to telaprevir crystals after crystallization induction time
experiments in the presence of 5 μg/mL predissolved polymer. (a) HPMC, (b) HPMCAS-MF, (c)
CA-Sub-090, (d) PVP, (e) phosphate buffer. The shape and size of the crystal is drastically
changed by the presence of polymer

3.5.3 Computational Simulations
The experimental results clearly indicate the importance of carboxylate groups. Yet, several
questions about structure-activity relationships remain unanswered: 1) why are two polymers with
carboxylic acid terminations, but different carbon sidechain lengths, such as A5a and A5b, so
drastically different in their effectiveness as nucleation inhibitors; 2) why are polymers with a
quaternary amine functional group, which is ionized at all pH values, ineffective inhibitors; and 3)
how do different functional groups influence the polymer conformation and ability to interact with
the drug? Consequently, a deeper understanding of structure-activity relationships is required and
computational modeling was thus employed as a complementary tool capable of providing more
detailed information about possible key interactions that could determine polymer effectiveness.
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3.5.3.1 Quantum Chemical Calculations
The electronic structure of a molecule is a rich source of information about its fundamental
properties. Density Functional Theory (DFT) calculations, using the PBE0 functional and the 631+G* basis set, were performed in an implicit medium, provided by the polarizable continuum
model (PCM), to account for aqueous solvent effects.136,137
Monomer conformations are shown in Figure 3-6. Those structures were obtained after performing
a conformational search procedure and a subsequent geometry optimization on the lowest energy
conformer. Along with each monomer structure, the molecular electrostatic potential (MEP) is
mapped over an iso-surface of the electronic density, a region of the space enclosing a given
probability of finding an electron. The MEP is expressed as a color scale where the different colors
indicate the value of the potential at that point of the surface. The color coding matches those of
the rainbow, with purple on one extreme, indicating positive charge accumulation, and red on the
opposite end, indicating an overall negative region of the MEP. Ideally, the information provided
by the MEP allows the recognition of atoms, groups, or regions of the molecule that are inclined
to interact with positively-charged, neutral, or negatively-charged species. The MEP-mapped
electronic density offers a visual indication about areas in where short (0 to ~0.2 nm) and medium
range (~0.2 to ~0.5 nm) non-covalent interactions are probable, namely electrostatics and
hydrogen bonding.
Figure 3-6 highlights the fact that monomer conformation is highly dependent on the nature of the
substituents. For instance, A1a, A2a, and A5a favor extended sidechain conformations, whereas
A1b, A2b, A4a, A5b, A6 and A7 prefer globular conformations. In other words, the latter
monomers show a predisposition for self-interaction. Additionally, the carboxylate termination in
the Adp and Sub polymers induces the chain to bend towards the cellulose ring due to potential
intramolecular hydrogen bond interactions. It is also clear that while the carboxylate termination
(A5a, A5b, A6, Adp and Sub) generates negative charge accumulation over the side chain terminus,
the alcohol (A1a and A1b) or amide termination (A2a and A2b) create positive charge
accumulation.
These quantum chemical results offer a first indication as to why A5a and A5b vary in
effectiveness. A5b tends to self-aggregate due to its long sidechain, contrary to A5a which prefers
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an extended conformation. In other words, the polymer with the longer sidechain (A5b) is more
likely to establish attractive intramolecular interactions using both hydrophobic and hydrogen
bonds, potentially restricting intermolecular interactions with drug molecules. This might also
explain why A6 and A7 are ineffective, since both tend to self-aggregate.
Figure 3-7 presents the free energies of solvation (ΔGsolv) of each monomer in PCM water. The
presence of charged groups, such as carboxylate and quaternary amines, contributes to more
negative free energies. When comparing ionized Adp versus protonated Adp-P, their ΔGsolv values
are drastically different. This supports the idea that sufficient amphiphilicity is only achieved when
the polymer is ionized, which in turn explains why polymers with a carboxylic acid termination
are only effective when ionized (e.g., neutral pH). In addition, the ΔGsolv of a monomer including
a protonated carboxylic acid, such as Adp-P, is similar to that of a monomer containing an alcohol
or an amide, which are equally ineffective. ΔGsolv provides significant information about the
behavior of the system and may give a first indication about polymer amphiphilicity.
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Figure 3-6 MEP-mapped electronic density iso-surfaces for cellulose monomers with chemically
diverse substituents. The rainbow coloring represents the charge accumulation over each region
of the molecule: purple indicates positive charge accumulation and red corresponds to a negative
region. The illustrations provide information about tendency to establish short- and mediumrange intramolecular interactions, such as electrostatic attractions or hydrogen bonding.
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Figure 3-7 Free energy of solvation (kcal/mol) in PCM-modeled water for the monomeric units
shown in Figures 1 and 6. Adp-P stands for protonated adipate. The terminal functional group is
shown in the bottom of each bar.

3.5.3.2 Molecular Dynamics Simulations
While MEP and solvation free energies of monomers provide useful information about structureactivity relationships in polymers, modeling of monomer units does not help to understand
interactions among side chains in a polymer, which might be another factor determining their
effectiveness. However, since quantum chemical simulations are computationally demanding for
large systems, classical force field molecular dynamics (MD) was employed to explore
conformations and dynamics of oligomer chains in water, to complement the information obtained
from the quantum chemical calculations of monomers.
Each oligomer included seven monomers, and three of those were substituted on the R 6 group to
give a degree of substitution of around 0.42, as shown in Figure 3-8. Representative conformations
of the oligomers extracted from MD trajectories are shown in Figure 3-9.
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Figure 3-8 Schematic representation of cellulose oligomers: (a) linear side-chained and (b)
branched side-chained.

A consistent color scheme for different polymers is used in Figures 3-7, 3-9 and 3-10. The radius
of gyration, Rg, (Figure 3-10a) and the solvent accessible surface (SAS) area (Figure 3-10b)
provide essential information about preferred oligomer conformations during the MD trajectory
(see Method section on detail of how Rg and SAS are computed).

Figure 3-9 Representative conformations of the model oligomers extracted from the MD
production trajectories
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Figure 3-10 (a) Average radius of gyration ‹Rg› and (b) solvent accessible surface area per atom
for a group of seven oligomers. Data processed from the production trajectories. The arithmetic
mean is marked by the black horizontal line, accompanied by candlesticks, centered on the
median, representing the standard deviation. The whisker bars denote the lower and higher
quartiles, meaning that 50% of all measurements are contained within these bars.

We derive the following observations from Figures 3-9 and 3-10. First, polymers with long
hydrocarbon side chains, A5b and A6, self-aggregate as evidenced by their lower Rg and SAS area
per atom, which agrees with quantum simulations showing A5b, A6 and A7 in globular
conformations, and A5a in an extended conformation. Second, similar Rg are observed for
oligomers with protonated (Adp-P) and ionized (Adp) carboxylic acid and amide (A2a) groups.
Third, Rg of the oligomer with the alcohol termination, A1a, is smaller than that of oligomers with
amide and carboxylic acid groups. Finally, the SAS area is slightly higher in the ionized Adp than
in protonated Adp-P, due to more extended sidechains when the carboxylic acid group is ionized,
as seen in Figure 3-9.
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Further, Radial Distribution Functions (RDF) (see Methods section for details) were computed
between groups of atoms schematically shown in Figure 3-11. In the first case, a terminal atom of
each R6 substituent was selected as one group. The RDF between all possible pairs of these atoms
is designated as the terminal-to-terminal RDF. In the second case, all carbon 5 (C5) atoms, where
the substituent sidechain is attached to the anhydroglucose ring, were selected as a group. The
RDF between all possible pairs of C5 atoms is denoted as the C5-to-C5 RDF. In the third case, a
terminal atom of each R6 substituent and the carbon 5 (C5) were selected. Then, an average RDF
was constructed with the information of the 3 sidechains. This is designated the single sidechain
average RDF. In the fourth case, one group contained all 3 C5 atoms and the other contained all 3
terminal atoms, such that the RDF includes information on all sidechains interacting with all C5s
simultaneously. This is named a total RDF.

Figure 3-11 Schematic representation showing the atom group definitions employed to calculate
RDFs. Each color represents a group. The dotted lines indicate sampled distances.
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Figures 3-12 and 3-13 provide information about the oligomer conformation dynamics throughout
the trajectory via RDFs. Figure 3-12a shows both the C5-to-C5 RDFs and the terminus-to-terminus
RDF. The C5-to-C5 RDFs attest to the observation that the structure of the main cellulose chain is
stiff and remains extended for A2a, Adp, Adp-P, and A5a, as indicated by a prominent maximum
at ~1.5 nm. In contrast, the main cellulose chain structures of A1a, A5b, and A6 are more flexible,
with two broad maxima observed at ~1.25 nm and ~1.5 nm. The results on Figure 3-12 strongly
correlate with those of Rg on Figure 3-10, suggesting that Rg primarily depends on the conformation
of the main cellulose chain and that the SAS area is well correlated with the conformation of the
substituent sidechains.
Figure 3-12b presents information on the interaction between sidechains in the oligomer, through
the terminus-to-terminus RDFs. There is only one terminus on the A1a, A2a, Adp and Adp-P
sidechains, and two termini in A5a, A5b, and A6. In the latter cases, the plot includes the RDFs
between all possible terminal combinations, as labeled on the curves.
Two observations are noteworthy: first, there appears evidence of hydrogen bonding between sidechain termini in A1a, A5a, and A5b. These three show maxima at close separations between OH
groups, and additionally, A5a and A5b show a narrow band at close separations between COOand OH groups. Interestingly, in the case of A6, there is clear evidence of repulsion between samecharge terminals, but close contacts between oppositely charged COO- and N+(CH3)3 groups.
Second, in sidechains with same-sign charges (Adp, A5b and A6), broad RDFs provide evidence
of repulsions between termini, with the notable exception of A5a, probably because the torsional
freedom of the sidechain is limited by its short length. Within the set of non-branched oligomers,
the only oligomer that shows evidence of repulsion between termini is Adp.
Figure 3-13 shows the single sidechain average and the total RDFs, between C5s and terminal
atoms. The RDF of Adp (COO-) has a predominant peak at ~0.8 nm. This peak is broadened in
A1a (OH), A2a (NH2) and Adp-P (COOH), showing a broader and noisier distribution. The RDF
analysis, as well as the inspection of the trajectories, indicates that A1a, A2a, and Adp-P sidechains
are more dynamic and flexible than those of Adp. This is probably due to the repulsion between
the partial negative charges located at the terminal carboxylate groups.
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It is noteworthy that classical simulations of an oligomer of Adp show more extended
conformations of the ionized sidechains compared to a more globular conformation of the
corresponding monomer observed in the quantum calculations. This important difference can be
attributed to the effect of the charged neighbor sidechains in polymer simulations. In the oligomer,
the other charged sidechains make it difficult for the COO- group to bend towards the cellulose,
whereas in the case of a single monomer, bending of the COO- group to the cellulose ring is
sterically unconstrained and energetically favorable.
There is a correspondence between the single sidechain average (blue) and total (green) RDFs of
A1a (OH), A2a (NH2), Adp (COO-), Adp-P (COOH) and A5a (branched with short hydrocarbon
chain) oligomers, showing that the sidechains prefer to extend, distancing themselves from the
cellulose rings. In contrast, the single sidechain average and total RDFs of A5b and A6 (branched
with long hydrocarbon chains) are notably different. Inspection of the trajectories reveals that the
two sidechains on the extremes of A5b and A6 oligomers lean towards the center of the polymer,
while the sidechain on the center bends towards either side of the polymer, as is exemplified in
Figure 3-9.
As a consequence, in A5b the C5 and COO- are separated by ~1.5 nm according to the single
sidechain average RDF, while the total C5 to COO- RDF has a maximum at ~0.5 nm. In other
words, the COO- groups of the sidechains on the extremes are most probably found nearby the
central C5, at ~0.5 nm, whereas COO- of the central sidechain locates close to the C5s on either
extreme, also at ~0.5 nm; however, all COO- groups are most probably found at ~1.5 nm from
their own C5.
A rather similar behavior is observed in A6. It self-aggregates, as it can be seen in Figure 3-9.
However, A6 shows richer dynamics than A5b. Therefore, the A6 RDF shows a broader range of
probable separations.
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Figure 3-12 Radial Distribution Function (RDF) for different oligomers. (a) C5-to-C5 RDF, (b)
terminus-to-terminus RDF.
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Figure 3-13 Radial Distribution Function (RDF) for different oligomers, showing the single
sidechain average RDF in blue, and the total RDF in green.

Discussion
The design of new polymeric materials for amorphous dispersions is essential to address issues
with the oral drug delivery of emerging poorly water-soluble therapeutics but is currently an
empirical process due to the lack of fundamental correlation between polymer structure and
performance. Herein, the impact of various chemical substituents on the effectiveness of polymers
as crystallization inhibitors has been evaluated explicitly to better understand structure-activity
relationships.
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The most effective polymers included CAP-Adp-085, CA-Sub-090, CA-Adp-067, CA-Adp-056
and CA-A5a-079, which share a common chemical feature: carboxylate groups. In contrast,
polymers with other terminal functional groups, such as alcohol, ether, amide, protonated
carboxylic acid, and quaternary amine groups were ineffective. However, Figure 3-2a clearly
shows that not all polymers that include carboxylic acid groups are effective crystallization
inhibitors: Pectin, PAA, and EUD L100 had minimal impact on induction times. These results
agree with previous reports indicating that PAA and EUD L100 are ineffective,49,148,149 probably
due to a combination of factors that include hydrophilicity, the absence of branches and/or bulky
groups that can form favorable interactions with the drug molecules, and prevent crystallization.49
No correlation was found between glass transition temperature or molecular weight and polymer
effectiveness. Furthermore, only a weak correlation between SP and polymer effectiveness existed
across this chemically diverse polymer set, in contrast to stronger correlations within more
structurally homogeneous polymer sets in previous literature reports.48,49 Calculated SPs appear to
be insufficient to accurately describe amphiphilicity across the broader range of complex polymer
molecular structures.
Alternatively, quantum chemical calculations of monomers and classical simulations of oligomers
provided revealing information regarding preferred structure conformation and thermodynamics
of solvation. These results indicate that effective cellulose polymers should not only have
carboxylate terminal groups, but these carboxylic acid groups must sufficiently enhance the
hydrophilicity of the polymer to counteract the formation of intramolecular hydrophobic
interactions.
Comparison of ΔGsolv between monomers can be used to indirectly estimate how much a group
contributes to the hydrophilicity of the polymer. For instance, charged groups, such as carboxylate
and quaternary amines, contribute to a more negative ΔGsolv; whereas monomers with a protonated
carboxylic acid, alcohol and amide groups have similar ΔGsolv values. According to literature
reports, ΔGsolv values are accurate within a margin of ~5 kcal/mol,150 which is less than the
variation in ΔGsolv between charged and non-charged monomers. Granted that ΔGsolv provides
essential information about the chemistry of the system and that it may give a first indication about
polymer amphiphilicity, there is a weak correlation between polymer effectiveness and ΔGsolv. On
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the one hand, this thermodynamic analysis may explain why polymers with carboxylic acid termini
are only effective when ionized (Figure 3-3), while polymers with amide, alcohol and protonated
carboxylic acid groups are ineffective. On the other hand, A5b (-COO-), A6 (-N+C(CH3)3 and COO-) and A7 (-N+C(CH3)3) have more negative ΔGsolv than neutral monomers, due to the
presence of charged groups, but they are ineffective. In other words, ΔGsolv in isolation is not
predictive of polymer effectiveness.
The ineffectiveness of A5b, A6, and A7 can be rationalized by considering the results of both
quantum chemical and classical simulations. These studies reveal that the polymers tend to selfaggregate, implying that the hydrophilicity conferred by the presence of charged groups is
insufficient to overcome the intramolecular hydrophobic interactions between the hydrocarbon
sidechains and the cellulose rings. Consequently, these polymers are not truly amphiphilic, which
appears to be an important requirement for effective materials. Thus, this study suggests that the
right balance between key substituent groups and the hydrocarbon sidechain length needs to be
met to create effective polymers. For polymers to be effective, it is essential that they possess both
sufficient hydrophobic regions to drive interactions with the drug, and adequate hydrophilicity to
promote solvation in an aqueous environment.
Previous studies have highlighted the importance of polymer conformation for crystallization
inhibition, as well as the role of ionization in impacting polymer conformation. AFM experiments
have previously shown that the conformation of the polymer on a crystal surface is a key
determinant of effectiveness at inhibiting crystal growth.62,63 For instance, HPMCAS, a commonly
used polymer with carboxylic acid groups, was effective at inhibiting crystal growth at neutral pH
and ineffective at low pH.62 When analyzing the surface topography by AFM, globules of polymer
were observed at low pH, while extended polymer chains were present at neutral pH.62 These
observations are in good agreement with MD simulations in chitosan nanohydrogels showing that
Rg depends on the percentage of protonated monomers, with large Rg values found in charged
chains and small Rg observed in neutral chains.151 Our findings also broadly agree with LennardJones MD simulations by Anwar, et al. who suggested that effective crystallization inhibitors
require the right balance between the affinity of the inhibitor for the crystallizing solute relative to
self-affinity and solvent affinity.132 Our observations are also in accordance with MD simulations
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by Mackenzie et al. showing that an optimal degree of polymer hydrophobicity is required to have
a good encapsulation efficiency in drug-polymer nanoparticles.84
Our results support the supposition that the solvated polymer conformation plays a major role in
its effectiveness as a crystallization inhibitor. The simulations provide critical insight, helping to
explain why structurally similar polymers vary in effectiveness. For instance, for the chemically
similar polymers A5a and A5b, the former polymer is effective because it has a more extended
conformation while A5b is not effective because it tends to self-aggregate. Without the information
provided from molecular modeling, it was difficult to explain why these two polymers differed so
drastically regarding impact on telaprevir crystallization.
This study highlights the importance of combining experimental results and computational
modeling when designing new polymeric materials for the delivery of poorly water-soluble drugs.
The combined quantum and classical computational approaches support experimental findings and
reveal how changes in the chemical structure alter the monomer and oligomer conformations and,
by inference, the availability of the polymer to effectively interact with drug molecules to disrupt
their self-association into an ordered crystal. In other words, it is difficult to make predictions
based on evaluation of the monomer chemical structure, because it is unclear how conformation
and chemistry will be changed upon oligomerization and solvation. We are optimistic that the
combination of experiments with molecular modeling will assist in achieving a molecular
understanding of how changes in polymer molecular structure can be extrapolated to differences
in effectiveness at disrupting crystallization.

Conclusion
This study combined experimental results and computational modeling to explain differences in
polymer effectiveness at inhibiting drug crystallization from solution. After analyzing a group of
newly synthesized chemically diverse cellulose-based polymers, including carboxylic acids, esters,
ethers, alcohols, amides, amines and sulfides groups, it was concluded that the effective polymers
contained carboxylate groups in combination with an optimal hydrocarbon chain length. As made
clear by quantum chemical calculations, the effectiveness of carboxylate groups was attributed to
a more favorable solvation free energy, in comparison to non-charged groups. Moreover,
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molecular dynamics simulations of oligomers showed that polymers with long hydrocarbon chains
tend to self-aggregate exhibiting shorter radii of gyration and solvent accessible surface area per
atom. The knowledge gained from this study will inform the next steps in polymer design, whereby
materials with ionized groups that are not hindered by intramolecular interactions will be
synthesized. This will be attained by finding the right balance between carboxylate groups and
hydrophobic sidechains, yielding promising new materials for amorphous dispersions. The
combined experimental-computational approach to optimize crystallization inhibition properties
of cellulose polymers is readily extendable for the rational design of polymers for other drug
delivery applications.
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4. CRYSTALLIZATION INHIBITION PROPERTIES OF CELLULOSE
ESTER AND ETHERS FOR A GROUP OF CHEMICALLY DIVERSE
DRUGS - EXPERIMENTAL AND COMPUTATIONAL INSIGHT

Abstract
Polymeric additives are commonly used to stabilize amorphous solid dispersions by influencing
the nucleation and growth of crystals. However, there is limited evidence regarding the
mechanisms by which polymers stabilize supersaturated drug solutions. The current study used
experiments and computational modeling to explore polymer‒drug interactions in aqueous
solutions. Nucleation induction times for nine drugs in the presence of five newly synthesized
cellulose-based polymers were evaluated. The polymers had carboxylic acids with additional
variations in the side-chain structure; (1) one with a single side chain and a carboxylic acid end,
(2) three with a branched side chain with a carboxylic and an alcohol end (varying the cellulose
linkage and the length of the hydrocarbon side-chain), and (3) one with a branched side chain with
two carboxylic acid ends. The polymers with a short side chain and one carboxylic acid were
effective, while the polymers with the two carboxylic acids and a long hydrocarbon chain were
less effective. Atomic force microscopy experiments, evaluating polymer adsorption onto
amorphous films of drug, indicated that the effective polymers were uniformly spread throughout
the surface. These results were supported by molecular dynamics simulations of a polymer chain
in the presence of a drug aggregate in an aqueous environment, where the effective materials had
more negative free energies of interaction.

Introduction
The incorporation of molecular modeling to assist the discovery of new drug candidates has been
crucial in recent years.152-155 Integrating modeling at the discovery stage allows researchers to
anticipate which chemical structures will provide superior interactions with target proteins. The
most promising drug candidates are synthesized and then tested for drug activity using high
throughput screening experiments.152 The use of computational modeling during these early stages
has been supported by the availability of protein crystalline structures, the fast development of

76

computing capabilities, and the design and implementation of new methodologies to determine
protein-ligand interaction energies.156
The optimization of drug candidates to provide optimal biopharmaceutical properties is essential,
and significant effort is devoted to improve their aqueous solubility.157 Most of the strategies to
increase drug solubility involve the use of additional components, namely excipients, which
interact with the drug molecules and influence the in vivo performance of the final drug
formulation. These components include surfactants, cyclodextrins, polymers, and co-solvents.
Amorphous solid dispersions (ASD) are one solubilization strategy that enables the creation of
supersaturated solutions, whereby the drug concentration exceeds the equilibrium crystalline
solubility in a given medium. Polymers are added to kinetically stabilize the amorphous solid
formulation, and maintain supersaturation for biorelevant time periods. However, variations in the
chemical structure of polymers drastically influence their ability to delay crystallization from
supersaturated solutions.49,148 This leads to two important questions in the field: (1) what chemical
functionalities are important for effective polymeric excipients for amorphous solid dispersion
drug delivery, and (2) what role do these chemical functionalities play.
The use of novel synthetic approaches has allowed the creation of promising polymers for ASDs,
also providing information about structural features important for effective crystallization
inhibitors.49,52-54,61,128,148,158,159 The polymers investigated to date can be divided into two groups:
synthetic copolymers, and cellulose-based polymers, and have been mainly inspired by the
polymers used in commercial ASD formulations.
Computational modeling approaches are helpful to explore how variations in the chemical
structure of the polymers can influence their tendency to self-interact and to interact with drug
molecules. Recently, the number of computational chemistry studies for drug-polymer systems
has increased considerably. Simulations offer molecular insight when experimental information is
limited.76-85,160 There are various types of computational methods applicable to chemical systems,
but the choice will depend on the problem, the properties of interest, and the size of the model
system.
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Quantum chemical calculations of monomer-drug binding energies in the gas phase have been one
of the most common approaches to study drug-polymer interactions.77,90,91 Atomistic and coarsegrained dynamics have also been used to study larger systems.76,81-85,94,95 Some of these studies
have aimed to better grasp the mechanism of incorporation of drug molecules into polymeric
carriers for nanoparticle drug delivery systems. The enthalpy of mixing is determined and
subsequently used for calculation of the Flory-Huggins interaction parameter, which offers an
indication of drug-polymer miscibility.81,83
There are limitations in the type of conclusions that can be drawn from the current methodologies
to calculate monomer-drug binding energies. First, the type of conformations typically chosen
involve relevant intermolecular interactions, such as hydrogen bonding, but a broad range of drugpolymer conformations are expected in ASDs. Second, intermolecular hydrogen bonds are
probably disrupted once an ASD comes into contact with an aqueous environment, and other
interactions may become more critical. Third, quantum mechanical calculations are limited to
small systems, e.g., monomers and dimers, due to high computational costs. It is debatable if the
conformations and interaction energies obtained with monomer-drug are representative of the
actual system, in which oligomers or polymers are present. Fourth, most of these simulations are
conducted in the gas phase, and the conformations found in the solvent may differ.
Atomistic molecular dynamics (MD) studies in this field demonstrate that modeling could be used
to calculate thermodynamic variables and assist in the process of determining how favorable
interactions are between two or more components.81,83 Furthermore, recent combined experimental
and computational studies in the area of ASDs have shown promise.148
Herein, a multifaceted approach has been employed to elucidate chemical features important for
polymeric crystallization inhibitors. This procedure involved the synthesis of new cellulose-based
polymers, the measurement of the crystallization inhibition properties of polymers for a group of
nine drugs, and the determination of free energies of interaction of polymer and drug. The
polymers explored were cellulose ethers and esters with carboxylic acid functionalities, Figure 41. The experimental measurements involved the determination of crystallization induction times,
and the analysis of polymer adsorption on amorphous films of the drug, using atomic force
microscopy (AFM). The computational approach involved the determination of free energies of
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polymer-drug interactions, as well as an analysis of the intramolecular interactions of the polymer
in the absence of drug based on the radius of gyration, solvent accessible surface area, and radial
distribution functions.

Materials
The model compounds used in this study were purchased from Euroasia Chemicals (Euroasia Ltd,
China), Attix Pharmaceuticals (Toronto, Ontario, Canada), Chempacific (Baltimore, MD),
ChemShuttle (Union City, CA), and Hawkins (Minneapolis, MN). Table 4-1 describes the supplier
for each compound. The new cellulose-based polymers were synthesized as described in the next
subsection. The aqueous medium used in all experiments was 100 mM sodium phosphate buffer
pH 6.8 prepared by adding 6.96 g sodium phosphate dibasic anhydrous and 7.04 g monosodium
phosphate monohydrate, made up to 1 L with deionized water.

Methods
4.4.1 Polymer Synthesis
The -carboxyl cellulose ester/ether derivatives used in this study were prepared through
a previously reported olefin cross-metathesis (CM) pathway.57,129,130,161 The mild nature of CM
(37 ˚C, 2-3 h) allows a wide variety of functional groups (e.g., carboxyl and different esters), and
the following hydrogenation reaction eliminates the crosslinking tendency, which would lead to
loss of solubility of ,-unsaturated CM products.56,61 Furthermore, instead of hydrogenation, a
tandem CM/thiol-Michael addition also removes ,-unsaturation, while affording branched
structures and additional functionality through the thioether.130,159 Acid-containing CM products
(from CM with acrylic acid) are not good Michael acceptors to react with thiols. For cellulose
ether derivatives, the stable ether linkages also permit further saponification of acrylate ester CM
products, providing branched adducts containing two carboxyl groups for every initial terminal
olefin.159
All polymers were made from olefin-terminated cellulose ester/ether derivatives, which
served as metathesis “handles” for functionalization with different CM partners: polymers CAA5a-079 and CA-A5b-067 was made from a commercial cellulose ester, i.e., cellulose acetate CA-
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320S, through esterification with undec-10-enoyl chloride57,130 and pent-4-enoyl chloride,56,130
respectively. Polymers ECA-0.69, ECB-0.69, ECC-0.69, and ECD-0.69 were made from
microcrystalline (MCC) through a one-pot etherification with ethyl iodide and 5-bromo-pent-1ene.61,159 Polymer synthesis were sorted by three reaction pathways, and corresponding references
are given as follows:
Reaction pathway 1: 5-Carboxypentyl derivative ECA-0.69 was prepared by CM of
EC2.30C5 with acrylic acid (AA) followed by hydrogenation reaction to eliminate the α,βunsaturation and provide a stable product.
Reaction pathway 2: Branched polymers A5a-079, CA-A5b-067, and ECB-0.69 were
synthesized by CM with hydroxyethyl acrylate (HEA) followed by a thiol-Michael addition with
3-mercaptopropionic acid (3MPA).
Reaction pathway 3: ECC-0.69, and ECD-0.69, were made by CM with methyl acrylate
(MA) or benzyl acrylate (BA), thiol-Michael addition with either 2-mercaptoethanol (2ME) or 3mercaptopropionic acid (3MPA); and a further saponification using tetrabutylammonium
hydroxide (TBAOH) to remove the ester and recover an additional carboxyl group.159 Such
structures would not be accessible for cellulose ester derivatives due to hydrolysis of backbone
ester linkages during saponification.

Table 4-1 Polymer abbreviations and equivalent notation
#

Polymer abbreviation

Equivalent abbreviation

1

CA-A5a-079

CA-Pen079-HEA-3MPA

2

CA-A5b-067

CA-Un067-HEA-3MPA

3

ECA-0.69

EC2.30C5-AA-H

4

ECB-0.69

EC2.30C5-HEA-3MPA

5

ECC-0.69

EC2.30C5-MA-2ME-TBAOH

6

ECD-0.69

EC2.30C5-BA-3MPA-TBAOH
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Figure 4-1 Molecular structures of synthesized cellulose polymers

Figure 4-2 Chemical structures of model compounds
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4.4.2 Nucleation Induction Times
Polymers were predissolved in a small amount of DMSO, and sonicated for 90 minutes at 50 ˚C
until fully dissolved. Next, small aliquots of the DMSO solution were added, using constant
agitation, to 20 mL of pH 6.8 100 mM buffer at 50 ˚C. After complete dissolution, the solutions
were equilibrated at room temperature, and the volume was adjusted to obtain 5 µg/mL polymer
solutions. The final solution had less than 1% DMSO. The methodology has been described by
Dong et al.159
Supersaturated solutions were created by adding a specific amount of the drug stock solution to 47
mL of phosphate buffer, maintained at 37 ˚C and 300 rpm. The crystallization induction time from
unseeded samples was measured using an SI Photonics UV/Vis spectrometer (Tucson, Arizona)
coupled to a fiber optic probe (path length 0.5 or 1 cm). Measurements at two different wavelengths
were recorded every minute. The increase in the non-absorbing wavelength and the decrease in the
absorbing wavelength were taken as the induction time.
The drug concentrations used for telaprevir corresponded to a concentration above its glass – liquid
phase separation (GLPS) concentration; and the drug concentrations used for the other eight drugs
were below the LLPS or GLPS concentration. Details about the experimental conditions used in
the nucleation induction time experiments are shown in Table 4-2. Table 4-3 describes the
crystalline and amorphous solubility values of the compounds studied; the values have been
previously determined in our group.
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Table 4-2 Experimental conditions used in nucleation induction time experiments
Drug

Stock
(mg/mL)

Solvent
used for
Stock
Solution

Drug
concentration in
supersaturated
solution (μg/mL)

UV
Probe
used

Maximum
Wavelength
(nm)

Baseline
Wavelength
(nm)

Supplier

Ritonavir

6

Methanol

20

1 cm

240

450

ChemShuttle

Atazanavir

10

Methanol

60

1 cm

280

450

ChemShuttle

Telaprevir

7

Methanol

150

0.5 cm

270

370

Attix
Pharmaceuticals

Nifedipine

10

Methanol

40

1 cm

352

450

Sigma Aldrich

Nevirapine

55

DMSO

500

0.2 cm

249

450

Chempacific

Griseofulvin

10

DMF

70

1 cm

330

450

Hawkins

Celecoxib

5

Methanol

22

1 cm

245

450

Attix
Pharmaceuticals

Ezetimibe

5

Methanol

10

1 cm

248

450

Attix
Pharmaceuticals

Danazol

5

Methanol

10

1 cm

288

450

Euroasia
Chemicals

Table 4-3 Crystalline and amorphous solubility values for model compounds studied
Drug

Crystalline Solubility
(μg/mL)

LLPS/GLPS Concentration
(μg/mL)

Ritonavir

1.5162

28162

Atazanavir

1.04163

66163

Telaprevir

4.625

9025

Nifedipine

1026

7326

Nevirapine

10570

87470

Griseofulvin

11.53

3573

Celecoxib

1.549

2249

Ezetimibe

0.9774

2074

Danazol

0.927

1327
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4.4.3 Atomic Force Microscopy (AFM)
A MultiMode 8 AFM (Bruker Nano Surfaces, Santa Barbara, CA) was employed to characterize
polymer interaction with amorphous surfaces. Samples were prepared by melting atazanavir onto
stainless steel AFM pucks, flattened using glass coverslips, and allowed to cool, leaving nominally
flat and smooth amorphous surfaces. AFM characterization was conducted in buffer solutions
containing 5 μg/mL polymer. Characterization was performed in tapping mode, utilizing NPG-10
(cantilever C, 0.24 N/m spring constant, 30 nm nominal tip radius) silicon nitride triangular probes
(Bruker Nano Surfaces, Santa Barbara, CA).
Both height and phase contrast images were obtained for each sample. Height plots provide
topographical information on surfaces by measuring cantilever tip deflection and relating this data
to the z-position of the surface. Phase contrast plots depict changes in cantilever resonance caused
by interactions with the surface. Such interactions are sensitive to material properties of the surface
and hence allow for discrimination between polymer species and the underlying amorphous
surface. Images were analyzed using NanoScope Analysis (v 1.x, Bruker Nano Surfaces, Santa
Barbara, CA).
4.4.4 Computational Simulations
Fully-atomistic classical MD simulations were performed to provide insight into the intra and
intermolecular interactions between polymer and drug molecules for systems including a polymer
chain (28 monomers) in water, a drug aggregate (25 drug molecules) in water, and a polymer chain
in the presence of a drug aggregate. Six different polymers (Figure 4-1) were used, and telaprevir
(TPV) and Atazanavir (ATZ) were the model compounds. Importantly, the total number of
molecules (187,457) was kept constant for all the simulations performed.
The MD simulations were carried out in GROMACS 5.0,142,143 using the CHARMM force
field.144,145
4.4.4.1 Construction of polymer chains
First, the structures of oligomers with four monomers were drawn in HyperChem 8.0.3.139 The
substitution patterns are shown in Table 4-4 and 4-5, where acetyl (Ac), ethyl (Et), A5x, and ECx
represent the groups shown in Figure 4-1.
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Table 4-4 Substitution patterns for cellulose ester derivatives
Carbon

Monomer 1

Monomer 2

Monomer 3

Monomer 4

C2

Ac

Ac

Ac

H

C3

Ac

Ac

H

H

C6

A5X group

Ac

A5X group

Ac

Table 4-5 Substitution patterns for cellulose ether derivatives
Carbon

Monomer 1

Monomer 2

Monomer 3

Monomer 4

C2

Et

Et

Et

Et

C3

Et

Et

Et

H

C6

ECX group

Et

ECX group

Et

Second, an energy minimization of the oligomers with 4 monomers was performed with the PolakRibière (conjugate-gradient) algorithm, using a maximum of 3 × 105 steps, and a root-mean-square
(RMS) gradient of 1.0 × 10−2 kcal Å−1 mol−1 as the convergence condition. The structures were
then submitted to the on-line topology building tool SwissParam,146 used to obtain topology files
in GROMACS format.
Using the include topology file provided by SwissParam, a residue topology file was constructed
by using the GROMACS Topology Tools program by Anton Feenstra. This residue topology file
was edited to create an initial, middle and end type residue, where every residue was composed of
4 monomers. Two hydrogen atoms and an oxygen atom were detached from the middle residue
type, making it open to be connected by covalent bonds to other residues on both extremes,
whereas the initial and end residue types were designed to be connected to only one residue on
their corresponding extremes.
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Then, a polymer chain composed of 28 monomers (7 repeating units of 4 monomers each) was
drawn in HyperChem 8.0.3 and minimized using the same conditions described in the previous
step.139
4.4.4.2 MD simulations of Single Chains
The polymers were solvated using the extended simple point charge (SPCE) water model. 14 Na+
ions were used as mobile counterions for the polymers (A5a, A5b, ECA, ECB, and ECC), and 28
Na+ ions were used for the ECD polymers. These ions served as counterions to the carboxylate
groups of the polymer. The largest chain had 1,298 atoms. The system included ∼187,400 water
molecules (varying depending on the absence or presence of drug molecules), in cubic boxes with
edges of up to 17.9 nm.
Two equilibration stages and a production run were performed in GROMACS 5.0. The velocityVerlet algorithm was used as an integrator. Periodic boundary conditions were employed with the
Verlet cut-off scheme for neighbor searching. Short-range electrostatic interactions were modeled
with a cut-off of 1 nm, and the Particle Mesh Ewald (PME)147 method was used for long-range
electrostatics. Van der Waals forces were calculated until a cut-off of 1 nm. Different energy
groups, corresponding to drug, polymer, solvent, and ions, are specified in the MD simulation
parameters files.
First, the system was minimized using a steepest descents algorithm (0.01 fs/step), and the
minimization was stopped when the maximum force was less than 100.0 kJ mol−1 nm−1.
Second, a canonical ensemble equilibration (NVT) was performed for 5 ns (1 fs/step) using the vrescale thermostat, at a reference temperature of 310 K, with a coupling constant (tau-t) of 0.2 ps.
Third, a fast isothermal-isobaric equilibration (NPT) was employed for 1 ns (1 fs/step) using the
v-rescale thermostat, at a reference temperature of 310 K, with a coupling constant (tau-t) of 0.2
ps; and the Berendsen barostat at a reference pressure of 1 bar, with a coupling constant (tau-p) of
0.2 ps.
Finally, the production run was performed for 5 ns (1 fs/step recording output every 2 ps) in the
isothermal-isobaric (NPT) ensemble using the Nosé-Hoover thermostat, at a reference temperature
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of 310 K, with coupling constant (tau-t) of 0.2 ps; and the Martyna-Tuckerman-Tobias-Klein
(MTTK) barostat at a reference pressure of 1 bar, with coupling constant (tau-p) of 1.0 ps.
The trajectories from the production run were examined. The radius of gyration (Rg), radial
distribution functions (RDF), solvent accessible surface (SAS) areas, and an estimate of the free
energy of solvation were analyzed for each type of oligomer. Details about the description Rg and
SAS can be found in our previous article.148
4.4.4.3 MD simulation in the gas phase to create drug aggregates
The starting chemical structures of telaprevir and atazanavir were extracted from a crystalline
structure report, and this conformation was then optimized.140,164 The sulfate molecules were
removed from the structure reported for atazanavir bisulfate, because we were interested in the
atazanavir free base. Using the Q-Chem 4.3141 computational chemistry package, the structures
were optimized using tight convergence criteria for the self-consistent field procedure. Density
Functional Theory (DFT) calculations, with the hybrid Perdew-Burke-Ernzerhof exchangecorrelation density functional (PBE0)134,135 with Pople’s 6-31+G* basis set were performed. The
structures were then submitted to the on-line topology building tool SwissParam,146 used to obtain
topology files in GROMACS format.
Twenty-five drug molecules were added to a cubic box with edges of up to 6.0 nm. The system
with atazanavir drug molecules underwent a 2 ns NVT equilibration followed by 6 ns NPT
equilibration, and the system with telaprevir drug molecules underwent a 0.5 ns NVT equilibration
followed by 2 ns NPT equilibration. The sole purpose of these simulations was to create aggregates
of drug molecules in the gas phase. For the NVT equilibration the v-rescale thermostat, at a
reference temperature of 310 K, with a coupling constant (tau-t) of 0.2 ps was used. For the NPT
equilibration, a coupling constant (tau-t) of 0.2 ps; and the MTTK barostat at a reference pressure
of 1 bar, with coupling constant (tau-p) of 1.0 ps were utilized.
4.4.4.4 Polymer chain – Drug MD Simulations
The aggregate of 25 drug molecules was placed in the presence of a polymer chain previously
equilibrated in the presence of water. The polymer chain structure corresponded to the structure
after the 5 ns NVT equilibration and the 1 ns NPT equilibration previously described. The
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simulations were performed starting with the drug aggregate and the polymer separated by a short
distance of approximately 1 to 2 nm. An NVT equilibration stage was performed (0.5 ns); followed
by a NPT equilibration (1 ns) using the v-rescale thermostat and the Berendsen barostat; a second
NPT equilibration (5 ns) using the Nosé-Hoover thermostat and the MTTK barostat; and and a
NPT production run (10 ns) using the Nosé-Hoover thermostat and the MTTK barostat.
The Lennard-Jones and Coulomb terms for short and 1-4 interactions were extracted for the
polymer + drug interaction. The GROMACS energy function was run for all energy groups, with
a flag to estimate for the free energy difference with respect an ideal gas state along the production
trajectory. Eq. 4-1 shows the description of the free energy estimate, where k is the Boltzmann
constant, T is the simulation temperature, 310 K, Upot is the potential energy for the polymer‒drug
interactions.
4-1

Results
4.5.1 Nucleation Induction Time
The crystallization inhibition properties of cellulose-based polymers were evaluated. The model
drugs used for the studies included fast, intermediate, and slow crystallizers. Griseofulvin,
celecoxib, ezetimibe, and danazol were fast crystallizers; telaprevir, nifedipine, and nevirapine
were intermediate; and ritonavir and atazanavir were slow crystallizers. The drugs were unionized
at the pH used in these experiments, pH 6.8; hence, ionic interactions between drug and polymer
were absent.
The polymers studied had carboxylic acids, and the degree of substitution concerning the
carboxylic acid functionality, shown in Figure 4-1, was kept constant for the polymers shown. The
main differences between the cellulose ethers and cellulose esters were: the linkage to cellulose
backbone and the nature of the starting material used to synthesize the polymers. Cellulose acetate
was used for the cellulose esters presented, while ethyl cellulose was the starting material for the
cellulose ethers shown.
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Figure 4-3 shows the effectiveness of two cellulose esters with the unique variation being the
hydrocarbon chain length; polymer CA-A5a-079 has a short chain length, while polymer CA A5b067 has a long chain length (Figure 4-1). The polymer with the short chain performs better than
the polymer with the long chain for all the compounds studied.
Consequently, the next set of polymers were designed with a short hydrocarbon chain. Cellulose
ethers were designed with variations in the position of the carboxylic acid group, as shown in
Figure 4-1. Figure 4-4 shows the nucleation induction times for the same group of drugs, in the
presence of cellulose ethers with a single chain ending with a carboxylic acid (ECA-069), one
branch with a carboxylic acid termination and one with an alcohol (ECB-069), and two branches
with a carboxylic acid termination (ECD-069). The polymer ECA-0.69 appears to be an effective
crystallization inhibitor, especially for the fast crystallizer compounds. For the more slowly
crystallizing compounds, i.e., those with longer induction times, the polymer with a single
carboxylic acid termination (ECB-069) is more effective than the polymer with two carboxylic
acid group terminations (ECD-069), while little difference is apparent between the two polymers
for the fast crystallizing compounds. Interestingly, although nucleation was detected based on the
increase in the scattering for griseofulvin and ezetimibe systems, it appears that the EC polymers
are also effective growth inhibitors for these model drugs. However, an in-depth understanding of
the crystal growth process was out of the scope of the current investigation.

Figure 4-3 Induction time for 9 drugs in pure buffer (black bars), or in buffer containing 5 μg/mL
of the cellulose ester polymers (green and blue bars), (n=3).
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Figure 4-4 Induction time for 9 drugs in buffer (black bars), or in buffer containing 5 μg/mL of
the cellulose ether polymers (red and gold bars) (n=3).

4.5.2 Adsorption of the polymer onto atazanavir amorphous films
Atomic force microscopy (AFM) was used to study how the polymer adsorption varies on
amorphous films of drug. Changes in topographical and phase contrast AFM images give an
indication about the tendency of the polymer to interact with the amorphous surface, which is
indirectly related to intra- and intermolecular interactions between drug, polymer and water.62
Figure 4-5 shows variations in phase and height for amorphous films of atazanavir exposed to
different polymer solutions. Globular structures are observed in the presence of A5b, ECA, ECB,
and ECD, whereas they are absent in the presence of A5a.
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Figure 4-5 2 μm × 2 μm AFM height and corresponding phase contrast images for atazanavir in
the absence (Ref) and presence of polymers (A5a, A5b, ECA, ECB, and ECD). Images were
captured in liquid at room temperature and with a 1 h incubation period. Scale bar represents 400
μm.

4.5.3 MD simulations of single polymer chains
The purpose of this section was to determine whether variations in the chemical structure of the
polymer translate into changes in the dynamic behavior of the chain. The radius of gyration,
solvent accessible surface area, estimated free energy of solvation, and radial distribution functions
were determined. These simulations were performed with single chains to simplify the system and
avoid interference by other components. The polymer chains were drawn to resemble the
composition of the different substituents. Nonetheless, the real polymers are not regioselectively
substituted, and as a result, have the different groups located in multiple positions.
Figure 4-6a shows the free energy of solvation, calculated from the MD production trajectory. This
indicates that the cellulose ester polymers (A5a and A5b) have more negative free energies of
solvation than the cellulose ether polymers based on ethyl cellulose (ECA, ECB, ECC, and ECD).
Figure 4-6b shows the solubility parameters calculated by the Fedors method for comparison
purposes, where more positive values indicate more hydrophilic materials. Importantly, the MD
simulations correspond to the ionized state of the polymers, the expected state under the
experimental conditions employed, while the solubility parameter calculations correspond to
unionized structures.
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The results from Figure 4-6a and 6b indicate that the process of solvation of the A5a and A5b
polymers is more favorable than for the EC polymers. When comparing A5a and A5b which only
differ in the length of the hydrocarbon chain, it is more favorable to solvate A5a (short chain) than
A5b (long chain), as expected. Next, when comparing A5a and ECB which possess similar chain
structures but differ in the linkage to the cellulose backbone (ester versus ether) and in the
additional substituent (acetyl versus ethyl, Figure 4-1), a drastic variation is observed in the
estimated free energy of solvation and in the solubility parameter. This indicates that although
chemical structures may look similar, small variations may influence the solvation process.
Figure 4-6a shows that among the EC derivatives, ECC has the more positive estimated free energy
of solvation which may indicate that it is harder to solubilize. This is an interesting observation
because the solubilization process for the ECC polymer was particularly challenging, due to
precipitation upon contact of the DMSO-polymer solution with buffer, and is the reason why
experimental results are not shown.

Figure 4-6 (a) Free energy of solvation for a group of seven oligomers with 28 monomeric units.
Data processed from the production trajectory. The arithmetic mean is marked by the black
horizontal line, accompanied by candlesticks, centered on the median, representing the standard
deviation. The whisker bars mark the lower and higher quartiles, meaning that 50% of all
measurements are contained within these bars. (b) Solubility parameter calculated by the Fedors
method.
The radius of gyration, Rg, (Figure 4-7a) and the solvent accessible surface area (SASA) per atom
(Figure 4-7b) were analyzed for the production trajectory for single chain systems. We have
previously used these quantities to analyze the structure of a wide range of cellulose ester polymers,
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and see that the Rg primarily depends on the conformation of the main cellulose chain, while the
SASA depends on the conformation of the side chains.148 The Rg values (Figure 4-7a) for the 28
monomer chains are in the 2.9 to 3.7 nm range. Two main observations were made from these
results: the A5a cellulose chain is more extended than the A5b chain, and the ECC chain has a
high distribution of Rg values during the trajectory indicating that this polymer structure is more
flexible and that the cellulose chain tends to have a greater variety of conformations.
The SASA values (Figure 4-7b) shows a higher area for the ECA, ECD, and A5a polymers,
indicating that the side chains are more extended in these systems; and the lowest value is for A5b
(long hydrocarbon chain) indicating that the side chains in A5b tend to be more agglomerated.
Simulations of a polymer chain with a nucleus of 25 drug molecules were performed.
Experimentally, the polymer is first dissolved and equilibrated in an aqueous environment,
followed by the addition of the drug solution. As a result, for this set of simulations, the polymer
structure chosen was that one corresponding to the equilibrated state after performing simulations
for single polymer chains systems. In other words, firstly, all the simulations with the single
polymer chains were performed; followed by the simulations with the drug and polymer chain. For
the drug-and-polymer simulations, a nucleus of drug molecules was first prepared in the gas phase
and solvated. The reasoning behind using a drug aggregate was the presence of these type of
structures during experiments, instead of single solvated drug molecules. A set of simulations was
performed starting with close contact between the polymer and the drug aggregate, approximately
1 to 2 nm of distance. It would be expected that the molecules would get closer if the interaction
is favorable, or would separate if the interaction is unfavorable.
Figure 4-7b and 4-7c show the Rg and SAS for the polymer during the production trajectory
corresponding to the simulations between polymer and drug aggregate. Interestingly, in some of
the cases, the polymer Rg tends to be smaller than for single chain simulations, which indicates
that the presence of the drug aggregate close by influences the structure of the main cellulose chain.
Interestingly, the A5b polymer is more agglomerated in the presence of ATZ and TPV, suggesting
that A5b and the drug aggregates repel, favoring the intramolecular interactions of A5b with itself.
The SASA results (Figure 7d) show a similar trend than in the absence of drug, where A5a has a
higher SASA per atom than A5b.
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Figure 4-7 (a,c) Average radius of gyration ⟨Rg⟩ and (b,d) solvent accessible surface area per
atom for a group of seven oligomers with 28 monomeric units. Data processed from the
production trajectories. (a, b) correspond to the conformations from the single chain simulations,
(c,d) correspond to the conformations from the polymer + drug simulations. The arithmetic mean
is marked by the black horizontal line, accompanied by candlesticks, centered on the median,
representing the standard deviation. The whisker bars mark the lower and higher quartiles,
meaning that 50% of all measurements are contained within these bars.

Analysis of the interaction between polymer and drug were performed. The radial distribution
function (RDF) between polymer and drug, which represents the probability of finding the polymer
chain at a certain distance from the nucleus of drug molecules is shown in Figure 4-8. Comparisons
for ATZ and TPV in the presence of A5a, A5b, ECA, ECB, and ECD are shown. The results
indicate that there is a higher probability of finding A5a closer to the drug molecules than A5b,
but there is a greater attraction between A5a and ATZ than between A5a and TPV, represented by
a higher peak. Regarding the EC polymers, there is a higher probability of finding ECA and ECB
close to the drug aggregate than ECD.
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Different energy groups were specified in the MD simulation parameters file to enable the
extraction of information about the intermolecular interactions between drug and polymer. Figure
4-9 shows an estimate of the free energy difference with respect to the ideal gas state, which is
calculated over the full 10 ns of the trajectory at 310 K. According to these results, A5b does not
interact with the nucleus of drug molecules, in either case: TPV or ATZ. Meanwhile, A5a interacts
with ATZ and TPV, with a more negative value for ATZ, indicating a more attractive interaction
between ATZ and A5a. ECA and ECB have an attractive interaction with TPV, but the interaction
appears to be stronger between ECB and TPV than between ECA and TPV, and ECD does not
interact with TPV. In contrast, ATZ has an attractive interaction with ECA, ECB, and ECD, but
the interaction is stronger with ECA and ECB than with ECD.

Figure 4-8 Radial distribution function (RDF) between polymer and drug molecules,
corresponding to the 10 ns production trajectory. The y-axis has the same scaling for the three
figures.
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Figure 4-9 Estimated free energy of interaction for different polymer + drug systems,
corresponding to the 10 ns production trajectory, and calculated with respect to the ideal gas
state, as described in Eq. 4-1.
Discussion
The increasing interest in amorphous solid dispersion as a strategy to improve drug solubility,
driven by the rising number of drugs with solubility issues, creates a need to find new materials
that delay crystallization from these metastable formulations. It has been reported that several
additives, such as polymers and bile salts, have crystallization inhibition properties, which makes
them attractive excipients for drug formulations.71,128,148,158,165 Herein, different cellulose-based
polymers with carboxylic acid functionalities were synthesized to determine how variations in
chemical structure influenced their performance at inhibiting drug crystallization. The polymers
synthesized had carboxylic acid functionalities, based on our previous observations showing that
polymers with carboxylic acids were more effective than those with amides, amines, or alcohols.148
We had previously studied the effectiveness of A5a and A5b for TPV and found that the variation
in the length of the hydrocarbon chain had a drastic impact on the effectiveness of the polymer,
with A5a (short chain) showing better effectiveness than A5b (long chain).148 These results
suggested that the intramolecular interactions in the polymer played a major role influencing their
effectiveness at inhibiting crystallization: a polymer that tends to self-associate has a lower
probability of interacting with drug molecules. However, one outstanding question was whether
the same trend would be obtained for other drugs, with chemical properties different from TPV.
This led to the exploration of the nucleation induction times for a group of nine drugs (Figure 4-2)
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in the presence of A5a and A5b. Interestingly, A5a performed better than A5b (Figure 4-3) for all
the compounds studied, suggesting that the polymer ineffectiveness was probably due to its
preferred self-interaction, which in turn leads to a low tendency to interact with the drug molecules.
The incorporation of simulations for single polymer chains with 28 monomers and simulations for
drug aggregates in the presence of one polymer chain at a close distance allows a better
understanding of what may be happening in solution. Figure 4-7 shows that A5a has a more
extended conformation than A5b, as evidenced from the Rg and SASA. It is also apparent that the
presence of the drug, TPV or ATZ, has an impact on the polymer intramolecular interactions.
Particularly, A5b tends to self-associate even more in the presence of ATZ and TPV, indicating
that the self-interaction is favored, rather than the drug + A5b interaction. The RDF results shown
in Figure 4-8 are in good agreement with these results, where the probability of finding A5a close
to the drug is much higher than the probability of finding A5b.
Given that A5a showed a good performance extending nucleation induction times, new polymer
candidates were created with similar structures but with an ether linkage to the cellulose backbone,
and with ethyl cellulose as the starting material. The creation of cellulose ether polymers provides
some potential advantages including hydrolytic stability under extreme pH conditions and the need
for fewer synthetic steps.
The cellulose ethers (ECA, ECB, ECC, and ECD) were of interest to determine how variations in
the position of the carboxylic acid functionality and the number of carboxylic acids influenced
their effectiveness. Unfortunately, ECC could not be used due to issues with polymer solubilization
in water. ECA included a single chain with a carboxylic acid termination, which permitted us to
evaluate polymer effectiveness in the absence of additional branches. ECA was an effective
crystallization inhibitor for all the compounds studied, but it was particularly effective for the fast
crystallizing compounds, increasing the nucleation times by orders of magnitude. According to the
Rg and SASA values in the absence of drug (Figure 4-7a,b), ECA has an extended conformation
where the main cellulose chain and the side chains are extended. This probably contributes to its
favorable interaction with different types of drug molecules. The RDF values in Figure 4-8 support
the favorable interaction of ECA with drug molecules, showing a high probability of finding ECA
close to ATZ and TPV, with higher peaks in the case of ATZ.
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ECB presented a similar structure to A5a, and ECD had two branches with carboxylic acids. Figure
4-4 shows that the presence of more carboxylic acid groups (ECD) does not improve the
effectiveness of the polymers as crystallization inhibitors. The polymer with one carboxylic acid
(ECB) performed better than the polymer with two carboxylic acids for most drugs; except for
griseofulvin and ezetimibe, where both polymers appeared equally effective. This observation was
initially counterintuitive considering that it has been seen that carboxylic acids substituents
typically lead to more effective polymers. Further, in previous studies, it appeared that polymers
with a higher DS with respect to COOH were better inhibitors, although the polymers evaluated
had other structural variations in addition to COOH DS.49 The SASA measurements in the absence
or presence of drug (TPV and ATZ) are larger for ECD than for ECB, indicating that the side
chains are more extended for ECD, which is expected since two negative charges are present,
instead of a single one. It is important to point out that, two charges were simulated for the ECD
polymer, but it is possible that under the experimental conditions used some of the carboxylic acid
groups are protonated while others are ionized.
Variations in the Rg of the polymer due to the presence of the drug aggregate can be explained in
two ways; one is that the polymer has more attractive interactions with itself, and the other one is
that the polymer is actively interacting with the drug aggregate, which results in the bending of the
chain. Therefore, an additional metric was required to determine the potential interaction between
polymer and drug. RDF values (Figure 4-8) show a higher probability of finding drug molecules
(TPV or ATZ) closer to ECB than to ECD, indicating a more attractive interaction between ECB
and the drug, than between ECD and the drug. The use of experimentally determined RDFs to
study solid mixtures of ASDs166, as well as the interaction energy for solid mixtures77,92 has been
described in the literature as an alternative to study intra- and intermolecular interactions between
drug molecules and polymer in the solid state. The results shown herein support the utility of this
approach for understanding solution behavior.
The AFM measurements provide insightful information about the interaction of the polymer at the
drug-water interface, precisely by providing visualization of how the polymer adsorbs to the
surface of the amorphous drug. It is hypothesized that variations in the polymer affinity for water
and drug will influence the conformation of the polymer adsorbed to the amorphous surface.
Previous studies of polymers adsorbed to crystalline surfaces demonstrated a relationship between
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the extent of polymer coverage on the surface and the rate of crystal growth.62 The current study
uses an amorphous surface which provides a better representation of the initial disordered phase
thought to be the first stage of the nucleation process.17
Clear differences are seen when comparing the surface of the atazanavir film in the presence of
the cellulose esters with short and long hydrocarbon chain length (Figure 4-5). The polymer with
short chain appears to be homogeneously dispersed through the surface (A5a), while unevenly
distributed large polymer globules are observed for the polymer with the long chain (A5b), in
agreement with the MD simulations, which show the tendency of the latter polymer to selfassociate. Smaller globular structures are observed for ECA, ECB, and ECD. ECA and ECB
structures have similar sizes and are uniformly spread throughout the surface, while larger globular
structures are observed for ECD. Figure 4-4 indicates that ECA, ECB, and ECD inhibit
crystallization for ATZ, with better performance exhibited by ECA and ECB. This suggests that
even though these two polymers form globular structures, they are still able to inhibit
crystallization. However, one of the main differences is the extent of surface coverage by these
globular structures, with larger coverage for ECA and ECB, followed by ECD, and finally A5b. It
is unsurprising that the EC polymers form these globular structures at the drug-water interface, as
the MD simulations of single polymer chains in water indicate that EC derivatives have more
positive energies of solvation (Figure 4-6). The SASA is lower for ECB than A5a, indicating that
the side chains are more contracted, and is approximately the same for ECA, ECD, and A5a (Figure
4-7b). The formation of globular structures onto the surface does not necessarily indicate that a
polymer is a bad crystallization inhibitor. It is also necessary to determine polymer coverage of
the surface and the size of the globular structures. It is possible that the formation of these globular
structures may impact the ability of the polymer to prevent crystal growth, with better performance
for polymers that are able to spread evenly and in an extended conformation, than for those that
form globules with a low extent of surface coverage.
Simulations of drug aggregates in the presence of polymers was intended to obtain a
thermodynamic quantity, the free energy of interaction between drug and polymer, as a general
indication of the likelihood of a polymer-drug interaction. The idea was inspired by protein +
ligand simulations, which use thermodynamic cycles to compare the variations in the interaction
energies when changing the chemistry of the ligand.80,152 These methodologies are widely used
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during discovery stages and are standardized for protein systems. There are multiple differences
between proteins and polysaccharides that make simulations with polysaccharides systems more
challenging. First, there are crystal structures available for proteins, which typically correspond to
their quaternary structure; while polysaccharides structures are constructed from scratch, there is
variability from polymer chain to polymer chain because most of these cellulose-based polymers
are not regioselectively substitued, which implies an extra level of preparation for the simulations,
where the structures are based on the percentages of substitution rather than in the actual position
in the polymer chain. Second, proteins typically have pockets where the ligand will more likely
interact, while drug molecules are expected to interact with different sections of the polymeric
materials. Finally, polysaccharides are more flexible than proteins because they lack a ternary or
quaternary structure. These factors make the simulation of polymer-drug systems more
challenging for this type of calculations.
In the present study, we estimated the free energies of interaction (Figure 4-9) based on the 10 ns
production trajectory. The results shown indicate that A5a interacts favorably with ATZ and TPV,
while A5b does not interact with the drug molecules. Similarly, ECA, and ECB have an attractive
interaction with ATZ and TPV, while ECD appears to have a weaker interaction. However, the
interaction between ECA and ATZ is stronger than between TPV and ECA. These results agree
with the experimental nucleation induction times shown in Figure 4-3 and 4-4, which suggest that
the estimated free energy of interaction between drug and polymer may give valuable information
about the tendency of the polymer to interact with the drug molecules and prevent crystallization.
Nevertheless, some of the limitations of the current methodology include the length of the
simulated trajectory and the computational resources needed, even though the simulation times are
in the nanoseconds range. The lack of an experimental structure for the polymer requires the extra
step of creating the polymer chain, and running simulations for single polymer chains in water to
obtain a structure that may resemble the one during the experiments. For these reasons, careful
planning is advised in the implementation of this type of methodology in an industrial setting,
where fast results will be needed to serve as a screening methodology for polymers. Nonetheless,
this study opens a promising extensive field to continue exploring, where other methodologies
such as simulated annealing MD may allow sampling a wider range of conformations by changing
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the temperature of the system, and other methods, such as semiempirical and tight-binding
approaches may provide useful information, at a fraction of the current computational cost.

Conclusion
This study involved a multifaceted approach to explain variations in the crystallization inhibition
properties of polymers. The results suggest that small changes in the chemical structure of the
polymer influence their ability to inhibit crystallization. Herein, we have shown that free energies
of interaction between a nucleus of drug molecules and a polymer chain can usefully predict
whether the polymers may be an effective crystallization inhibitor. These results are also supported
by variations in the polymer adsorption onto amorphous films of drug, as determined by AFM,
which indicate the tendency of the polymer to interact with a drug surface.
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5. INFLUENCE OF POLYMER AND DRUG LOADING ON THE
RELEASE PROFILE AND MEMBRANE TRANSPORT OF
TELAPREVIR

This chapter is a reprint with minor modifications of a manuscript published in Molecular
Pharmaceutics in March 2018 with the same title by: Laura I. Mosquera-Giraldo, Na Li, Venecia
R. Wilson, Brittany L.B. Nichols, Kevin J. Edgar, and Lynne S. Taylor.

Abstract
During the dissolution of amorphous solid dispersions (ASDs), various phase transformations can
occur, which will ultimately impact the degree of supersaturation. This study employed dissolution
and diffusion measurements to compare the performance of various ASD formulations based on
the maximum amount of free drug in solution that was able to permeate through a cellulose-based
membrane. Telaprevir (TPV) was used as the model drug compound, and ASDs were prepared
with different drug loadings and using four different polymers. Four possible scenarios that can
influence TPV mass flow rates upon ASD dissolution were described and supported by
experimental data: (1) a system dissolves readily and completely, undergoes phase separation via
glass–liquid phase separation (GLPS), forming drug-rich aggregates, and reaches the maximum
anticipated mass flow rate; (2) where the maximum mass flow rate decreases due to substantial
mixing of the polymer into drug-rich phase, and/or due to the formation of soluble polymer–drug
complexes; (3) a system does not undergo GLPS due to slow drug release and/or matrix
crystallization; and (4) a system does not undergo GLPS due to rapid crystallization from
supersaturated solutions generated during dissolution. The results described herein support the
importance of the combined use of dissolution–diffusion measurements to determine the maximum
level of supersaturation achievable for diverse drug formulations.

Introduction
Creation of a successful oral drug formulation of a poorly water-soluble compound involves the
exploration of multiple strategies to optimize drug concentrations in the bloodstream by improving
solubility in gastrointestinal fluids.23,125 Approaches to increase drug solubility include salts,
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cocrystals, surfactants, cosolvents, cyclodextrins, and amorphous systems. Amorphous solid
dispersions (ASDs) are often considered because they enable the creation of supersaturated
solutions upon dissolution. However, the crystallization propensity of the drug needs to be
evaluated when selecting polymeric excipients to stabilize the formulation.
The solute in the supersaturated solution created by dissolving an ASD can precipitate as a
crystalline or amorphous form.24 Crystalline material can form when the supersaturation exceeds
a certain threshold. In the absence of crystallization, the liquid–liquid phase separation (LLPS)24
or glass–liquid phase separation (GLPS)3,25 concentrations represent the concentration boundary
above which amorphous drug-rich aggregates are created; experimental concentrations where such
phase transitions occur are typically in good agreement with the theoretical amorphous
solubility.3,24-26,28
The significance of phase transition to a noncrystalline form is exemplified by diffusive flux
measurements showing that the mass flow rate reaches a plateau once these amorphous drug
aggregates are created.25,26 The implications from these results are that (1) every system has a
limiting mass flow rate value determined by its amorphous solubility, (2) an “apparent” increase
in the concentration above the amorphous solubility is not translated into a larger mass flow rate,
and (3) precipitation is not necessarily bad; a solution containing an amorphous precipitate has a
larger mass flow rate than one containing a crystalline precipitate, whereby the amorphous
precipitate can act as a “drug reservoir”.31
In vitro performance of pharmaceutical formulations is typically measured using dissolution
profiles, which offer useful information about drug release and supersaturation duration.
Nonetheless, dissolution results may be misleading in some situations because high concentrations
may not correlate with more “free drug” in solution. For instance, high drug concentrations can be
observed when using surfactants73 or when drug-excipient complexes are formed.167 However, the
amount of free drug actually may be reduced in these systems causing a decrease in the mass flow
rate through a side-by-side diffusion cell. Thus, it is advantageous to combine the dissolution and
mass flow rate measurements to better differentiate between formulations.
Diffusion rate measurements have been employed in recent years to provide insight into solution
phenomena.73,149,168-170 Researchers have explored areas, including (1) whether the limiting step in
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the membrane diffusion process is the aqueous boundary layer (ABL) and/or the membrane;149 (2)
the possibility of complex formation, reducing the amount of free drug available to permeate; 167
(3) correlation between in vitro and in vivo measurements;169,171 and (4) determining and
optimizing diffusion systems and membranes to better anticipate in vivo outcomes.170
Recently, Stewart et al. reported that variations in the drug physicochemical properties influence
the rate-limiting step for drug diffusion, which could be useful during the development of oral
dosage forms, and to predict the in vivo formulation performance.149 Diffusion measurements have
also been used to ascertain whether there is complexation, or if micellization causes a real
advantage in terms of diffusion. For instance, Wegiel et al. determined that high resveratrol
concentrations achieved upon the dissolution of ASD formulations in hydroxypropyl methyl
cellulose acetate succinate (HPMCAS) are due to the formation of soluble drug–polymer
complexes, causing a decrease in the mass flow rate through a diffusion cell.167 Recently, the
impact of solubilizing additives on supersaturation and membrane transport has been explored
using diffusion cell measurements.72,73,100,172 Supersaturation is typically estimated using
concentration ratios; however, it has been pointed out that diffusion measurements are more
rigorous, permitting accurate determination of thermodynamic supersaturation when using
solubilizing additives, such as surfactants and bile salts.72,73
Another common question when developing an enabling formulation is how does solid-state
stability influence the performance of the formulation during dissolution? Phase separation in a
polymer–drug system during storage causes the formation of drug-rich domains that can crystallize
before the drug is released into solution, which will cause an unanticipated ASD behavior.173 Li et
al. has described that an ASD can absorb water in multiple stages: during the preparation of the
ASD due to the use of a hygroscopic solvent or a hygroscopic polymer, during ASD storage due
to relative humidity, or during the hydration step throughout ASD dissolution. These results
highlight the importance of carefully controlling variables that can influence water sorption during
ASD preparation and storage.174
The purpose of this study was to compare various drug formulations in terms of the drug release
(donor compartment) and the mass flow rate (receiver compartment) through a diffusion cell, to
better evaluate formulation performance and to further probe how dissolution profiles correlate to
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mass transfer rates. Telaprevir (TPV) was used as the model compound for these experiments. The
commercial formulation of this compound is an ASD (Incivex®), which includes HPMCAS and
SDS.105 TPV has a dry glass transition temperature (Tg) of 103 ˚C,25 and the wet amorphous
precipitate has a Tg of 52 ˚C.25 Therefore, TPV undergoes GLPS when the drug concentration in
solution exceeds approximately 90‒100 μg/mL, resulting in a constant mass flow rate at higher
concentrations when assessed using a side-by-side diffusion cell with a cellulose acetate
membrane.25 Specifically, this study explores: (1) how variations in polymer type and drug loading
cause variations in the maximum mass flow rate; (2) how complexation, matrix crystallization,
and dissolution rate impact the maximum mass flow rate for a particular system; and (3) how the
incorporation of surfactants influences drug dissolution and mass flow rate values.

Materials
TPV was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada); HPMCAS-MF was
from Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan); HPMC (Methocel E5) was supplied by Dow
Chemical Company (Midland, Michigan); PVPVA (Kollidon VA 64) from the BASF Corporation;
and the cellulose derivative cellulose acetate suberate (CA Sub) was synthesized by Dr. Edgar’s
group at Virginia Tech, with a degree of substitution DS(acetate) of 1.82 and DS(suberate) of 0.9,
and a molecular weight of 21.2 kDa.55 Regenerated cellulose membrane with a molecular weight
cutoff (MWCO) of 6‒8 KDa was acquired from Spectrum Laboratories, Inc. (Rancho Dominguez,
California). Phenol was purchased from Sigma-Aldrich (St. Louis, Missouri), and sulfuric acid
was purchased from Thermo Fisher (Waltham, Massachusetts). The aqueous medium used in all
of the experiments was 100 mM sodium phosphate buffer, pH 6.8, prepared by adding 6.96 g of
sodium phosphate dibasic anhydrous and 7.04 g of monosodium phosphate monohydrate make up
to 1 L of deionized water.

Methods
5.4.1 Preparation of ASDs by Rotary Evaporation
TPV‒polymer ASDs were prepared at 1:9, 3:7, and 1:1 weight ratios. Methanol was used to
dissolve solids for the preparation of HPMCAS and PVPVA ASDs, while a 2:1 v/v mixture of
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dichloromethane and methanol was used to prepare HPMC ASDs, and THF was used for CA Sub
ASDs.
Mixtures were sonicated until all solids dissolved. The solvent was removed using a Buchi
Rotavapor-R (New Caste, Delaware) with a water bath at 30˚C. The samples were kept in a vacuum
oven at room temperature for 24 h.
5.4.2 X-ray Diffraction Measurements
Powder X-ray diffraction (XRPD) patterns for TPV ASDs were performed using a Rigaku
SmartlabTM diffractometer (Rigaku Americas, Texas, USA), using a Cu Kα radiation source
operating at 40 kV and 44 mA. The results were recorded over a scan range of 5‒45° 2θ.
5.4.3 Differential Scanning Calorimetry (DSC)
The ASD thermal analysis was performed using a TA Q2000 differential scanning calorimeter
(TA Instruments, Newcastle, Delaware). The instrument was calibrated for enthalpy and
temperature using indium and tin. Nitrogen (50 mL min-1) of nitrogen was used as the purge gas.
The sample (3-5 mg) was added to aluminum Tzero sample pans. Modulated DSC was used; the
samples were heated at a rate of 5 °C min-1, from 25 to 180 °C, with a modulation amplitude of
1°C min-1 every 60 s. The results shown correspond to the first heating cycle.
5.4.4 Diffusion Experiments
5.4.4.1 Diffusion Measurements during ASD Dissolution
A side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania) with a 30 mm orifice
diameter was used to simultaneously measure ASD dissolution (donor compartment) and mass
flow rate (receiver compartment). Both chambers had a 34 mL volume capacity, and they were
separated by a regenerated cellulose membrane with a MWCO of 6‒8 KDa. Each compartment
contained 32 mL of 100 mM sodium phosphate buffer pH 6.8, with temperature controlled at 37 °C.
The donor compartment had a crossed-shaped stir bar (2.0 cm), and the receiver compartment had
an octagonal shaped stir bar (1.0 cm).
Fiber optic probes coupled to a SI Photonics UV spectrometer (Tuscon, Arizona) were inserted
into the donor (path length 5 mm) and receiver cells (path length 10 mm), and the change in the
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absorbance as a function of time was measured at 270 nm, using a baseline correction at 370 nm.
The concentration vs time plots from the donor compartment reflect the ASD dissolution profile.
The flux was calculated from the slope of concentration vs time plots from the receiver
compartment.
Importantly, only the time points after the ASD reached the maximum concentration in solution
were used for the flux calculations, and for systems that undergo fast crystallization (PVPVA
systems), the mass flow rate corresponds to values before crystallization occurred (Table 5-1).
Finally, the mass flow rate values in μg/mL×min were normalized to a volume of 32 mL to obtain
μg/min values.
Table 5-1Time Points for Mass Flow Rate Measurements
system

time points for mass flow rate
measurements (min)

90% HPMCAS: 10% TPV

10 to 60

70 % HPMCAS: 30% TPV

100 to 200

50 % HPMCAS: 50% TPV

800 to 1000

47.5 % HPMCAS: 47.5% TPV: 5% SDS

200 to 400

90% HPMC: 10% TPV

60 to 120

70 % HPMC: 30% TPV

150 to 200

50 % HPMC: 50% TPV

300 to 400

90% PVPVA: 10% TPV

10 to 30

70% PVPVA: 30% TPV

35 to 60

50% PVPVA: 50% TPV

35 to 60

90% CA Sub: 10% TPV

80 to 120

5.4.4.2 Diffusion Measurements with Predissolved Polymer in the Donor Compartment
Diffusion measurements were also performed in the presence of 1.05 mg/mL of pre-dissolved
polymer and 120 μg/mL of drug, to resemble the concentrations of polymer and drug in a 90%
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polymer: 10% drug ASD. The polymers used were HPMCAS, HPMC, PVPVA and CA Sub. These
experiments were conducted to investigate the potential for solution complexation between
polymer and drug.
5.4.5 Crystalline Solubility Determination
An excess of crystalline TPV was added to 10 mL of 100 mM sodium phosphate buffer pH 6.8,
which contained a polymer (HPMCAS, HPMC, PVPVA, and CA Sub) at a concentration of 1.05
mg/mL. The samples were mixed at 300 rpm and 37°C for 72 h. Then, the samples were
centrifuged at 14,800 rpm (21,100xg), for 45 min and at 37 ºC using a Sorvall™ Legend™ Micro
21R Microcentrifuge (ThermoFischer Scientific, Hanover park, Illinois) equipped with a 24
×1.5/2.0 mL rotor with Click Seal biocontainment lid. The concentration of the supernatant was
determined using a SI Photonics UV spectrometer coupled to a fiber optic probe (path length 10
mm) at a wavelength of 270 nm and using a baseline correction at 370 nm. Samples were analyzed
in triplicate. The standard curve presented good linearity (R2 > 0.999) over the relevant
concentration range.
5.4.6 Amorphous Solubility Determination
Solutions (10 mL) containing 1.05 mg/mL of dissolved polymer were equilibrated at 37°C. TPV
(7 mg/mL stock solution in methanol) was added to the polymer solution to a TPV concentration
of 120 μg/mL, using constant agitation, followed by centrifugation, with the same conditions used
for the crystalline solubility determination. The supernatant was diluted 1:5 in methanol, and the
concentration was determined using the SI Photonics UV spectrometer coupled to a fiber optic
probe (path length 10 mm). The concentration of 1.05 mg/mL of polymer and 120 μg/mL of TPV
was selected to represent the concentrations of the drug and polymer in a 90% polymer:10% TPV
ASD following the complete release into the diffusion cell.
5.4.7 Dynamic Light Scattering (DLS)
The particle size and zeta potential of scattering species present in supersaturated TPV solutions
were measured using a Nano-Zetasizer and dispersion technology software (DTS) (Malvern
Instruments, Westborough, MA). Square polystyrene disposable cuvettes (12 mm) were used for
particle size analysis, and disposable capillary cells were used to measure the zeta potential.
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Samples were prepared by adding 120 μg/mL of a methanolic TPV solution (7 mg/mL) to 10 mL
buffer with and without predissolved polymer (1050 μg/mL) at 37 ˚C, the solution had less than
2% methanol in buffer v/v. The diameter values were determined using a refractive index of 1.330
for all of the samples, and the viscosity was adjusted based on the experimentally determined
values. More details about the viscosity measurements can be found in the Appendix B (Table B1).
5.4.8 Polymer Aqueous Solubility Determination
The aqueous solubility was measured (Table B2). The polymer (0.5 g) was dispersed in 10 mL of
pH 6.8 buffer at 37°C and magnetically stirred (200 rpm, 24 hours). The suspension was then
centrifuged for 1 h at 14,000 g using a Thermo Scientific Sorvall Legend X1R centrifuge (made
in Germany) and a ThermoScientific Fiberlite F15-8×50cy rotor (made in the U.S.A). One
milliliter of the supernatant was collected, and the solvent was evaporated in an oven (100°C, 10
h). The dissolved polymer weight was calculated by subtracting the weight of salt in the buffer
solution (6.8 mg/mL). The dissolved polymer concentration (w/v) was then calculated by dividing
the dissolved polymer weight by the volume of solution withdrawn. This procedure was repeated
3 times for each polymer, and the average solubility was reported along with the standard deviation.
The buffer employed for this section was a potassium phosphate buffer (1 L, 0.05 M, and pH 6.8),
which was prepared by adding 6.80 g of potassium phosphate monobasic and using a 0.5 M NaOH
solution to adjust the pH.
5.4.9 Determination of Drug Concentration in Amorphous Aggregates Created after ASD
Dissolution by Using Fluorescence Spectroscopy
5.4.9.1 Generation of Standard Curve
TPV samples in a concentration range of 90‒200 μg/mL were prepared in a pH 6.8 sodium
phosphate buffer solution containing 2 μg/mL of Nile red. A 500 μg/mL methanolic Nile red stock
solution and a 7 mg/mL methanolic TPV stock solution were used to prepare the calibration curve.
Samples were vortexed for 10 s before taking fluorescence emission spectra on a Shimadzu RF5301 PC Spectrofluorophotometer (Kyoto, Japan). The excitation wavelength was 520 nm with an
excitation slit width of 3 nm, an emission slit width of 5 nm, and a sampling interval of 0.2 nm.
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5.4.9.2 Amount of Amorphous Aggregates Generated during ASD Dissolution
TPV ASD dissolution was performed in 15 mL of 2 μg/mL Nile red in pH 6.8 phosphate buffer.
The total concentration of TPV added in all samples was 150 μg/mL. The ASDs were stirred to
allow the formation of amorphous aggregates in solution. The 90% PVPVA ASDs were stirred for
20 min, the 90% HPMCAS ASDs for 30 min, and both the 70% HPMCAS ASDs and the 90% CA
Sub ASDs for 1 h at 300 rpm at 37 ºC before sampling. Samples (4 mL) were removed and filtered
using a 1.0 μm Tisch Glass Fiber Syringe Filter (North Bend, Ohio) to remove undissolved ASD
but allow the amorphous aggregates to pass throughout the filter; the first 2 mL of filtrate was
discarded. The fluorescence emission spectra were collected using the parameters described above.
5.4.10 Determination of polymer concentration in amorphous aggregates created after
ASD dissolution by using ultraviolet spectroscopy colorimetric methods
5.4.10.1 Determination of the Amount of PVPVA Associated with the Drug-rich Phase
PVPVA was assayed by exploiting the well-known reaction between polyvinylpyrrolidone and
iodine.175 Colorimetric standards (5–50 μg/mL) of TPV were prepared in an aqueous solution
containing 0.2 M citric acid and 6 mM iodine. ASD dissolution was performed by adding 22.50
mg of 90% PVPVA: 10% TPV ASD in 15 mL of a pH 6.8 phosphate buffer stirred at a speed of
300 rpm at 37 ºC for 20 min. Samples were filtered with a 1.0 μm Tisch Glass Fiber Syringe Filter
(North Bend, Ohio). The filtrate was then centrifuged at 14,800 rpm (21,100g) for 40 min using a
Sorvall™ Legend™ Micro 21R Microcentrifuge. The pellet contains the GLPS particles and any
polymer associated with those particles (both on the surface and inside the particles). Pellet
samples were prepared by redissolving the pellet in 100 μL of methanol and adding it to 2.3 mL
of an aqueous solution containing 83 mM citric acid and 1 mM iodine. The samples were then
vortexed for 10 s and allowed to stand for 15 min to let the color to mature. All samples were
analyzed at 470 nm on a Varian Cary 300 Bio UV-visible Spectrophotometer (Palo Alto,
California).
5.4.10.2 Determination of the Amount of Cellulose-Based Polymers Associated with the
Drug-rich Phase
For the cellulose-based polymers a sulfuric acid–phenol colorimetric method was employed; this
assay was developed for the analysis of sugars and related substances.176 The following ASDs
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were analyzed using this method: 90% CA Sub, 90% HPMCAS, and 70% HPMCAS. The same
stirring times described in the fluorescence section were used. Samples were filtered using a 1.0
μm Tisch Glass Fiber Syringe Filter (North Bend, Ohio); the first 2 mL of filtrate was discarded.
The filtrate was centrifuged at 14,800 rpm and for 40 min. The pellet was redissolved in a 5%
methanol: 95% water solution. Then, 5 mL of sulfuric acid and 50 µL of phenol were added to 2
mL of the sample solution, followed by 24 h incubation to allow the color to mature. Separate
colorimetric standards were prepared for HPMCAS and CA Sub, each ranged from 5–100 μg/mL.
5.4.11 Determination of Polymer and Drug Release during Dissolution of 50% HPMCAS:
50% TPV ASD with and without Surfactant
ASD dissolution was performed in a 100 mL jacketed beaker, at 300 rpm, and at 37 ºC. Sodium
phosphate buffer (pH 6.8, 75 mL, 100 mM) along with TPV ASD (22.5 mg of the 50% HPMCAS:
50% TPV ASD, or 23.7 mg of the 47.5% HPMCAS: 47% TPV: 5% SDS ASD), was added.
Samples (700 µL) were taken at different time points. Samples were filtered using a 1.0 μm glass
fiber syringe filter and diluted by taking 300 µL of the filtered sample and 1700 µL of the buffer.
The samples were vortexed, and then the concentration of TPV was determined using an SI
Photonics UV spectrometer coupled to a 400 Series optic bench, which allows the use of cuvettes.
Absorbances at 270 nm (maximum wavelength) and 370 nm (nonabsorbing wavelength) were
recorded for all of the samples.
The sulfuric acid–phenol colorimetric method was used to determine the polymer concentration
during dissolution. The method involved adding 1 mL of the diluted sample, 2.5 mL of sulfuric
acid, and 25 µL of phenol and allowed the mixture to stand for 24 h to let the color to mature. The
SI Photonics UV spectrometer coupled to a 400 Series optic bench was used, and absorbance was
recorded at 490 nm (maximum wavelength) and 596 nm (nonabsorbing wavelength) for all of the
samples. Separate colorimetric standards corresponding to 5–100 μg/mL HPMCAS were prepared.
An additional calibration curve in the presence of SDS at a concentration of 15 μg/mL was created
to determine if SDS would interfere with the color determination, but no effect could be observed
at this concentration.
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5.4.12 Microscopy Studies
5.4.12.1 Cryo-SEM in Supersaturated TPV Drug Solutions
A FEI NOVA nanoSEM field emission SEM (Hillsboro, Oregon) with a GATAN Alto 2500 Cryo
unit was used for the cryo-SEM imaging. The cryo unit consisted of a freezing unit, a turbopumped cryo preparation unit, and a cryo-stage attached to the microscope stage. For the sample
preparation, a specific amount of ASD was added to 10 mL of phosphate buffer pH 6.8 100 mM.
The sample was stirred for 2 h at 300 rpm and 37 ˚C. A few microliters of the solution were added
into three holes of a cryo-holder, which was then immersed into liquid nitrogen. Subsequently, the
sample was placed in the cryo-stage and fractured, followed by an increase in temperature to ‒100
˚C to allow a sublimation period of 6 min. The temperature was then decreased and once it reached
∼ ‒120 ˚C the sample was sputtered with platinum for 120 s.
Samples were imaged in the microscope stage, using the Everhart−Thornley detector (ETD) and
through-the-lens detector (TLD). The parameters were 5 kV accelerating voltage, ∼ 5 − 6 mm
working distance, beam spot size of 3, 30 μm aperture and magnifications in the 5,000 − 30,000×
range.
5.4.12.2 Preparation of Thin Films
Thin films of TPV, polymer, and ASDs were prepared using a spin coater (Chemat Technology
Inc, Northridge, CA). Solids were dissolved in a 1:1 v/v methanol:dichloromethane mixture to a
final concentration of 50 mg/mL. Stock solutions containing CA Sub were prepared using THF.
Stock solution (15 µL) was deposited on a substrate, followed by spinning at 50 rpm for 6 s and
3100 rpm for 30 s. All experiments were carried out in a glovebox with a dry nitrogen purge and
RH values below 18 % to eliminate water vapor induced phase separation.174
5.4.12.3 Scanning Electron Microscopy (SEM)
Thin films were spin-coated onto 5 × 7 mm silicon wafers. Samples were then immersed in 2 mL
pH 6.8 phosphate buffer solutions for a certain time and air dried. These samples were further
dried under vacuum at room temperature overnight. Samples were coated with platinum prior to
analysis.
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An FEI NOVA nanoSEM was used for SEM imaging. The accelerating voltage was 5 keV and a
beam spot size of 3 was used.
5.4.12.4 Atomic Force Microscopy and Lorentz Contact Resonance Measurements (AFMLCR)
Thin films were prepared on 10 × 10 mm silicon wafers. For film erosion experiments, films were
immersed in pH 6.8 buffer for a certain time and then air-dried. All samples were further dried in
a vacuum oven overnight prior to analysis.
A nanoIR2 AFM-IR instrument (Anasys Instruments Inc., Santa Barbara, CA) coupled with
Thermalever cantilevers (Model: EXP-AN2‒300, Anasys Instruments, Santa Barbara, CA) was
used for AFM-LCR imaging and mechanical spectra collection. An LCR magnet was used to
generate the magnetic field. Oscillation of the cantilever was then produced by passing an
oscillating current through the cantilever, perpendicular to the magnetic field. The contact
resonance frequency of each cantilever differed, and therefore the same cantilever was used within
a set of samples for comparison purposes.
To collect nanomechanical spectra, the cantilever was driven from 100 Hz to 1000 kHz with a scan
rate of 100 kHz/s. An LCR drive strength of 50 % was used for both spectra collection and LCR
imaging. The cantilever was pointed at domains of interest for the collection of spectra. The
amplitude of the cantilever oscillation was recorded as a function of frequency. The resonance
frequencies varied depending on the stiffness of the region of interest.
For LCR imaging, a frequency close to the peak resonance frequency of interest, identified in the
nanomechanical spectra, was chosen to generate maximum contrast. This slight peak shift was
caused by the additional torque induced by the friction between the sample and the moving
cantilever; whereas the peak frequencies in the mechanical spectra were obtained from a still
cantilever.173 The first flexural resonance peak (usually the first and largest peak) was chosen due
to its high sensitivity and stiffness selectivity. A scan rate of 0.3 Hz was used.
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Results and Discussion
In vitro performance of pharmaceutical formulations is typically measured using dissolution
profiles, which offer information about the drug release and supersaturation stability, assisting the
formulation screening process. In this study, additional steps have been incorporated to better
understand the drug release and phase behavior of TPV ASDs prepared with different polymers
and drug loadings. These investigations focused on (1) the composition of polymer‒drug films
upon buffer immersion; (2) dissolution profiles; and (3) mass flow rate measurements. This
approach enables the free drug concentration evolved from a given formulation to be assessed
regarding the diffusive flux, and it also provides information about how variations in polymer type
and loading influence the hydration step and dissolution profiles.
The polymers chosen to prepare ASDs were selected based on previously conducted induction
time experiments which showed that HPMCAS, HPMC, and CA Sub were highly effective at
inhibiting TPV crystallization, while PVPVA was less effective.148 Furthermore, in terms of
solubility parameters and aqueous solubility, PVPVA and HPMC can be considered to be more
hydrophilic, while HPMCAS and CA Sub are more hydrophobic polymers (Table B2).
Figure 5-1 shows the mass flow rate as a function of TPV concentration, following dissolution
(Figure 5-1a) of different amounts of an ASD consisting of 90% HPMCAS: 10% TPV in the donor
compartment. The dissolution profiles indicate that ASDs dissolve rapidly, and completely release
TPV, since the apparent concentrations correspond well to the expected concentrations based on
how much ASD was added. Also shown for comparison, as a control, are the mass flow rate values
for supersaturated solutions generated by the antisolvent addition of TPV to the buffer (Figure 51b). The mass flow rate profiles are similar for both systems, being characterized by a linear
increase in the mass flow rate as a function of the concentration up to the GLPS concentration,
followed by a plateau.
For concentrations above 90 μg/mL, ASD dissolution led to the formation of turbid solutions. DLS,
fluorescence spectroscopy, and cryo-SEM images (Figures 5-1c and B1) provided evidence for the
formation of a disordered drug-rich phase with a diameter of approximately 300 nm. Cryo-SEM
imaging was employed to directly visualize the drug-rich aggregates created upon the dissolution
of ASDs. Figure 5-1c shows the aggregates after dissolving a 90% HPMCAS: 10% TPV ASD to
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yield a solution concentration of 100 μg/mL TPV. These results indicate that this ASD undergoes
GLPS when concentrations higher than 90 μg/mL are generated following dissolution.
Creation of a drug-rich phase when dissolving a 90% HPMCAS: 10% TPV ASD is favored due to
a fast drug release and maintenance of supersaturation; this explains the good agreement between
the mass flow rate values obtained after ASD dissolution and when using the antisolvent method
(Figure 5-1b). However, several other systems explored herein did not exhibit this pattern of
behavior, showing lower maximum mass flow rate values. The underlying causes appeared to be
multifaceted and include slow release rate, crystallization of the drug in the matrix, solution
crystallization, polymer mixing with the drug-rich phase, and drug‒polymer complexation. These
scenarios are summarized in Figure 5-2, and examples of each pattern of behavior with supporting
evidence for the underlying cause are presented below.

Figure 5-1 (a) Dissolution profiles for 90%HPMCAS: 10%TPV ASD in the donor compartment.
ASD amounts added would yield TPV solution concentrations of 10‒160 μg/mL if all of the
drug was released. Weights refer to mg ASD added to the 32 mL buffer. (b) Mass flow rate as a
function of concentration (theoretical amount if ASD fully dissolves) in the receiver
compartment: (blue squares) following ASD dissolution in donor compartment and (red squares)
after adding a small volume of a concentrated methanolic TPV solution to the donor
compartment. The y-axis in Figure 5-1a is described as the apparent concentration because the
aggregates created at concentrations above 90 μg/mL have different optical properties than those
of the free drug in solution, hence any value > GLPS concentration does not represent a
molecularly dissolved drug. (c) Cryo-SEM image showing the formation of the amorphous
aggregates upon the dissolution of a 90%HPMCAS: 10% TPV ASD to yield a solution
concentration of 100 μg/mL, a concentration > GLPS concentration.
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Figure 5-2 Schematic summarizing factors that can influence the observed mass flow rate
through a side-by-side diffusion cell. The green dotted line represents the TPV GLPS
concentration Case 1: A system that dissolves readily and completely, undergoes phase
separation via GLPS forming drug-rich aggregates, and it reaches maximum anticipated mass
flow rate. Case 2: The maximum mass flow rate decreased due to the substantial mixing of the
polymer into the drug-rich phase, reducing the activity of the amorphous drug, and/or due to the
formation of soluble polymer-drug complexes. Case 3: Surfactant addition increases the drug
release rate allowing a higher mass flow rate. In the absence of surfactant, the system does not
undergo GLPS due to slow drug release. Case 4: A system that does not undergo GLPS due to
rapid crystallization from the supersaturated solution generated upon dissolution.
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5.5.1 Case 1: Maximum Achievable Mass Flow Rate when ASDs Dissolve to Highly
Supersaturated Solutions and Undergo Glass-Liquid Phase Separation
Formation of a drug-rich phase upon dissolution of an ASD can be advantageous because this
second phase will serve as a drug-reservoir to maintain a constant passive diffusive flux until the
drug-rich phase is exhausted.31,177 Figure 5-3 shows the dissolution profiles for ASDs that were
found to undergo GLPS upon dissolution. These were ASDs with 90% HPMCAS, 90% HPMC,
90% PVPVA, 70% HPMCAS, and 70% HPMC. All of these systems reached the maximum mass
flow rate (Figure 5-3f).
An additional consideration is the stability of the supersaturated solution once these amorphous
aggregates are created in solution. Supersaturated solutions created after dissolving 90% PVPVA:
10%TPV ASDs were less stable than those generated from the HPMCAS or HPMC dispersions
(Figure 5-3e). The 90% PVPVA ASD underwent GLPS and reached the maximum mass flow rate,
but after 40 min, the mass flow rate decreased due to crystallization; hence, the supersaturation
advantage of this formulation was lost.
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Figure 5-3 (a, b, c, d, e) TPV dissolution profiles for ASDs that undergo GLPS, where the black
line denotes the TPV GLPS concentration (~90 μg/mL). Dissolution profiles were measured in
the donor compartment of a diffusion cell, and the ASD added corresponds to a TPV
concentration of ca. 150 µg/mL (assuming complete dissolution). HPMCAS ASD profiles are
shown in red, HPMC ASD profiles in blue, and the PVPVA ASD profile in green. (f) Mass flow
rate measurements were performed simultaneously with ASD dissolution; values from the time
points after the maximum donor concentration was achieved (Table 5-1), where the black line
denotes the mass flow rate limit when exceeding GLPS concentration that was determined using
antisolvent addition experiments (Figure 5-1).

To better understand the ASD hydration step and dissolution mechanisms, miscible films of these
ASDs were prepared, immersed in buffer solution, dried, and analyzed by EM and AFM-LCR
techniques. The SEM images (Figure 5-4) show that the ASD films developed heterogeneous
domains after immersion in buffer, which gradually disappeared until samples were fully dissolved.
Interestingly, the rate of the disappearance of the heterogeneous domains depended on the drug
loading, with a faster disappearance in low drug loading formulations. This is consistent with the
dissolution profiles (Figure 5-3). After immersion for 20 min, for 10% TPV ASDs with HPMC,
HPMCAS, and PVPVA, most of the film had dissolved.
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Figure 5-4 SEM images for 90%PVPVA‒10%TPV, 90% HPMCAS: 10% TPV, 70% HPMCAS:
30% TPV, 90%HPMC: 10%TPV, and 70%HPMC: 10%TPV thin films after buffer immersion
for different time intervals. (The dark regions and holes indicate the absence of film. The
residual films are highlighted in circles.)

AFM-LCR experiments (Figure 5-5) permitted further study of the evolution of film structure
following partial dissolution. The initially homogeneous films were found to dissolve rapidly in a
nonuniform way based on the evolution of the topography (Figures 5-5a, d, and g).
LCR images of 10% TPV ASDs with HPMC, HPMCAS, and PVPVA are shown in Figures 5-5b,
c, e, f, h, and i, respectively. For the HPMC and HPMCAS systems, the discrete regions (darker
colored areas in the topographical images, Figures 5-5a, d, and g) are the silicon substrate surface.
This was inferred based on the similar contact resonance frequency values between these regions
and the uncoated substrate, and it indicates regions where material has dissolved. The continuous
phase is the undissolved material. Good agreement is observed between SEM images, AFM
topographical images, and LCR images (obtained at frequency similar to that used for the ASD
film prior to immersion). Thus, it appears that the originally homogeneous film underwent rapid
dissolution of some of the material, leaving a network-like structure of undissolved material.
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The 90%PVPVA: 10% TPV film dissolved differently from the corresponding cellulosic
dispersions, with the formation of circular pits. LCR measurements confirmed that the circular
regions were the silicon substrate, exposed when the ASD film dissolved, while the continuous
phase was undissolved material.

90%HPMC-10%TPV
(a)

topography

90%PVPVA-10%TPV

90%HPMCAS-10%TPV
(d)

topography

(g)

topography

(b) LCR 138kHz (substrate)

(e) LCR 138kHz (substrate)

(h) LCR 140kHz (substrate)

(c)

(f)

(i)

LCR 135kHz (ASD)

LCR 135kHz (ASD)

LCR 137kHz (ASD)

Figure 5-5 AFM height LCR images of 90% HPMCAS: 10% TPV and 90%HPMC: 10%TPV
thin films upon buffer immersion for 15 s.
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5.5.2 Case 2: System with Lower Maximum Mass Flow Rate due to Polymer‒Drug
Mixing in the Drug-rich Phase and the Formation of Polymer‒Drug Soluble
Complexes
The newly synthesized polymer CA Sub was used to prepare ASDs based on the results of our
previous study, where it was found to show good solution crystallization inhibition properties.148
Figure 5-6 shows the dissolution profiles and mass flow rate values when the 90% CA Sub: 10%
TPV ASD is added to the diffusion cell donor compartment. CA Sub is more hydrophobic than
HPMCAS, with a water solubility of 3 ±1 mg/mL, vs. 21 ± 6 mg/mL for HPMCAS-MF. As a
result, a slower drug release is seen for the CA Sub dispersion. The slower dissolution rate is also
apparent from the SEM images (Figure 5-7), where it can be seen that the 90% CA Sub: 10% TPV
films remained homogeneous even after 5 min of contact with water, with heterogeneous features
evolving after immersion for 20 min. Similarly, the AFM experiments showed identical surface
features before and after 10 min of buffer immersion, and the mechanical spectra indicated a
uniform surface composition (Figure B2). These results suggested that the film remained nearly
unchanged after 10 min of immersion, consistent with the slow dissolution rate observed.
Even though CA Sub is more hydrophobic than the other systems discussed above, this ASD did
dissolve and undergo GLPS, as demonstrated by the formations of amorphous aggregates in
solution (Figure 5-6c). However, although the apparent drug concentrations following the
dissolution of the various CA Sub ASDs (Figure 5-6a) were similar to those observed for the
corresponding HPMCAS ASDs (Figure 5-1), the mass flow rate values were consistently lower
for solutions derived from the CA Sub dispersions (Figure 5-6b). For 90% HPMCAS, HPMC, or
PVPVA ASDs, the maximum mass flow rate was ~1.1 µg/min (Figure 5-3f), while the 90% CA
Sub dispersions exhibited a maximum mass flow rate of roughly 0.7 µg/min (Figure 5-6b). Three
possible explanations may be posited for this observation. First, a mixture of free TPV and a
soluble TPV‒CA Sub complex may be present in the donor compartment, affording an amount of
free drug in solution lower than that of the total concentration, leading to a lower mass flow rate.167
Second, the polymer may mix with the drug-rich phase, reducing the chemical potential of TPV in
the amorphous aggregate, and hence decreasing the maximum mass flow rate of the system. Third,
the CA Sub polymer may alter membrane properties, e.g., by polymer adsorption due to a chemical
interaction between the cellulose acetate membrane and the polymer.
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To eliminate altered membrane properties as a potential cause, diffusion experiments were
performed with a different type of membrane. A hydrophobic PVDF membrane impregnated with
lecithin again led to higher mass flow rates for HPMCAS versus CA Sub dispersions (Table B3),
suggesting that membrane‒polymer interactions were not responsible for the decreased mass flow
rate for the latter system. Likewise, no membrane‒polymer interactions were found for the
HPMCAS-MF, HPMC, and PVPVA systems.
To probe soluble complex formation, TPV crystalline solubility and GLPS concentration were
measured in the presence of a high concentration of predissolved polymer (1.05 mg/mL), with
results shown in Table 5-2. TPV crystalline solubility and GLPS concentration (as determined
using the centrifugation method) were notably higher in the presence of CA Sub, while the other
polymers had minimal impact. Diffusion experiments were also conducted using addition of a
methanolic TPV solution to buffer containing predissolved polymer (1.05 mg/mL), and it was
found that the mass flow rate of a given concentration of the dissolved drug was lower when CA
Sub was present; this effect was not seen with other polymers (Table 5-2). These two observations
are consistent with the formation of the soluble polymer‒drug complexes which reduce free TPV
concentration, resulting in a reduced mass flow rate at a given concentration. A similar effect has
been observed for resveratrol and HPMCAS.167 It is also possible that very small insoluble
complexes were not removed by centrifugation.
Finally, the concentration of polymer in the drug-rich phase formed after ASD dissolution was
measured to determine whether the lower maximum mass flow rate observed for the CA Sub
system could be explained by substantial mixing of the polymer with this second phase. This
hypothesis was based on previous solution studies of mixtures of poorly water-soluble drugs that
are miscible in the amorphous aggregate phase. For these systems, the amorphous solubility of
each drug is reduced by the presence of the second drug in the drug-rich phase.28,162,178 However,
reduced amorphous drug solubility has not been reported previously for polymer-drug mixtures,
most likely because in most instances, the amount of polymer in the drug-rich phase is not
sufficient to depress the drug amorphous solubility.
Interestingly, it was determined that the amount of CA Sub was much higher in the TPV-rich phase
in comparison to other polymers (Table 5-3). CA Sub presents the lowest aqueous solubility,
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followed by HPMCAS, and PVPVA, and the amounts of polymer in the drug-rich phase appear to
depend on the polymer solubility (Table B2). The fraction of polymer in the drug-rich phase was
less than 0.3 for PVPVA and HPMCAS ASDs, but it was approximately 0.9 for the CA Sub ASD.
Hence, the dispersed phase in the case of CA Sub might be more correctly termed a polymer-rich
phase.
In summary, the mass flow rate of dissolved 90% CA Sub: 10% TPV ASDs is impacted by two
phenomena: (1) the formation of soluble TPV‒CA Sub complexes; and (2) the substantial mixing
of CA Sub with the drug-rich phase, causing a reduction in the chemical potential of the drug in
the dispersed phase. These two phenomena explain why the CA Sub system has a lower mass flow
rate than HPMCAS dispersions, even though both systems show the same apparent concentration
based on dissolution profiles.

Figure 5-6 Dissolution and mass flow rate values for 90% CA Sub: 10% TPV ASDs (n=3). (a)
Apparent concentration vs time when adding different amounts of a 90% CA Sub: 10% TPV
ASD to the donor compartment. (b) Mass flow rate vs concentration (theoretical amount if all the
ASD dissolves) in the receiver compartment: (blue squares) following ASD dissolution in the
donor compartment, and (red squares) after adding a methanolic TPV solution in the donor
compartment. Mass flow rates measured at time points after the maximum donor concentration
was achieved and before crystallization occurred, Table 5-1. (c) Cryo-SEM image showing the
formation of amorphous aggregates upon the dissolution of a 90% CA Sub: 10% TPV ASD at
concentrations > GLPS.
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90%CA sub - 10%TPV
1s

90%CA sub - 10%TPV
5min

90%CA sub - 10%TPV
20min

1 mm

1 mm

3 mm

Figure 5-7 SEM images of 90% CA Sub: 10% TPV thin films upon buffer immersion for
variable times.

Table 5-2 Properties of Amorphous TPV Aggregates in the Presence of Predissolved Polymer
(1.05 mg/mL)
polymer

crystalline
Solubility
(μg/mL)

amorphous
solubility /
GLPS (μg/mL)

mass flow
rate (μg/min)

diameter
(nm)a

Z
potential
(mV)

HPMCAS

11 ± 1

102 ± 3

1.07 ± 0.05

99 ± 3

-9.8 ± 0.8

HPMC

11 ± 2

96 ± 1

1.10 ± 0.05

147 ± 6

0.0 ± 0.8

156 ± 15

-2.7 ± 0.4

76 ± 3

-23.6 ±
0.5

1.04 ± 0.01b
PVPVA

4.7 ± 0.2

100 ± 4

CA Sub

25 ± 2

111 ± 3d

0.11 ± 0.01c
0.91 ± 0.05

Diameter was calculated using the viscosity of the 1050 μg/mL polymer solution. bMass flow rate before TPV
crystallizes in the presence of PVPVA (between 10 and 30 min). c Mass flow rate after TPV crystallizes in the presence
of PVPVA (between 96 and 120 min). The mass flow rate was measured between 96 and 120 min for HPMC,
HPMCAS and CA Sub. dThe GLPS value reported is a mixture of free drug and soluble drug‒polymer complex.
a
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Table 5-3 Amount of polymer and drug in the TPV-rich phase when dissolving certain ASDs
that undergo GLPS upon dissolution.
ASD composition

amount of polymer

amount of drug in

fraction of polymer

in drug-rich phase

the drug-rich

in the drug-rich

(μg)

phase (μg)

phasea

415 ± 102

1593 ± 15

0.21

310 ± 33

837 ± 14

0.27

10% TPV: 90% CA Sub

9407 ± 1396

1080 ± 6

0.90

10% TPV: 90% PVPVA

203 ± 28

706 ± 19

0.22

10% TPV: 90%
HPMCAS
30% TPV: 70%
HPMCAS

a

The fraction of polymer associated with the drug rich-phase corresponds to the ratio between the amount of polymer
and the amount of polymer and drug in the drug-rich phase. The experimental details are described in the methodology
section.

5.5.3 Case 3: System Unable to Reach Maximum Mass Flow Rate Due To Slow Drug
Release – Impact of Surfactant Addition
The X-ray diffraction patterns and the DSC thermogram for the 50% HPMCAS and the 47.5%
HPMCAS + 5% SDS dispersions indicate that they are amorphous and miscible respectively, as
they displayed a single Tg event (Figure 5-8). The 50% HPMCAS: 50% TPV ASD dissolved
slowly (Figure 5-9a) and did not undergo GLPS due to matrix crystallization (Figure 5-9e). As a
result, the maximum mass flow rate was reduced (Figure 5-9c). The apparent concentration shown
in Figure 5-9a exceeded the amorphous solubility after 600 min due to interference from
undissolved ASD particles. The slow TPV release was confirmed based on SEM hydration
experiments which showed that the amount of solids left (TPV) in the film was higher than that of
when using lower drug loading (Figure B3 vs Figure 5-4). A plausible explanation for matrix
crystallization is the slow and incongruent release of drug and polymer. Incongruent release was
confirmed experimentally, where it was found that HPMCAS released faster from the matrix than
TPV (Figure 5-10a). For example, after 1 h of dissolution, approximately twice as much polymer
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was released into the solution as drug. This would lead to a considerable increase in the relative
concentration of TPV vs polymer in the undissolved matrix. Formation of a TPV-rich layer at the
interface of the dissolving particle would thus render the system more susceptible to crystallization,
since the polymer concentration is reduced, hence diminishing the ability of the polymer to inhibit
crystallization. The phenomenon of incongruent release has been reported for other systems.32,179181

Figure 5-10b shows that the dissolution rate of TPV was increased when SDS surfactant was
incorporated in the ASD, reducing crystallization from the matrix. In other words, the drug was
released faster than matrix crystallization occurred, although release was still not complete. This
led to concentrations above the amorphous solubility, and the expected high mass flow rate. The
addition of surfactants has also been reported to boost the drug release rate in other ASD systems.36
Microscopy (Figures 5-9f, and 5-9g) illustrated the more rapid dissolution of the amorphous film
when SDS is present. However, incongruent release of the drug and polymer was still observed
for this system (Figure 5-10b). In fact, the differences in the dissolution rates of the drug and
polymer were more pronounced in the presence of the surfactant and occurred at an earlier time
point relative to the dispersion without SDS. The concentration of SDS in solution for the
47.5%HPMCAS + 5%SDS ASDs is approximately 15 μg/mL, which is well below its critical
micelle concentration; hence, significant drug solubilization is not expected for these systems.
It is also important to highlight that although SDS improves drug release from the matrix,
decreasing the likelihood of matrix crystallization, it may promote solution crystallization. This
has been noted for other compounds

69

and is exemplified in the case of TPV by Figure 5-9d.

Hence, when using surfactants to promote matrix release, attention also needs to be focused on the
surfactant impact on subsequent supersaturation maintenance following release. In the case of TPV,
supersaturation is likely to be maintained in the presence of the surfactant for a time sufficient to
enable drug absorption in vivo. In contrast, other surfactant species, such as bile salts, have been
effective at preventing solution crystallization for TPV and other drug systems, and therefore may
enable promising strategies to promote drug release in high drug loading ASD formulations, which
requires further study.69-71
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Figure 5-8 (a) DSC thermogram, and (b) x-ray diffraction patterns for 50% HPMCAS: 50%
TPV, and 47.5% HPMCAS: 47.5% TPV: 5%SDS
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Figure 5-9 (a, b, d) Dissolution profiles for HPMCAS-TPV, in the absence and presence of SDS.
(a, b) 10 mg ASD added to give ca. 150 µg/mL TPV (assuming complete dissolution), n=3. (c)
Maximum mass flow rate. (d) Representative solution-time concentration profiles showing that
the addition of SDS to the ASD formulation improves the dissolution rate, but leads to a shorter
crystallization time from solution (15 mg of ASD added to give ca. 230 µg/mL TPV). (e, f, g)
Optical microcopy images of ASD particles after adding buffer. (e) Matrix crystallization
observed in a 50%HPMCAS: 50%TPV ASD, and (f, g) fast dissolution and minimal
crystallization seen for a 47.5%HPMCAS: 47.5%TPV: 5%SDS ASD.
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Figure 5-10 TPV and HPMCAS concentrations from dissolution of ASDs; blue dotted line
denotes TPV GLPS concentration (~90 μg/mL), ASD added gives TPV concentration ca. 150
µg/mL (assuming complete dissolution); (n=3). (a) 50% HPMCAS: 50% TPV ASD, and (b)
47.5% HPMCAS: 47.5% TPV: 5% SDS ASDs.

5.5.4 Case 4: Systems Unable to Reach the Maximum Mass Flow Rate Due To
Crystallization from Solution
In contrast to case 3, where TPV crystallized in the matrix due to the slow drug release,
formulations corresponding to 30% TPV: 70% PVPVA and 50% TPV: 50% PVPVA dissolved
quickly, but did not undergo GLPS due to rapid crystallization of TPV from solution (Figures 511a,b). Consequently, the highest mass flow rate values observed (Figure 5-11c, determined before
crystallization occurred) are lower than those for systems that undergo GLPS.
The X-ray diffraction patterns in Figure 12b indicate that the 70% PVPVA and the 50% PVPVA
dispersions are amorphous within the detection limits of this method. However, the DSC
thermograms (Figure 5-12a) show a single Tg for the 50% PVPVA ASD and two overlapping Tg
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values for the 70% PVPVA ASD. This result suggests that the 70% PVPVA: 30% TPV ASD is
not fully miscible. It has been reported that polymer‒drug miscibility can impact the dissolution
process.32 Particularly, ASDs prepared with PVPVA are more prone to phase separation due to the
polymer hygroscopicity.32,173,182 We have previously studied the miscibility of TPV‒polymer films
using AFM-based imaging techniques, and we have shown that TPV‒PVPA ASDs have a
tendency to phase separate, probably due to the acquisition of water during the preparation and
storage.173 The poor performance by the PVPVA ASDs can be attributed to two factors: (1) the
possible phase separation between polymer and drug in the solid state, and (2) its low effectiveness
as a solution crystallization inhibitor due to its relative hydrophilicity, which favors interactions
with water rather than with the hydrophobic TPV.
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Figure 5-11 (a, b) TPV dissolution profiles for PVPVA-TPV ASDs. The black line denotes the
TPV GLPS concentration (90 μg/mL), ASD was added to give a TPV concentration ca. 150
µg/mL (assuming complete dissolution). (c) Maximum mass flow rate values.
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Figure 5-12 (a) DSC thermogram and (b) X-ray diffraction patterns for 50%PVPVA: 50% TPV
and 70%PVPVA: 30% TPV.

Conclusion
An optimal ASD formulation should generate and maintain supersaturation, as well as create drugrich colloidal species that can serve as the reservoir to maintain the drug supersaturation despite
ongoing drug permeation. In this study, we have shown different cases that convey the complexity
of the dissolution process of TPV ASDs and emphasize the importance of using mass flow
experiments to compare the performance of various formulations. We have demonstrated that drug
loading, polymer selection, and surfactant addition critically influence the release profile of an
ASD and the maximum achievable flux. Most systems with low drug loading underwent GLPS,
exhibited the maximum possible mass flow rates, and are expected to be able to enhance
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bioavailability in vivo. However, despite the advantage of the faster dissolution kinetics for the
low drug loading ASDs, high drug loading ASDs are normally preferred due to having a more
patient-friendly dosage form size and cost-related concerns in formulation design. We have shown
that slow drug release can result in undesirable situations, such as matrix crystallization, which
can be averted by adding a surfactant to the formulation that facilitates ASD wetting during
dissolution. In addition, polymer selection strongly affects drug‒polymer interactions, which can
lead to different drug release profiles, various abilities to inhibit crystallization in the ASD matrix
and in solution, complex-formation, and polymer‒drug mixing in the drug-rich phase. We
anticipate that these findings about the dissolution kinetics and phase behavior of ASDs will
benefit the screening of ASD formulations.
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6. POLYMER DESIGN – TAILORING POLYMER PROPERTIES TO
IMPROVE THE PERFORMANCE OF AMORPHOUS SOLID
DISPERSIONS

Abstract
Effective polymeric materials for amorphous solid dispersions (ASDs) should facilitate drug
release into solution and subsequent kinetic stabilization to avoid crystallization. In this study,
eight newly synthesized polymers were tested. Nucleation induction times for four different drugs
(telaprevir (TPV), atazanavir, griseofulvin, and ezetimibe), and mass flow rates after ASD
dissolution for 10% and 50% TPV formulations were measured. Polymers with carboxylic acid
groups were effective crystallization inhibitors, while those with a quaternary amine or a bile salt
conjugate were ineffective. The exploration of hydroxypropyl cellulose (HPC) derivatives with
different degrees of substitution (DS) of carboxylic acids indicates that there is an optimal level of
carboxylic acids and of the hydrocarbon side-chain length. HPC polymers with a DS of 0.64 to
1.06 and a hydrocarbon side-chain of C5 were optimal regarding crystallization inhibition and
mass flow rates. Finally, a comparison of the mass flow rates when using polymers with carboxylic
acids, but prepared from three different chemical sources, revealed that the HPC derivatives
showed the best performance, which was attributed to their higher aqueous solubility.

Introduction
Excipients are an essential part of pharmaceutical formulations, improving the manufacturability,
delivery, and stability of medicines.75,183 The previously held notion that excipients are inert
components has changed in light of numerous studies indicating essential interactions between
excipients and drugs or between excipients and membrane transporters.75,184-186 Such interactions
can ultimately impact drug bioavailability. Therefore, fundamental studies exploring excipient
properties and drug-excipient interactions are vital to enable accurate prediction of formulation
performance.187,188
Marketed drug products typically draw from the same set of excipients that have been used for
many years.126 This trend is partially explained by the complexity associated with adding a new
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excipient to a commercial formulation,75,187 in particular, the need for additional safety and
efficacy studies.75,187,189 These extra tests can increase the timeline and investment needed to get a
product to the market.
Considering the arduous process required for excipient approval, it is desirable to understand the
excipient function at a fundamental level, enabling the rational design of new, effective materials.
One area of current interest is the design of polymeric excipients for amorphous solid dispersions
(ASDs). ASDs are formed by producing a molecular mixture of drug and polymer and dissolve to
yield supersaturated drug solutions with the goal of improving drug bioavailability.
Polymers are used in ASDs to facilitate the dissolution process and to inhibit drug crystallization.23
The increased interest in ASDs as an approach to formulate drug products and to support
preclinical toxicology studies157,190-192 has motivated the synthesis of new excipients to improve
ASD performance. The recent design and evaluation of copolymers53,54 and cellulose-based
derivatives61,148,159,193,194 have shed light on chemical and structural features important for effective
crystallization inhibition by polymers.
The screening process of polymers typically involves measurement of nucleation induction times
because they allow evaluation of the polymer ability to inhibit crystallization from solution, an
important characteristic needed for effective polymers.49,148 Moreover, the dissolution of ASDs
can involve multiple solution phenomena that can impact the performance of the solid
dispersion.32,195 Potential phenomena include: amorphous-amorphous phase separation,182
complexation,167 micellization, creation of an amorphous-drug rich phase, crystallization from
solution, and matrix crystallization.196 As a result, it is important to incorporate additional
screening methodologies that allow the comparison of ASDs formulated with different polymers.
For instance, mass flow rates are a useful metric to compare different formulations because they
only depend on the amount of free drug in solution and thus help to unravel the complexity of the
dissolution process.171,196
The purpose of this study was to compare newly-synthesized, cellulose-based polymers as
potential polymeric carriers for ASDs. Nucleation induction times for a group of four different
drugs provided information about their ability to inhibit solution crystallization. Mass flow rate
measurements after ASD dissolution, for formulations prepared with 10 different polymers, and
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using two different drug loadings (10% and 50%) allowed comparisons of release potential at high
and low drug loadings. The polymers evaluated herein were designed to probe the impact of
various chemical modifications on performance: (1) varying the starting material (cellulose acetate,
ethyl cellulose, and hydroxypropyl cellulose derivatives); (2) changing the degree of substitution
of carboxylic acids in combination with varying the side chain hydrocarbon chain length; (3)
replacing a negatively charged carboxylic acid group with a positively-charged quaternary amine
group; and (4) appending a bile salt to a cellulose polymer.

Materials
The model compounds used in this study were purchased from Attix Pharmaceuticals (Toronto,
Ontario, Canada), ChemShuttle (Union City, CA), and Hawkins (Minneapolis, MN). Table 6-1
describes the suppliers for the different compounds, and Figure 6-2 shows the chemical structures.
The newly synthesized polymers are shown in Figure -6-1, and the description of the composition
of each polymer is shown in Table 6-2. The aqueous medium used in all experiments was 100 mM
sodium phosphate buffer pH 6.8, prepared by adding 6.96 g sodium phosphate dibasic anhydrous
and 7.04 g monosodium phosphate monohydrate, made up to 1 L with deionized water.
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Figure 6-1 Molecular structures of synthesized cellulose polymers.

Figure 6-2 Chemical structures of model compounds.
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Methods
6.4.1 Nucleation Induction Times
Hydroxypropyl cellulose (HPC) based polymers were directly added to 20 mL of pH 6.8, 100 mM
phosphate buffer, and sonicated at 40 ˚C until fully dissolved. Solutions were equilibrated at room
temperature (22 ± 2°C), and the volume was adjusted to 100 mL. The final polymer solution
concentration was 5 μg/mL.
EC-2.30-C5, CA Sub 0.9, HPC-AETMA-1.06 and HPC-MLCAC-1.06 polymers were first
predissolved in a small amount DMSO, and the solution was sonicated at room temperature until
fully dissolved. The DMSO solution was slowly added to the buffer, with constant agitation. The
final polymer solution concentration was 5 μg/mL and the solution had less than 1% of DMSO.
Supersaturated solutions were created by adding a specific amount of the drug stock solution to 47
mL of phosphate buffer, maintained at 37 ˚C and 300 rpm. The crystallization induction time from
unseeded samples was measured using an SI Photonics UV/Vis spectrometer (Tucson, Arizona)
coupled to a fiber optic probe. Measurements at two different wavelengths were recorded every
minute. The increase in the non-absorbing wavelength and the concurrent decrease in the
absorbing wavelength were taken as the induction time.
The drug concentrations used for TPV corresponded to a concentration above its glass – liquid
phase separation (GLPS) concentration, while the drug concentrations used for the other drugs
were below the LLPS or GLPS concentration. Details about the experimental conditions used in
the nucleation induction time experiments are shown in Table 6-1.
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Table 6-1 Experimental conditions used in nucleation induction time experiments
Drug

Stock
(mg/mL)

Solvent
used for
Stock
Solution

Drug
concentration in
supersaturated
solution (μg/mL)

UV
Probe
used

Maximum
Wavelength
(nm)

Base Line
Wavelength
(nm)

Supplier

Griseofulvin

10

DMF

70

1 cm

330

450

Hawkins

Ezetimibe

5

Methanol

10

1 cm

248

450

Attix
Pharmaceuticals

Telaprevir

7

Methanol

150

0.5 cm

270

370

Attix
Pharmaceuticals

Atazanavir

10

Methanol

60

1 cm

280

450

ChemShuttle

Table 6-2 The degree of substitution (DS) and aqueous solubility for newly synthesized cellulose
polymers.
R1

R2

Solubility
in buffer
(mg/mL)

0.28

C6-COOH

Ac

3.0 ± 1.0

2.30

0.01

C5-COOH

Et

1.061

0.64

1.56

0.80

C5-COOH

HP

41.0 ± 3.3

HPC-C5-1.06

1.06

1.14

0.80

C5-COOH

HP

40.3 ± 9.4

HPC-C5-2.88

2.88

0.00

0.12

C5-COOH

HP

31.9 ± 1.2

HPC-C3-1.23

1.23

0.97

0.80

C3-COOH

HP

20.3 ± 2.3

HPC-C7-1.25

1.25

0.95

0.80

C7-COOH

HP

7.2 ± 2.0

HPC-AETMA1.06

1.06

1.14

0.80

C5-AETMA

HP

HPC-MLCAC1.06

1.06

1.14

0.80

C5-MLCAC-H

HP

DS

DS

DS

(R1)

(R2)

(OH)

CA-Sub-0.9

0.90

1.82

EC-2.30-C5

0.69

HPC-C5-0.64

Polymer

3.1 ± 0.9
0.5 ± 0.4
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6.4.2 Determination of mass flow rate for ASDs
To determine the performance of different TPV ASDs, the mass flow rate was measured using a
side-by-side diffusion cell. These measurements allowed us to compare formulations regarding
their mass flow rate values.
10% TPV: 90% polymer ASD films were directly prepared in 40 mL vials by dissolving 45 mg
polymer in THF and sonicated until all the material was dissolved, followed by the addition of a 5
mg TPV solution in THF (total amount of THF was less than 4 mL). Similarly, the 50% TPV: 50%
polymer films were prepared by dissolving 5 mg polymer in THF, followed by the addition of a 5
mg TPV solution in THF (total amount of THF was less than 3 mL). The mixtures were sonicated,
and the solvent was removed using a Buchi Rotavapor-R (New Castle, Delaware) with a water
bath at room temperature, and using a slow rotating speed. The samples were kept in a vacuum
oven at room temperature for 24 hours.
To these vials, 32 mL of sodium phosphate buffer at 37 ˚C was added. The solution was kept at 37
˚C with stirring at 300 rpm for 200 minutes for the 10% TPV: 90% polymer ASDs, and for 240
minutes for the 50% TPV: 50% polymer ASDs. Then, the 32 mL solution was added to the donor
compartment of a side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania), and the
receiver compartment was filled with 32 mL of sodium phosphate buffer. The donor and receiver
compartment were separated by a regenerated cellulose membrane with a MWCO of 6-8 KDa, and
both chambers had octagonal shaped stir bars (1.0 cm).
A fiber optic probe coupled to a SI Photonics UV spectrometer (Tuscon, Arizona) was inserted
into the receiver cell (path length 10 mm), and the change in absorbance as a function of time was
measured at 270 nm, using a baseline correction at 370 nm, over 1 hour taking one minute
acquisitions. The mass flow rate was calculated from the slope of concentration vs. time plots from
the receiver compartment.
6.4.3 Determination of mass flow rate for supersaturated ATZ solutions
Diffusion measurements were also performed to confirm the performance of polymers at inhibiting
ATZ crystallization. Various polymers were predissolved at 5 μg/mL, 60 μg/mL of ATZ was added
to this solution. The concentration as a function of time was recorded in the receiver compartment.
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Changes in the slope of the mass flow are due to ATZ crystallization in the donor compartment.
Therefore, this method was a useful complementary method, to ratify ATZ nucleation induction
time results. The same diffusion cell system described in the previous section was used for these
experiments.
6.4.4 Polymer solubility in buffer
The methodology to determine polymer solubility has been described in detail in our previous
publication.196 The solubility values are shown in Table 6-2.

Results
The performance of various cellulose-based polymers was evaluated regarding crystallization
induction times, and mass flow measurements after ASD dissolution. First, nucleation induction
times were determined for three sets of polymers: (1) cellulose acetate and ethyl cellulose polymers
with carboxylic acid functionalities, (2) hydroxypropyl cellulose derivatives with various degrees
of substitution of carboxylic acids, and different hydrocarbon chain lengths, and (3) hydroxypropyl
cellulose derivatives with two additional functionalities: a quaternary amine, and a bile salt
conjugate. Second, ASDs with 50% TPV: 50% polymer, and 10% TPV: 90% polymer were
prepared, and mass flow measurements were used to compare the performance of the cellulose
derivatives.
6.5.1 Nucleation induction times in the presence of cellulose acetate and ethyl cellulose
polymers with carboxylic acid functionalities
Crystallization induction times in the presence of CA Sub and EC-2.30-C5 were measured for a
group of four different drugs. These two polymers were chosen because they have shown good
crystallization inhibition properties for TPV.61,148 These polymers include a single side chain with
a carboxylic acid termination, but differ in that CA Sub is a cellulose ester while EC-2.30-C5 is a
cellulose ether. In addition, the hydrocarbon chain length and DS vary, with more details provided
in Figure 6-1 and Table 6-2. The drugs were selected to evaluate the generality of polymeric
crystallization inhibition for drugs of different chemistry and crystallization tendencies. Ezetimibe
and griseofulvin are fast crystallizers, telaprevir is an intermediate crystallizer, and atazanavir is a
slow crystallizer based on the induction times for the drugs in the absence of polymers.
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Figure 6-3 shows that both polymers inhibit crystallization of the four drug model compounds,
whereby EC-2.30-C5 is more effective for three out of the four drugs tested, and similarly effective
for the fourth compound.

Figure 6-3 Nucleation induction time for four different drugs in the presence of CA Sub and EC2.30-C5, at a polymer concentration of 5 μg/mL (n=3).

6.5.2 Nucleation induction times in the presence of HPC derivatives
The polymers CA Sub and EC-2.30-C5 have limited aqueous solubility (Table 6-2) due to the
properties of the starting cellulose derivative. To address this issue, a new set of polymers was
prepared, using a more hydrophilic polymer as the starting material, namely HPC. These polymers
also included carboxylic acid functionalities but had higher aqueous solubilities (Table 6-2). Figure
6-4 summarizes the nucleation induction times for the four drugs in the presence of the
commercially available HPC polymer, and six newly synthesized derivatives. The polymers are
cellulose ethers, with a carboxylic acid termination, three different hydrocarbon chain lengths (C3,
C5, and C7) and different degrees of substitution (DS), ranging from 0.64 to 2.88.
Nucleation induction times are increased by the presence of polymer but clear variations in
effectiveness are observed (Figure 6-4). First, crystallization times are reduced when chemical
modifications are made to HPC. Second, among the HPC derivatives, HPC C5-0.64 and HPC-C51.06 seem to be more effective than the other HPC-C5 derivatives, which suggests that for a side
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chain containing a given number of C atoms, further increase in DS of COOH is not advantageous
regarding yielding more effective inhibitors. Third, the polymer with the shorter hydrocarbon
chain HPC-C3-0.65 is less effective than the counterpart with longer chain HPC C5-0.64. Fourth,
the HPC-C7-1.25 appears to be an effective crystallization inhibitor, especially for the
hydrophobic drug atazanavir. Thus, there seems to be a balance between the DS of COOH and the
number of carbon atoms in the side chain.
In addition to the nucleation induction times, diffusion measurements in the presence of
predissolved polymer were performed for atazanavir (Figure 6-5). Variations in the slope of the
concentration versus time profiles are due to the crystallization (nucleation and growth) of
atazanavir in the donor compartment. This was used as an additional method to confirm the
effectiveness of the different polymers to inhibit atazanavir crystallization considering that
atazanavir forms nanocrystals that potentially interfere with the nucleation induction time
measurements. Figure 6-5 indicates that HPC-C5-1.06 and HPC-C7-1.27 are effective inhibitors
for atazanavir, followed by HPC-C5-0.64 and HPC-C5-288; and the lowest effectiveness for HPCC3-0.64.
Then, two additional polymers were synthesized with a C5 chain length and a DS of 1.06 but using
other functionalities: a quaternary amine and a bile salt conjugate. Figure 6-6 shows that both
derivatives were ineffective crystallization inhibitors for the four different drugs explored.
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Figure 6-4 Nucleation induction time for four different drugs in the presence of HPC derivatives
with various degrees of carboxylic acids (n=3). The notation of the different polymers refers to
the starting material (HPC), the side chain length (CX), and the DS of the functional group
added.
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Figure 6-5 Mass flow rate measurements for atazanavir supersaturated solutions (n=3). The
change in slope is due to the nucleation and growth of crystals in the donor compartment, which
reduces the mass flow through a side by side diffusion cell.
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Figure 6-6 Nucleation induction time for four different drugs in the presence of HPC derivatives
with a quaternary amine and bile salt functionality (n=3).

6.5.3 Mass flow measurements for 10%TPV: 90% Polymer and 50%TPV: 50% Polymer
ASDs
ASDs of TPV and polymer were prepared using two different drug loadings to test the polymer
performance as ASD matrices. This test allowed the use of small amounts of polymer and drug by
preparing the ASD film directly in the dissolution vial. In addition, mass flow measurements were
performed after 200 minutes for the 90% polymer ASDs, and 240 minutes for the 50% polymer
ASDs. We have previously shown that mass flow measurements are a powerful technique to screen
excipients because they reflect the real advantage of a particular formulation.196
Figure 6-7 shows the mass flow measurements for the different formulations explored. CA Sub
and EC-2.30-C5 were used because both polymers show good crystallization inhibition properties
but are more hydrophobic than their HPC counterparts. In addition, HPC derivatives with different
chain lengths and DS of COOH were used, and finally, HPC derivatives with the quaternary amine
and bile salt conjugate were tested.
A concentration of 156 μg/mL of TPV is expected if the polymer fully releases the drug and
stabilizes the drug in solution. This concentration is well above TPV GLPS concentration of 90
μg/mL, and hence complete release is expected to result in the formation of drug-rich aggregates
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if crystallization is avoided. Based on previous studies, the maximum attainable mass flow for
TPV is 1.1 μg/min, assuming that the system undergoes GLPS.
The 10% drug loading CA Sub and the EC-2.30-C5 ASDs show a lower mass flow than the
majority of the HPC derivatives with carboxylic acid functionalities, except for the HPC-C3-1.32.
More pronounced differences in the performance of the HPC polymers are seen when using the
50% drug loading ASDs, where HPC, HPC-C5-0.64, and HPC-C5-106 show larger mass flow
values than HPC-C5-2.88, HPC-C3-1.32, and HPC-C7-1.25.
The HPC-C5-AETMA-1.06 (-N+C(CH3)3) shows a good performance when using a 10% drug
loading ASD, but a large standard deviation is observed when the drug loading is increased to 50%,
which can be explained due to the crystallization of some of the samples. Lastly, the polymer with
the bile salt conjugate (HPC-C5-MLCAC-1.06) had the lowest performance, which can be
attributed to the increased hydrophobicity due to the added bile salt motif.

Figure 6-7 Mass flow rate after 200 minutes for 90-10 ASD and 240 minutes for 50-50 ASDs.
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Discussion
The design of novel excipients to stabilize amorphous formulations requires the combination of
various characteristics that allow optimal ASD performance, regarding dissolution rate and
supersaturation maintenance. The polymer needs to stabilize the drug in the solid state, release the
drug into solution, and maintain the drug in solution over biorelevant time frames.
Moreover, in the same way as when designing new drug molecules the amount of material is a
limiting factor, the screening of new excipients creates the need for methodologies that allow for
comparison of polymers without requiring large amounts of material. Herein, two different
screening procedures have been followed to determine which polymers could be promising
excipients: nucleation induction times to compare the ability of various polymers to maintain drug
supersaturation, and diffusion cell measurements to test various ASD formulations in terms of the
maximum mass flow achievable, which will depend on multiple factors including release rate and
extent, tendency for matrix crystallization, and ability of polymer to prevent solution
crystallization, among others, but is a good in vitro surrogate for the processes that need to occur
in vivo for gastrointestinal absorption .
Initially, polymers with carboxylic acid functionalities were designed based on our previous
studies indicating that the presence of this functional group is important of effective polymeric
crystallization inhibitors of TPV.61,148,159 Figure 6-3 shows that the carboxylic acid containing EC2.30-C5 and CA-Sub indeed delayed drug crystallization, even when using low concentrations of
polymer (5 μg/mL). However, the polymer aqueous solubility will play a major role in the kinetics
of the ASD dissolution process, especially at low drug loadings, as evaluated in this study; it has
been suggested that the dissolution process for a 10% drug loading ASDs is controlled by the
polymer, whereas when using 50% drug loading ASDs, release becomes drug-controlled.32,195 In
turn, release rates will impact the mass flow rate. Thus although EC-2.30-C5 and CA-Sub
polymers are excellent solution crystallization inhibitors, they have relatively low aqueous
solubility (Table 6-2), and this contributes to the lower mass flow values observed for these
systems which are about 60% of the mass flow rates seen for dispersions prepared from the more
soluble HPC counterparts.
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The lower mass flow values observed for the ASDs with EC-2.30-C5 and CA-Sub provided the
motivation to explore more hydrophilic cellulose materials. The HPC starting material has an
increased aqueous solubility; hence, the derivatives created from this source should also have
improved solubility, assuming small chemical variations. Regarding nucleation induction time
effects, the modifications to HPC structure resulted in a decrease in the ability to inhibit
crystallization. From the three hydrocarbon chain lengths (C3, C5, and C7) tested, it was
determined that the C5 polymers had the best performance for the compounds used, while the C3
polymer had the lowest effectiveness.
Within the group of polymer with C5 hydrocarbon chain length, it could be further noted that a
DS COOH of 0.64 to 1.06 provided optimal crystallization inhibition with further increases in
COOH DS leading to impaired inhibition.
Figure 6-7 shows the mass flow values for 10% and 50% drug loading formulations prepared with
the HPC derivatives. The mass flow values for the 10% drug loading formulations are typically
larger than for the 50% drug loading ASDs for the majority of the HPC derivatives. The improved
mass flow at a 10% drug loading is consistent with a polymer-controlled dissolution mechanism
whereby the HPC derivatives afford a fast drug-release due to their enhanced aqueous solubility.
Considering that most commercial formulations have larger than 10% drug loadings, it is also
important to consider higher drug loading ASDs. High mass flow values were observed for the
HPC, HPC-C5-0.64, and HPC-C5-1.06 50% ASDs. Finally, the HPC-C3 and HPC-C7 polymers
exhibited a lower mass flow rate than the HPC-C5 derivatives. These results from the mass flow
measurements agree broadly with the observations from the nucleation induction time
measurements.
We have consistently found that cellulose derivatives with COOH groups make good
crystallization inhibitors. The ionizable COOH group is thought to impart amphiphilicity to the
polymer, driving interactions with both the drug and solvent. Herein, it was hypothesized that
positively-charged polymers of similar backbone chemistry to their negatively charged
counterparts will be effective crystallization inhibitors. In the past, we determined that a cellulose
ester with a quaternary amine termination was an ineffective polymer.148 However, it was difficult
to establish whether the low effectiveness of this polymer was due to the quaternary amine per se,
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or to the relatively long, C8, hydrocarbon chain length.148 Within the framework of the current
study, HPC-C5-1.06 (-COO-) and HPC-C5-AETMA-1.06 (-N+C(CH3)3) are structural analogs,
differing only in the functional group at the end of the chain (Figure 6-1), allowing us to test the
hypothesis. Nucleation induction times showed that HPC-C5-AETMA-1.06 (-N+C(CH3)3) was an
ineffective crystallization inhibitor for the four drug compounds employed (Figure 6-6), while
HPC-C5-1.06 (-COO-) was effective (Figure 6-4). This result suggests that the presence of a
charged group is not sufficient to provide crystallization inhibition properties. It is likely that our
amphiphilicity hypothesis still holds, and the quaternary amine group is more hydrophobic than
the COO- group due to the trimethyl substitution.
We also explored the hypothesis that cellulose derivatives conjugated with a bile salt can be
effective crystallization inhibitors. This hypothesis is based on recent studies from our group
showing that different bile salts are effective crystal nucleation and growth inhibitors.33,69-72 The
polymer HPC-C5-MLCAC included a covalently attached bile salt, but was an ineffective
crystallization inhibitor (Figure 6-6) and gave rise to low mass flowrates (Figure 6-7). This is
probably due to the increase in polymer hydrophobicity as a result of the added bile salt motif.
However, different modifications can be applied to future bile salt conjugates to improve their
aqueous solubility, and possibly their performance as crystallization inhibitors. For example,
decreasing the DS of the bile salt conjugate; and/or including additional chemical variations to the
cholesterol motif, such as carboxylic or sulfonic acid groups, as found in naturally occurring bile
salts may improve polymer performance leading to the expected synergies in crystallization
inhibition.

Conclusion
Herein, two different screening procedures have been followed to compare the performance of
eight newly synthesized polymers; nucleation induction times and diffusion cell measurements.
The results indicate that the ability of a polymer to inhibit crystallization as well as its aqueous
solubility will determine its final performance in an ASD. Even though carboxylic acid groups are
important to create effective crystallization inhibitors, there is an optimal DS level of 0.64 to 1.06
with a C5 side chain. In addition, polymers prepared with hydroxypropyl cellulose as the starting
material exhibited larger mass flow rates than those made with ethyl cellulose or cellulose acetate,
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as a result of the improved aqueous solubility of HPC. The preparation of HPC derivatives with a
quaternary amine and a conjugated bile salt allowed us to test two hypotheses. HPC derivatives
with a quaternary amine (positive charge) were less effective than those prepared with carboxylic
acids, suggesting that the presence of a charged group is not sufficient to provide crystallization
inhibition properties. HPC derivatives with a bile salt conjugate were ineffective crystallization
inhibitors, and showed lower mass flow values than those polymers with a carboxylic acid
functionality, suggesting that additional modifications are required to improve the polymer
hydrophilicity and its performance as an ASD matrix.
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APPENDIX A

Supporting Information for Chapter 4
Description of the physicochemical properties for the newly synthesized polymers
Table A1. Degree of substitution (DS), solubility parameter (SP), molecular weight (MW), and
dispersity (Ð) for newly synthesized cellulose polymers.

#

Polymer
abbreviation

DS

DS

DS

SP
DS

(R1)

(R2)

(R3)

(OH)

R1

R2

R3

(MPa1/2)

Tg

Mw

(˚C)

(kDa)

Ð

Solvent

a

1

CP-Tod-202

2.02

0.98

-

-

TOD

Pr

-

20.67

21

82.6

-

THF

2

CAB-Adp-081

0.81

1.99

0.14

0.06

Adp

Bu

Ac

22.08

82

9.5

-

THF

3

CAP-Adp-085

0.85

2.09

0.04

0.02

Adp

Pr

Ac

22.46

110

9.7

-

THF

4

CAP-Seb-024

0.24

2.09

0.04

0.63

Seb

Pr

Ac

23.04

116

18.8

-

THF

5

CA-Sub-090

0.9

1.82

-

0.28

Sub

Ac

-

23.18

81

21.2

-

THF

6

CA-Adp-067

0.67

1.82

-

0.51

Adp

Ac

-

24.21

134

20.5

-

THF

7

CA-Adp-056

0.56

1.82

-

0.62

Adp

Ac

-

24.47

154

60.3

1.60

THFb

8

CA-A1a-056

0.56

1.82

-

0.62

A1a

Ac

-

25.21

138

37.8

1.89

THFb

9

CAP-A1b-057

0.57

2.09

0.04

0.30

A1b

Pr

Ac

22.46

70

13.6

2.75

THFb

10

CAB-A1b-059

0.59

1.99

0.14

0.28

A1b

Bu

Ac

22.03

53

50.7

3.37

THFb

11

CA-A2a-079

0.79

1.82

-

0.39

A2a

Ac

-

25.42

124

37

1.43

DMSO

12

CA-A2b-067

0.67

1.82

-

0.51

A2b

Ac

-

22.95

139

38.2

1.67

THFb

13

CA-A3-056

0.56

1.82

-

0.62

A3

Ac

-

21.66

76

180

1.55

THFb

14

CA-A4-056

0.56

1.82

-

0.62

A4

Ac

-

25.02

41

100

1.78

THFb

15

CA-A5a-079

0.79

1.82

-

0.39

A5a

Ac

-

25.54

63

-

-

DMSO

16

CA-A5b-067

0.67c

1.82

-

0.51

A5b

Ac

-

24.29

6d, 89

-

-

DMSO

17

CA-A6-067

0.67

1.82

-

0.51

A6

Ac

-

21.40

88

-

-

DMSO
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18

CA-A7-067

0.67

1.82

-

0.51

A7

Ac

-

21.83

103

aSolubility

-

-

DMSO

parameter (SP) calculation does not account for ionization bMaximum concentration
of polymer achievable was 5 μg/mL. Even though the polymer is soluble in organic solvent at
higher concentrations, it was observed to precipitate upon contact with water. Therefore, those
polymers were only tested at 5 μg/mL. cDue to the partial conversion (87%) of the reaction,130 the
actual DS of A5b is 0.58, with DS of A4b 0.09. dThe lower temperature endothermal transition
was attributed to the segmental movement of the sidechain. Nomenclature rules: The polymer
abbreviations in this manuscript follow a format XX-Xxx-000 (e.g. CA-A1a-056). In the first part
XX represents the starting cellulose ester used. For example, CA denotes cellulose acetate (DSAc
= 1.82) and CP denotes cellulose propionate (DSpr = 0.98), as indicated in the table. The middle
part Xxx denotes the functional side chain and digits in the last part denotes the DS of the side
chain. For example, in CA-A1a-056; A1a denotes the functional group is A1a as shown in Figure
1, and the number 056 denotes the DS of A1a is 0.56.

Table A2. Polymer abbreviations for newly synthesized materials.
#

Polymer abbreviation

Equivalent abbreviation

1

CP-Tod-202

CP-Tod-202

2

CAB-Adp-081

CAB Adp 0.81

3

CAP-Adp-085

CAP Adp 0.85

4

CAP-Seb-024

CAP Seb 0.24

5

CA-Sub-090

CA 320S Sub 0.9

6

CA-Adp-067

CA 320S Adp 0.67

7

CA-Adp-056

CA-Pen056-AA-H

8

CA-A1a-056

CA-Pen056-Hb

9

CAP-A1b-057

CAP-Un057-Hb

10

CAB-A1b-059

CAB-Un059-Hb

11

CA-A2a-079

CA-Pen079-Aam-H

12

CA-A2b-067

CA-Un067-Aam-H

13

CA-A3-056

CA-Pen056-PEG-H

14

CA-A4-056

CA-Pen056-HEA-H

15

CA-A5a-079

CA-Pen079-HEA-3MPA

16

CA-A5b-067

CA-Un067-HEA-3MPA

17

CA-A7-067

CA-Un067-TMA-2ME

18

CA-A6-067

CA-Un067-TMA-3MPA
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APPENDIX B

1. Viscosity measurements for polymer solutions in the absence and presence of
methanol
The viscosity for polymer solutions corresponding to a concentration of 1050 μg/mL was measured
at room temperature (25 ˚C) using an SV-10 Vibro Viscosimeter (San Jose, California).
Measurements were performed in the absence and presence of 1.71% methanol w/volume.

Table B1 Viscosity measurements for polymer solutions (1050 μg/mL) at room temperature (25˚C)
Viscosity in the absence of Viscosity in the presence of
methanol (cP)
1.71% methanol w/v (cP)
CA Suberate

1.50 ± 0.03

1.45 ± 0.03

HPMC (Methocel E)

1.48 ± 0.03

1.42 ± 0.03

HPMCAS-MF

1.57 ± 0.04

1.56 ± 0.04

PVPVA

1.35 ± 0.09

1.27 ± 0.07
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2. Solubility parameter calculation
The solubility parameter for the ASDs polymers (Table B2) were calculated by the Fedors
method131 and using a similar procedure than the one reported by Babcock et al.133 It considers the
energy of vaporization, molar volume and the degree of substitution for the diverse chemical
features. The methodology has been discussed in detail in the supporting information in the paper
by Dong et al.61
Table B2. Solubility parameter and aqueous solubility for polymers used in amorphous solid
dispersions

Polymer

CA Suberate

HPMC (Methocel
E)a

HPMCAS-MFb

PVPVA
a

Substituent

DS

Suberate

0.90

Acetyl

1.82

Hydroxyl

0.28

Methoxyl

1.9

Hydroxypropyl

0.23

Hydroxyl

0.87

Methoxyl

1.89

Hydroxypropyl

0.25

Acetyl

0.55

Succinoyl

0.28

Hydroxyl

0.03

-

-

Solubility
Parameter
(MPa1/2)

Aqueous
Solubility
(mg/mL)c

23.18

3.3 ± 1.3

23.93

37.1 ± 0.5

21.47

20.5 ± 5.9

23.59

45.9 ± 2.2

The degrees of substitution for Methocel E5 were obtained from report by colorcon. bThe degrees
of substitution for HPMCAS-MF were obtained from the values reported by Babcock et al133,
which correspond to the Shin-Etsu Chemical Co polymers. cSolubility determined in 100 mM
phosphate buffer.
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3. Control Experiment using Hydrophobic PVDF membrane
Similarly than using a regenerated cellulose membrane, a hydrophobic polyvinylidene fluoride
Durapore® membrane (HVHP type, 125 μm thickness, and 0.45 μm pore size) impregnated with
a 2%w/v lecithin predissolved in n-dodecane was used. This type of membrane is typically used
for PAMPA (parallel artificial membrane permeability assay).

Table B3 Mass flow comparison when using Durapore® PVDF membrane versus cellulose
membrane MWCO 6-8 KDa
Amount of dispersion added 90
%polymer: 10% TPV (mg)

Mass flow in 90% HPMCAS
ASD dispersion

Mass flow in 90%CA 320
Sub 0.9 ASD

12a

0.76 ± 0.04

0.64 ± 0.01

10b

0.42 ± 0.03

0.33 ± 0.02

15b

0.61 ± 0.04

0.46 ± 0.03

Diffusion experiment using Durapore PVDF hydrophobic filter impregnated with 150 μl of 2%
lecithin solution in n-dodecane, b) Diffusion experiment using regenerated cellulose membrane
with MWCO 6-8 KDa.
a
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4. Cryo-SEM images corresponding to supersaturated drug solutions created by
solvent-shifting method or by ASD dissolution.

Figure B1 Cryo-SEM images corresponding to ASD dissolution, 90% HPMCAS-MF: 10% TPV
ASDs, samples taken after 2 hours. Different ASD amounts were dissolved to obtain 90, 100, 130,
150, 200 μg/ml TPV.
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5. Mechanical spectra, and SEM images for ASDs
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0.9

Figure B2 Mechanical spectra, contact resonance frequencies, and AFM height image for 90% CA
Sub: 10% TPV thin films upon buffer immersion for 10 minutes.

Figure B3 SEM images for 50% HPMCAS: 50% TPV, and 47.5% HPMCAS: 47.5% TPV: 5%SDS
thin films after buffer immersion for different time intervals.
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